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ABSTRACT OF THE DISSERTATION 
HIV TAT AND MORPHINE-INDUCED NEURODEGENERATION IN A BECLIN 1 
HEMIZYGOUS MOUSE MODEL 
by 
Jessica Audrey Lapierre 
Florida International University, 2018 
Miami, Florida 
Professor Nazira El-Hage, Major Professor 
Early in infection, HIV crosses the blood-brain barrier and induces neuropathology. Viral 
presence in the CNS coupled with secretion of neurotoxic proteins causes 
neuroinflammation, glial dysfunction, excitotoxicity, and neuronal death. Despite advances 
in combined antiretroviral therapy, HIV-infected patients present with a spectrum of 
cognitive and psychomotor deficits collectively referred to as HIV-associated neurological 
disorders (HAND). A subset of HAND patients abuses drugs such as opiates like heroin 
and morphine show an exacerbation and rapid progression of HIV neuropathology; 
however, the mechanisms of this synergy are not well understood. Autophagy is a 
lysosomal degradative process which eliminates and recycles cytosolic components and 
is implicated in facilitating HIV-1 replication in the CNS and periphery, and in Tat-induced 
neurodegeneration. When a key initiator of autophagy Beclin 1 was silenced using 
siRNAs, there was a marked reduction of HIV-1 replication in human microglia and 
astrocytes and the corresponding inflammatory response. As such, the goal of the current 
study is to determine if diminished Beclin 1 is neuroprotective against Tat-and morphine-
induced neurodegeneration using heterozygous Beclin 1 (Becn1+/-) mice. Examination of 
Tat-and morphine-induced inflammatory molecule secretion revealed that Becn1+/- mixed 
astrocyte and microglia (glia) exhibited attenuated secretion of cytokine IL-6 and 
 vii 
chemokines RANTES and MCP-1 compared to control (C57BL/6J) glia, an effect 
mediated through the μ-opioid receptor. Dysregulation of autophagy-related gene 
expression and excessive intracellular calcium accumulation were limited in Becn1+/- glia. 
When determining the effects of Tat-and morphine co-exposure on neuronal survival in 
vitro, we found Becn1+/- neurons were particularly sensitive to injury, excitotoxicity, and 
toxic exposures; however, when C57BL/6J neurons were exposed to conditioned media 
of C57BL/6J and Becn1+/- glia treated with Tat and morphine, neurons treated with 
Becn1+/- supernatant had better outcomes than those treated with C57BL/6J conditioned 
media. Furthermore, despite minimal difference between strains in locomotor assessment, 
we observed significantly greater striatal neuron losses in adult C57BL/6J mice exposed 
to intrastriatal Tat-and systemic morphine compared to Becn1+/- mice. Our studies 
demonstrate the potential of targeting Beclin 1 in glia for the prevention of Tat and opiate-
induced CNS dysfunction. 
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CHAPTER 1: AN INTRODUCTION TO HIV-ASSOCIATED NEUROLOGICAL 
DISORDERS (HAND) AND AUTOPHAGY IN THE CONTEXT OF OPIATE ABUSE  
 
1.1  Introduction 
Human immunodeficiency virus (HIV) is a lentivirus member of the Retroviridae family 
which causes systemic infection and can ultimately lead to acquired immunodeficiency 
syndrome (AIDS) [1]. Currently, over 36 million people worldwide are living with HIV/AIDS 
with approximately 1 million people dying of AIDS-related illnesses [2]. Characterized as 
an immune system disorder, the virus targets primarily CD4+ T cells as well as antigen-
presenting cells such as macrophages and dendritic cells [3]. During infection, the HIV 
envelope glycoprotein gp120 interacts with the host CD4 receptor which induces a 
conformational change in the envelope protein allowing the gp41 protein to also bind host 
co-receptors C-C motif chemokine receptor 5 (CCR5) or C-X-C motif chemokine receptor 
4 (CXCR4) found on the surfaces of antigen presenting cells and memory CD4+ T cells 
[4]. The viral selectivity or preference for one co-receptor over the other is termed as 
tropism, whereby R5-tropic viruses prefer the CCR5 co-receptor and X4-tropic prefer the 
CXCR4 co-receptor. Once infection is established, the virus is able to efficiently evade 
antiviral defense mechanisms while depleting CD4+ T cells and other immune cells, 
creating viral reservoirs,  enhancing its own replication, and inducing the release of 
inflammatory cytokines in the process [5]. Despite all of this, it is not the systemic viremia 
that is responsible for the mortality due to HIV infection but rather the widespread 
exhaustion of the immune system leading to the increased susceptibility to opportunistic 
pathogens [6].  In addition, viral proteins which are produced and/or secreted by infected 
cells may trigger toxic effects to neighboring cells. These prospective apoptotic viral 
proteins including the envelope protein gp120, viral protein R (Vpr), viral infectivity protein 
2 
(Vif), negative factor (Nef) and the transactivator of transcription (Tat), are important in 
mediating the infectivity and replication of the virus [7]. It was only with the advent and 
evolution of antiretroviral therapy that viral titers have become manageable leading to a 
drastic decrease in the mortality of infected persons.  
 
Though HIV primarily affects the immune system, it can cross the blood brain barrier (BBB) 
during early infection and affect the nervous system [8, 9]. The most well characterized 
mechanism is termed the “Trojan horse” theory where infected monocytes (CD14+CD16+) 
cross the BBB due to increased response to chemokines such as CCL2 (also known as 
MCP-1) which are induced by viral presence in the CNS [10, 11]. Within 4 to 8 days of 
peripheral infection, the virus enters the CNS and is spread to various other cell types 
including other monocytes/macrophages, microglia, endothelial cells, and to a lesser 
extent, astrocytes [12]. The productive and latent infection within these replication-
competent cells, despite long term antiretroviral treatment, establishes and maintains the 
CNS as a viral reservoir capable of releasing neurotoxic viral proteins.   
 
Despite the advances in combined antiretroviral therapy (cART), HIV infection in the brain 
remains persistent while causing a myriad of neurological problems including cognitive 
dysfunction, behavioral changes, and motor impairment. These neurological side effects 
of HIV infection in the nervous system are collectively known as HIV-Associated 
Neurological Disorders (HAND) and are seen in a percentage of the HIV infected 
population [13, 14]. In addition, certain trends in co-morbidities have emerged within 
subsets of HIV infected patients such as within the opiate using community. With 
approximately 30% of HIV infected persons being injection drug users (IDU), research has 
shown that the neural dysfunction and progression of HAND is accelerated in opiate drug 
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abusers [15]. It is important to note that synthetic opioids are also used for analgesic 
treatment of neuropathic pain.  Numerous mechanisms have been proposed to explain 
opiate exacerbation of HIV pathogenesis, most of which are based upon host pathways 
utilized by the virus. One such target of increasing interest is the autophagy pathway which 
is utilized by HIV to enhance its own viral biogenesis [16]. 
 
The term “autophagy” was created by Christian de Duve in 1963, winner of the 1974 Nobel 
Prize in Physiology for the discovery of lysosomes and peroxisomes [17]. Derived from 
the Greek auto- meaning “self” and phagein meaning “to eat”, he described the observed 
cellular process wherein cytosolic organelles are delivered to the lysosome within double-
membraned vesicles as seen through electron microscope. Initially described as “focal 
cytoplasmic degradation,” studies documented the multistage process in which 
sequestered components of cytoplasm were brought to lysosomes for the reutilization of 
cellular materials [18]. It was with de Duve’s study of glucagon-induced cell degradation 
in the liver that lysosomes were recognized as the site of intracellular autophagy [19, 20]. 
Figure 1.1 Summary of mammalian autophagy pathways. 
Autophagy is classified as one of three types: Macroautophagy, microautophagy, and chaperone-
mediated autophagy. Macroautophagy (herein termed autophagy), can be broken down into 3 
stages: initiation, nucleation, and expansion representing the activation of the pathway, early 
formation of the phagophore membrane, and elongation of the membrane to form the completed 
autophagosome. Recreated from [21]. 
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The autophagy pathway can be characterized as one of three types (Figure 1.1; adapted 
from  [21]), macroautophagy, microautophagy, or chaperone-mediated autophagy, each 
mediated by their respective autophagy-related genes, all of which terminate at the 
lysosome [22]. These three pathways predominantly differ in the locations where 
engulfment occurs, and the proteins involved in the process. The most studied of these is 
macroautophagy and will henceforth be referred to as autophagy. From its discovery in 
1963 to today, the attention to autophagy in research has shifted from understanding of 
the mechanism to determining its roles in physiology and the pathogenesis of disease.  
 
Numerous connections between autophagy and the pathogenesis of HIV are reported. 
The role of autophagy as an immune regulator provides a link between the pathway and 
the HIV immune response. As such, exploring that link between autophagy and HIV 
pathogenesis is of increasing interest. During HIV infection, autophagy was reported to be 
downregulated in both macrophages and dendritic cells, with macrophages and CD4+ T 
cells shown to accumulate autophagic vacuoles [16, 23]. The effects of HIV on autophagy 
in immune cells may provide the ideal state for viral persistence, immune evasion, and 
cell death in the CNS and periphery. Based on this research, autophagy is of particular 
interest for study because of its contributions to HIV neuropathology. 
 
1.2  Brief overview of the HIV genome  
As previously mentioned, HIV is a lentivirus belonging to the Retroviridae family and is 
transmitted as a single stranded, positive-sense, enveloped RNA virus [1]. Measuring 
about 100 nm in diameter, each virus contains a lipid bilayer viral envelope that 
encompasses the capsid, or protein shell, and the matrix which in turn hold the genetic 
information [24]. Within the capsid are two single strands of RNA which contains the virus’s 
5 
nine genes encoding 15 viral proteins, and the viral enzymes reverse transcriptase (RT) 
and integrase (IN) that are responsible for conversion of RNA to DNA and integration of 
viral DNA into the host genome respectively (Figure 1.2) [25-27]. The viral genome 
contains various structural and functional proteins and enzymes allowing for the replication 
and production of new viruses, but these have other roles in HIV persistence and 
pathogenesis.   
 
The genes encoding the structural proteins include gag, pol, and env. Gag, or group-
specific antigen, codes for a precursor to the p55 gag polyprotein which is processed by 
the viral enzyme protease into the numerous structural peptides such as p17/MA, p24/CA, 
and p7/NC which make up the matrix, capsid, and nucleocapsid proteins [26, 27]. The pol 
gene codes for numerous viral enzymes which are essential to viral infection, integration, 
Figure 1.2 Diagram depicting components of HIV virion and the viral genome 
The HIV genome consists of 9 genes encoding 15 proteins utilized for viral replication and infection 
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and replication. These include the reverse transcriptase (RT), integrase (IN), RNase H, 
and protease (PR) enzymes, the last of which is used to process the primary protein 
products such as the gag proteins [27, 28].  The env protein might be considered one of 
the most important structural proteins in terms of the study of HIV in the sense that it 
encodes the gp160 envelope protein which is the main determinant of HIV tropism and 
infectious capability. Cleaved by a host cell protease, gp160 is processed in the 
endoplasmic reticulum into two proteins, glycoprotein gp120 and transmembrane protein 
gp41, whose respective functions are for CD4 receptor binding and target cell 
attachment/fusion in HIV entry [27, 29]. The remaining genes encode both essential and 
accessory regulatory proteins which function to enhance viral reproduction (Table 1.1). 
These include the essential proteins, Tat and regulator of RNA splicing and transport 
(Rev), and the accessory proteins, Nef, Vpr, Vif, and virus protein U (Vpu) [27]. Of these, 
it is the viral protein Tat which, due to its significant role in HIV replication and widespread 
effects in various tissues, will be the focus of the work presented.  
 
Structurally, HIV Tat is a 14-15kDa protein which is generally expressed as either a 72-
amino acid protein encoded by only one exon, or a 86-101 amino acid protein encoded by 
Table 1.1 HIV gene products and functions 
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two exons; these differences are dependent on viral strain and play significant roles in HIV 
infectivity (Figure 1.3) [30].  In the early stages of infection, very low levels of RNA 
transcripts are made, allowing for small production of Tat protein. Despite the limited 
amount of Tat, it facilitates the rapid enhancement of viral replication. As such, it is one of 
the first proteins to be expressed after initial infection [31]. The approximately 10 amino 
acid basic domain of Tat, consisting of mostly arginine and lysine residues, binds to an 
RNA stem-loop structure near the 5’ long terminal repeat (LTR) region which is known as 
the trans-activation response element or TAR region [32, 33]. Binding to TAR activates 
the recruitment and interaction with a host protein complex named positive transcription 
elongation factor b (P-TEFb) which consists of cyclin-dependent kinase (CDK9) and cyclin 
T1 (CycT1). Tat also associates with RNA polymerase II complexes through CDK9 and it 
is through both of these interactions that allow Tat to increase the rate of whole-genome 
transcription and the production of full-length viral RNA [32, 34, 35]. Tat is often considered 
one of the most interesting viral proteins to study due to its multifaceted characteristics 
and functions. The basic domain of Tat is largely used for binding not only to TAR, but 
also various cell surface receptors which confer its pathogenicity [31, 36]. The RGD 
domain found in exon 2 has also been shown to bind integrin receptors to facilitate cellular 
entry [37]. Additionally, Tat contains a protein transduction domain which allows for its 
passage across plasma membranes into cells, as well as a nuclear localization signal 
which facilitates further translocation into the nucleus [31, 38]. Given that Tat is actively 
secreted by HIV infected cells [39, 40], these characteristics make the protein a menace 
not only to infected cells, but also to bystander cells within the environment. 
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1.3  HIV-Associated Neurological Disorders (HAND) 
The term “AIDS dementia complex” (ADC) was coined in 1987 by Navia and Price to 
describe complications affecting central and peripheral nervous systems in HIV-infected 
patients [41, 42]. Progressive encephalopathy from HIV infection in the brains of patients 
was detected and later called sub-acute encephalitis or HIV-encephalitis (HIVE), which is 
the main pathology recognized [43]. Following autopsy of HIV-infected patients’ brain 
tissue, inspection revealed perivascular macrophage and lymphocyte infiltration, 
multinucleated giant cells, myelin loss, and white matter astrogliosis [44-47]. As imaging 
techniques improve, earlier diagnostic techniques for brain abnormalities through non-
invasive imaging methods such as functional magnetic resonance imaging (fMRI), 
positron emission tomography (PET), and magnetic resonance spectroscopy (MRS) are 
gradually coming to the forefront [48]. AIDS dementia was associated with motor deficits 
and neurological impairments; however, the symptoms observed in patients were broad 
with varying levels of severity. As such, the term HIV-associated neurological disorders 
(HAND) was implemented to encompass the range of neurological deficits attributed to 
Figure 1.3 Functional domains of HIV Tat 
HIV Tat protein comprised of an N-terminal proline-rich domain, a cysteine-rich domain, a core, a 
basic domain (basic), and a glutamine-rich domain within the 1-72 amino acid exon 1. Full length 
HIV Tat includes a second exon with an RGD (Arg-Gly-Asp) domain and contains 101 amino acids.  
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HIV infection in the CNS. HAND is thought to be a consequence of HIVE with its 
characteristic inflammation leading to cognitive, motor, and behavioral impairments. 
Clinically, HAND is differentiated into three categories based upon severity: asymptomatic 
neurological impairment (ANI), mild neurological disorder (MND), and HIV-associated 
dementia (HAD) being the most severe [49]. With the advent of combined anti-retroviral 
therapy (cART), the prevalence of HAD has drastically decreased; however, occurrence 
of ANI and MND have remained steady [50]. The risk of HAND increases with age, as do 
other risk factors such as cardiovascular disease, co-infection with hepatitis C, and 
substance abuse [51]. There are varying effects of HIV infection in the CNS, depending 
on the cell type affected, which produce the characteristics of HAND (Figure 1.4). 
 
1.3.1 Microglial activation contributions to HAND 
Perivascular macrophages and microglia are the predominant actively infected cell types 
within the CNS and aid in viral persistence as a cellular reservoir for HIV [52-54]. As such, 
glial reactions to infection and uninfected bystanders putative contributors to the 
neurotoxicity and neuroinflammation in HAND [47]. Functionally, microglia survey the CNS 
environment and aid in the clearance of debris, accumulated proteins, or invading 
pathogens and are the primary source of inflammatory cytokines in the brain [55]. 
However, when infected by HIV, microglia facilitate the biogenesis, replication, and 
release of new virions while still producing proinflammatory cytokines such as IL-1β, IL-6, 
TNF-α, MCP-1 and IL-8 [56]. In addition to the production of virus, infected microglia 
secrete the viral protein Tat which is neurotoxic [57]. Tat mRNA, protein, and antibodies 
to Tat are detectable in the CNS of HIV-infected patients with higher levels observed in 
HAND [58-60]. Secretion of Tat into the cellular environment can propagate microglial 
activation and enhanced secretion of neurotoxic factors which may add to neuronal injury.  
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1.3.2 Astrocytic dysfunction in HAND 
Astrocytes are the most abundant cell type in the brain and serve to maintain an optimal 
microenvironment for neurons. The functions of astrocytes are varied including uptake of 
neurotransmitters, BBB maintenance, nutrient metabolism, growth factor secretion, and 
modulating synaptic transmission [61, 62]. The extent of astrocyte infection is controversial 
because the level of virion production is markedly less than microglia [63]. Post-mortem 
studies looking at astrocyte activation following HIV infection have detected the presence 
of early HIV proteins such as Nef, Gag, and Rev which support the concept of astrocytic 
infection [64]. Regardless, the effects of HIV on astrocytes include impairing BBB function, 
HIV Tat inducing the production of cytokines, chemokines, and activation of nitric oxide 
synthase [65-68]. TNF-α released by activated microglia and astrocytes inhibits glutamate 
uptake in astrocytes through excitatory amino acid receptors. The buildup of extracellular 
glutamate can subsequently lead to neuronal excitotoxicity [69, 70].  
 
1.3.3 Cumulative effect of HIV infection on neurons 
In general, it is not believed that neurons can support HIV infection or sustain replication 
despite the expression of cell-surface receptors such as CCR5 and CXCR4 [71]. However, 
it has been well documented that the presence of these receptors still render neurons 
susceptible to injury by viral proteins such as Tat and gp120 and by glial-derived 
inflammatory cytokines, which may explain neuronal damage observed in HAND [72, 73]. 
In addition, neurons are subject to the fluctuations of the brain environment due to HIV-
infection in other brain cells. As discussed above, microglia and astrocytes which are 
normally charged with the maintenance of homeostasis, can be dysfunctional upon HIV 
infection leading to the influx of inflammatory cytokines (IL-1β, IL-6) and accumulation of 
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normally non-toxic substances (nitric oxide, glutamate) leading to excitotoxicity and 
neuronal death.  For example, it has been shown that Tat and gp120 are able to interact 
with N-methyl-D-aspartate receptors (NMDARs) which propagate excitatory signal 
transmission from glutamate binding through regulation of ion (Ca2+, Na+, K+) flux. The 
direct binding of Tat or gp120 to NMDARs on human neurons may cause lethal influx of 
calcium ions [74, 75]. These viral proteins may have direct toxicity on neurons through 
Figure 1.4 Overview of the effects of HIV on the CNS 
HIV-infected monocytes and circulating virus cross the blood brain barrier to spread infection in the 
CNS. Infected macrophages and microglial cells release neurotoxic viral proteins that trigger 
astrocyte activation, which results in increased glutamate release and reduced glutamate uptake. 
Elevated extracellular glutamate levels cause neuronal ion imbalances that lead to aberrant 
synaptodendritic pruning and neuronal injury. Infection and viral protein presence lead to microglial 
activation and increased production of chemokines and cytokines and reactive oxygen species that 
contribute to neuronal injury. 
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pathways such as mitogen-activated protein kinase (MAPK) p38 signaling cascades 
leading to caspase activation and apoptosis [76, 77].  
 
1.4  Interlinked epidemics between HIV and opiate drug abuse 
The use of injection drugs is a significant risk factor to the acquisition and spread of HIV 
due to the sharing of needles [78]. Those HIV infected individuals who use opiates for the 
treatment of neuropathic pain are also at risk for the exacerbation ofsevere HAND. Drugs 
of abuse (morphine, cocaine, and methamphetamine) have been reported to compromise 
the immune system which when in combination with HIV, leads to an exacerbated immune 
depletion. Studies have reported that drug users tend to have increased risk for HIV 
infection, poor adherence to and efficacy of cART, and increase viral replication [79]. With 
respect to HAND, drug abusers show a dramatic increase in neuroinflammation, oxidative 
stress, alteration in BBB integrity, and frequency of HIVE [80, 81]. In addition, chronic 
exposure to opioids has been shown to worsen brain pathology, even in patients adhering 
to cART treatment, with symptoms of heightened CNS inflammation and increased 
cognitive deficits [82-84]. Clinically, patients chronically using opiates are found to have 
higher levels of microglial activation driving immune cell recruitment and 
neuroinflammation [85]. As such, the clinical characteristics of HIV infection in the brain 
can be accelerated and exacerbated by drug abuse [86].  
 
Morphine is an opiate derived from the Papaver somniferum or opium poppy with 
analgesic characteristics that act directly on the CNS [87]. Within the brain, morphine is 
glucuronidated through the phase II metabolic actions of UDP-glucuronosyl transferase-
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2B7. Of the metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide 
(M6G) (Figure 1.5; adapted from [88]), only M6G is able to bind to μ-opioid receptors 
(MORs) and have analgesic effects [89]. Structurally, morphine mimics endogenous 
opioids such as endorphins and binds as an agonist primarily to MORs located throughout 
the brain (with high densities in the caudate nucleus, putamen, hypothalamus and 
amygdala) and elsewhere [90, 91]. The three most well-known classifications of opioid 
receptor are the  (mu),  (kappa), and  (delta) receptors, with -opioid receptor (MOR) 
having the strongest affinity for morphine, the -opioid receptor (DOR) having a mild 
affinity, and the -opioid receptor (KOR) having little to no affinity [92, 93]. These opioid 
receptors are inhibitory G-coupled protein receptors (GPCRs) which respond to ligand 
binding by activating inhibitory (Gi) protein second messengers which inhibit the activity of 
adenylate cyclase and prevent cyclic AMP (cAMP) production. Reduced cAMP leads to 
opening of K+ channels while additional G proteins block influx of Ca2+ leading to 
hyperpolarization and reduced likelihood of an action potential. This quieting along pain 
sensory pathways ultimately leads to the sensation of pain relief or nociception depending 
Figure 1.5 Morphine metabolism 
Morphine is primarily metabolized in the liver by uridine-5’-diphosphate (UDP) 
glucuronosyltransferase and at nanomolar concentrations in the brain to morphine-3-glucuronide 
(M3G) and morphine-6-glucuronide (M6G). 
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on the receptor activated (Figure 1.6) [94]. MOR activation is also associated with reward 
pathways of the dopaminergic system which constitute the risk of opiate abuse [95]. The 
DOR may supplement MOR activity given that it can also affect reward pathways; 
however, it can only modulate existing MOR activity and as such, has less risk for 
addiction. The KOR counteracts MOR/KOR activity and has an anti-reward effect [96, 97]. 
It is important to note that studies have found activation of opioid receptors in immune 
cells to modulate inflammatory processes which likely contributes to neuroinflammation 
[98]. Though a “typical” opiate abuser would be considered as an individual who abuses 
heroin, an alternatively derived form of morphine, there is rising abuse of prescription 
opiates [62]. Chronic opiate abuse was reported to advance neurodegenerative changes 
in the CNS similar to Alzheimer’s disease (AD) from a clinical study in Edinburgh, UK [99]. 
As such, there is compelling evidence to investigate the interactions of HIV and opiate 
abuse in the context of HAND. 
Figure 1.6 Mechanisms of opioid receptor signaling 
Morphine binding to the opioid receptor causes dissociation of inhibitory G-proteins Gα and Gβγ 
subunits which subsequently act on effector proteins and channels. Agonist stimulation leads to 
Gα-mediated inhibition of cyclic adenosine monophosphate (cAMP) production and K+ channel 
opening. Gβγ subunit binding to Ca2+ channels cause channel closing leading to hyperpolarization 
of the cell. AC = adenylate cyclase. 
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In vitro studies with HIV/Tat and morphine have demonstrated how opioid exposure can 
play a key role in the enhanced pathogenesis of the virus within the CNS. As described 
earlier, HIV can show differing effects on the CNS depending on the cell type being 
targeted. Tight junction proteins such as ZO-1 and occludin are dysregulated when 
exposed to morphine alone or in combination with Tat indicative of BBB integrity 
compromise. This dysfunction was also associated with increases in intracellular Ca2+ 
within brain microvascular endothelial cells and increased transmigration across the BBB 
[81].  In striatal neurons, morphine has been presented to enhance HIV/Tat toxicity 
through caspase cascade mechanisms mediated specifically through opioid receptors 
[100, 101]. Later studies showed that while HIV/Tat exposure in combination with 
morphine may have inherent toxicity to neurons, the most harmful of neurotoxic effects of 
are mediated through the activation of MORs on glial cells [102]. It is suggested that MOR 
agonists are able to potentiate the expression of the HIV co-receptors CCR5 and CXCR4 
on peripheral and brain cells which facilitates viral entry [103]. Within infected glial cells 
such as microglia and astrocytes, HIV/Tat release triggers cytokine release, subsequent 
neuroinflammation, destabilizes intracellular ion homeostasis, and increases extracellular 
glutamate, ATP levels, and ROS/RNS which have all been shown to be modulated by 
morphine co-exposure [104-107].This disruption in glial utility culminates in reactive 
microglia and astrocytes which ultimately causes neuronal injury [54]. It is therefore clear 
that presence of HIV in the CNS has detrimental effects to normal function on numerous 
levels. In addition, the abuse of opioids potentiates this damage and hastens the 
acceleration to neurological impairment. Despite this knowledge, an underlying 
mechanism mediating this exacerbation remains unclear. Herein we provide evidence 
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supporting the autophagy pathway as a potentially significant facilitator of HIV and opioid 
induced neurodegeneration.  
 
1.5  Mechanisms of Autophagy  
The process of autophagy is an evolutionarily conserved, highly regulated pathway in 
which cytosolic material including superfluous and damaged organelles, cytosolic 
proteins, and invasive microbes are degraded and recycled for components. This pathway 
is present at basal levels within all cells and acts as a response to increases in cellular 
stress as a means of avoiding cell death and an alternative to the ubiquitin-proteasome 
system. The defining feature of autophagy is the formation of the double-membrane bound 
phagophore and autophagosome (Figure 2) which when visualized using electron 
microscopy, acts as the gold standard for verifying activity [108]. The actions of autophagy 
are dependent on the genes and their respective proteins which have been categorized 
from studies in Saccharomyces cerevisiae. The autophagy machinery (Table 1.2; adapted 
from [108]) consists of over 34 autophagy-related genes (ATG) which have been identified 
from genetic studies in yeast, most having eukaryotic homologs with high protein 
sequence identity [109, 110].  
 
The autophagy pathway can be divided into three morphological stages (Figure 2): 
induction, elongation and closure, and maturation. Induction is the first step in the pathway 
and is a consequence of a variety of signaling pathways acting on one of two targets, 
mammalian target of rapamycin (mTOR) and adenosine monophosphate activated protein 
kinase (AMPK). These protein kinases act as sensors for the cellular environment with 
AMPK being activated upon starvation conditions (and mTOR being inhibited) to directly 
modulate the phosphorylation of the unc-51-like kinase (ULK1/2) complex [111, 112].  
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Under nutrient-rich conditions, mTOR phosphorylates thus inhibiting the ULK1/2 and 
ATG13 complex activity which in turn disrupts the interaction between ULK1/2 and AMPK 
[113, 114]. Alternatively, when autophagy is induced under starvation, mTOR is freed from 
the complex, leading to the activation of ULK1/2 and phosphorylation of ATG 13 and 
RB1CC1 [115]. Once the ULK 1/2 complex has been activated and translocates to the site 
of autophagosome formation, vesicle nucleation occurs which is characterized by the 
recruitment of the class III phosphatidylinositol 3-kinase (PI3K) nucleation complex 
consisting of Beclin 1, catalytic subunit type 3 (PIK3C3) also called vacuolar protein sorting 
34 (Vps34), PIK3 regulatory subunit 4 (PIK3R4) also called vacuolar protein sorting 15 
(Vps15), activating molecule in BECN1 regulated autophagy protein 1 (AMBRA1), ATG14 
or ultraviolet radiation associated (UVRAG), and Bax-interacting factor 1 (BIF1; also 
known as SH3GLB1) [116]. Beclin 1 interacts with and is negatively regulated by the anti-
Table 1.2 Mammalian autophagic machinery involved in autophagosome formation 
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apoptotic proteins BCL-2 and BCL-XL at the endoplasmic reticulum [117]. The 
displacement of BCL-2 by BCL-2 homology 3 (BH3)-only proteins or phosphorylation by 
c-Jun N-terminal kinase (JNK) causes the PI3K nucleation complex to be recruited to the 
induction site at the endoplasmic reticulum where it is phosphorylated by ULK1 [118]. 
Formation of the PI3K complex activates the kinase functions of PIK3C3 to phosphorylate 
phosphatidylinositol yielding the signaling lipid phosphatidylinositol 3-phosphate (PI3P) 
which is required for the assembly of the phagophore membrane [119].  
 
The next step in the autophagy process is membrane elongation which uses two ubiquitin-
like conjugation systems, the ATG5-ATG12/ATG16 complex and the LC3 complex [120]. 
In complex with WIPI 1/2 are ATG2 and the transmembrane protein ATG9 which conducts 
a membrane cycling system between peripheral sites and the phagophore assembly site 
or pre-autophagosomal structure (PAS) [121]. Under nutrient rich conditions, ATG9A 
localizes to the trans-Golgi network as well as to late endosomes. ATG9-positive 
membranes are shuttled to the phagophore assembly site for growth of the 
autophagosome based upon the activity of ULK 1/2 [122, 123]. During this process of 
phagophore formation, the PI3P molecule recruits ubiquitin-like conjugation systems 
ATG5-ATG12/ATG16 complex and the LC3 complex [120]. ATG5-ATG12/ATG16 
complex assembly is initiated by ATG7 acting as an E1-like enzyme on ATG12 followed 
by ATG10, an E2-like enzyme, which conjugates ATG5 to ATG12. ATG16 is also recruited 
and the complex localizes to the autophagosome elongation site. The LC3 complex 
contains microtubule associated 1A/1B-light chain 3 (LC3) and GABA receptor-associated 
protein (GABARAP) in addition to ATG7, ATG3 (E2-like enzyme), and ATG4. ATG4 is a 
cysteine protease and upon activation, cleaves pro-LC3 at its C-terminal glycine [124-
126]. The membrane lipid phosphatidylethanolamine (PE) is then conjugated to the newly 
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cleaved soluble LC3-I by ATG7 and ATG3. This conjugation product of LC3-PE, now 
known as LC3-II, is subsequently incorporated into the inner and outer membranes of the 
autophagosome while it reaches closure [127]. The ATG5-ATG12/ATG16 complex also 
plays a role in the lipidation process of LC3 by acting as an E3-like ligase to enable LC3-
PE conjugation. Isolation membrane bound LC3-II acts as both a scaffolding protein and 
an anchor for the binding of autophagy adaptors which mediate selectivity [128].  
 
Before autophagic clearance, ubiquitin binding proteins such as the adaptor protein 
sequestosome 1 (p62/SQSTM1) are tethered to the ubiquitin-like proteins LC3 or 
GABARAP and regulate protein cargo degradation [128-130]. Structures which have been 
targeted for degradation through autophagy are often ubiquitinated and bind autophagy 
receptors containing ubiquitin-binding domains and LC3-interacting regions (LIR) to 
encourage the cargos engulfment into autophagosomes [130].   P62/SQSTM1 is a widely 
multifunctional adaptor protein which is involved with biological processes such as 
removal of toxic protein aggregates and is indispensable for basal autophagy [131, 132]. 
With the autophagosome now whole and carrying its cytosolic cargo, it undergoes 
maturation during which the induction and elongation complexes dissociate from the 
membrane and can be delivered via microtubules upon close proximity to the lysosome 
[133]. The fusion of the autophagosome with acidic endosomes and lysosomes to form 
autolysosomes is mediated through soluble NSF attachment protein receptors (SNAREs) 
[134]. Once fusion has occurred, captured cargo is degraded by acidic hydrolytic enzymes 
and proteases within the lysosome yielding macromolecule components which can be 
recycled for alternative use [108].   
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1.6  Importance of Beclin 1 in autophagy 
Given that autophagy is a largely complex process with a number of contributing proteins, 
it is important to determine which proteins may play the most significant roles. In particular, 
the studies of this dissertation focus on the initiation protein Beclin 1. The mammalian 
Beclin 1 is encoded by the BECN1 gene with the yeast equivalent being autophagy-related 
gene 6 (Atg6) [135]; it plays a central role in autophagy and is also described as a 
haploinsufficient tumor suppressor [136, 137]. Notably, Beclin 1 participates in various 
other signaling pathways such as endocytosis, phagocytosis, vacuolar protein sorting, and 
cytokinesis, independent of its role in autophagy [138]. As previously described, Beclin 1 
acts as a subunit within the PI3K complex during autophagy initiation to mediate the 
formation of phosphatidylinositol 3-phosphate [129]. Much of its functional significance lies 
in its many interacting partners which are generally associated with formation of 
autophagosomes or with endocytosis. The mammalian protein consists of three domains: 
a central coiled-coil domain (CCD), an evolutionarily conserved domain (ECD) and a BH3-
only domain (Figure 1.7 adapted from [138]). The CCD domain of Beclin 1 interacts with 
the CCD of UVRAG, a positive regulator of autophagy. This interaction allows Beclin 1 to 
act as a type scaffold protein to allow UVRAG contact with PI3K and other proteins, 
promoting starvation-independent autophagy [139]. The ECD of Beclin 1 is essential for 
binding another autophagy protein Vps34 as well as its tumor suppressing functions [140]. 
The BH3-only domain ties Beclin 1 to the BCL-2 family of proteins which are pro-survival 
in function and sense cell damage or dysfunction. This domain interacts with the BH3 
domains on BCL-2 and BCL-XL and inhibit autophagy by blocking Beclin 1 interaction with 
PI3K; however, this interaction is largely diminished upon starvation [141]. Nutrient 
starvation, which induces autophagy, can stimulate the dissociation of Beclin 1 from its 
inhibitors, either by activating BH3-only proteins or by phosphorylation of BCL-2 that may 
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reduce its affinity for Beclin 1 and BH3-only proteins. As such, anti-apoptotic BCL-2 family 
members and pro-apoptotic BH3-only proteins may participate in the inhibition and 
induction of autophagy, respectively Despite being a BH3-only protein which are pro-
apoptotic, Beclin 1 is considered to be pro-survival [142]. Studies with Beclin 1 mutants 
have displayed the importance of the protein to numerous processes, particularly 
embryonic development, tumorigenesis, and protein aggregation diseases. Where 
homozygous beclin1-/- mice die early in embryogenesis, heterozygous beclin1+/- mice have 
not only decreased autophagy, but also increased incidence of spontaneous tumors [136, 
137].  
 
1.7  Functions of Autophagy 
1.7.1 Autophagy and basal metabolism and homeostasis  
The autophagy process can be described as either non-selective or selective dependent 
on the cargo being taken up: non-selective being used for the turnover of bulk cytoplasm 
and selective autophagy targeting specific organelles such as mitochondria (mitophagy), 
peroxisomes (pexophagy), or clearance of microbes (xenophagy) [108]. The basal 
Figure 1.7 Functional domains of the autophagy protein Beclin 1 
Beclin 1 contains distinct functional domains: BH3 interacting domain, coiled-coil domain, nuclear 
export signal, and evolutionarily conserved domain. Adapted from [138]  
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functions of autophagy serve to enhance cellular survival by adapting to fluctuations in 
nutrient conditions as well as to regulate cellular energy homeostasis. In the process, the 
pool of cellular precursors is replenished by degrading cytosolic proteins in response to 
starvation and nutrient depletion [143]. These catabolic products include amino acids, 
lipids, and sugars to be utilized for generation of new proteins, membranes, 
gluconeogenesis, ATP, nucleotide and carbohydrate synthesis, and glycolysis [144]. In 
the liver, amino acids generated through autophagy can be used for gluconeogenesis to 
maintain systemic glycemia under starvation conditions while autophagic degradation of 
liver lipid droplets also produced free fatty acids from triglycerides [145, 146].  ATP can 
also be generated by way of newly produced lipids and amino acids entering the 
tricarboxylic acid cycle and oxidative phosphorylation or through sugars undergoing 
glycolysis which also maintains sugar levels [144]. However, these functions can be 
abused in disease conditions such as cancer. Due to their rapid replicative characteristics, 
tumor cells exhibit metabolic stress additionally caused by decreased nutrient availability 
and hypoxic conditions. To counteract these stressors, tumors and their surrounding 
fibroblasts couple and reprogram their metabolism to use autophagy as a protector by 
reducing oxidative stress and maintaining genomic stability [147]. Additionally, the 
breakdown of glutamine in cancer cells yields ammonia which has been shown to also 
stimulate autophagy in nearby cells [148]. Metabolic coupling has also been seen under 
normal conditions in the brain where astrocytes and neurons exchange metabolites to 
maintain homeostasis [149, 150]. As research in autophagy has expanded, other functions 
have emerged beyond maintaining cellular homeostasis including the maintenance of 
mitochondria, cell differentiation and development, monitoring of unfolded proteins, 
protein secretion, and the trafficking of proteins to the plasma membrane [151-153].  
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Autophagy can be induced as a response to cellular stress from external stimuli such as 
oxidants, hypoxia, infectious agents, and stressors of the endoplasmic reticulum [154]. 
The degradative capabilities of autophagy are particularly important for the clearance of 
damaged and/or aggregated proteins and organelles, especially in situations where the 
proteasome clearance pathway has been impaired or overwhelmed [155, 156]. Genetic 
studies with mice have shown the importance of autophagic intracellular quality control of 
proteins. Deletion of autophagy genes such as Atg5 or Atg7 in the mouse liver induced 
the cytoplasmic accumulation of abnormal ubiquitinated proteins and organelles [157, 
158]. In addition, liver-specific Atg7-/- mice have been shown to develop hepatomegaly 
and hepatic failure illustrating the crucial role of autophagy in locations of high protein 
turnover such as the liver.  Ubiquitin accumulation has also been reported in other tissues 
such as some endocrine glands, the heart, skeletal muscle, and kidneys; however, to a 
lesser degree [158, 159]. 
 
1.7.2 Autophagy in apoptosis induction 
Outside of the pro-survival functions of autophagy, there are correlations to the induction 
of apoptosis which are not completely understood. Studies have observed an 
accumulation of autophagosomes preceding cell death which was originally termed 
autophagic cell death [160]. However, studies have been varied with autophagy being able 
to act as both a protagonist and antagonist of apoptosis, largely dependent on the cellular 
context and environment. Many links between apoptotic signaling and autophagy lie in the 
crosstalk between pro-apoptotic signals which can induce autophagy as well as the 
binding of Beclin 1 to pro-survival protein BCL-2 [141, 161]. Studies on mice lacking the 
BH3 proteins BAK and BAX which regulate the release of mitochondrial proteins during 
apoptosis demonstrated that upon exposure to DNA damaging stimuli, cell were still able 
24 
to die through autophagic cell death mediated by ATG5 and Beclin 1 [162]. In fact, a 
number of the ATG genes which regulate autophagy also regulate apoptosis regulators 
such as p53 and the death inducing signaling complex (DISC) [163]. Under normal 
conditions, autophagy plays several maintenance roles in a variety of tissues; however, 
as research in the topic expands, its roles in disease states are gradually coming to light. 
The formation and accumulation of protein aggregates has been associated with several 
human diseases known as conformational diseases or proteopathies. In these diseases, 
a particular protein may be misfolded as a result of mutation, improper clearance through 
either the proteasome or autophagy pathways, or defective chaperones [155]. These 
misfolded proteins tend to form aggregates leading to cellular dysfunction in organs such 
as the lungs, liver and brain [156]. 
 
1.7.3 Autophagy in infectious diseases 
The roles of autophagy in the adaptive and innate immune systems have been extensively 
studied over recent years with functions including the clearance of pathogens, facilitation 
of antigen presentation, and regulation of the inflammatory response [164, 165]. In 
particular, the clearance of potentially threatening intracellular pathogens through 
autophagy called xenophagy, acts as an additional defense mechanism [166]. While 
pathogens such as bacteria Mycobacterium tuberculosis and Pseudomonas aeruginosa 
and viruses like herpes simplex virus type 1 (HSV-1) are identifiable as substrates for 
autophagic clearance, a number of pathogens have evolved mechanisms of evasion to 
avoid degradation or manipulation to support growth such as HIV and hepatitis B and C 
viruses [164]. In addition to direct action on invading pathogens, autophagy can also 
regulate inflammation through signaling cascades of the inflammasome within myeloid 
cells of the innate immune system. This can result in modulation of cytokines such as IL1β, 
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IL-18, and IFNγ, activation of natural killer cells, and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) signaling [167]. Though stimulation of autophagy 
may not be required for degradation, these cascades may be initiated by their targeting to 
the autophagosomes formed by basal autophagy. The contribution of autophagy to the 
functions of immune cells is widely dependent on cell type due to varying levels of basal 
autophagy; however, it is of particular importance to antigen-presenting cells which have 
the highest levels of basal autophagy [168]. Regardless, in most immune cells, autophagy 
aids in cellular survival by avoiding apoptotic or inflammasome activated pyroptotic 
mechanisms through the mounting of a strong autophagic response [169, 170].     
 
Despite the role of autophagy in immunity and pathogen clearance, the pathway’s 
interactions with HIV are complex due to the variety of cells affected which may or may 
not be infected. Dendritic cells, for example, have drastic downregulation of autophagy 
when exposed to viral envelope proteins by activating mTOR which results in protection 
of the virus from autophagy-mediated degradation and subsequent increase in CD4+ T 
cell infection [171]. This study also showed that inhibition of autophagy can impair toll-like 
receptor (TLR) mediated innate responses, affect antigen processing, as well as MHC 
class II antigen presentation to CD4+ T cells.  Studies with macrophages infected with HIV 
show an increased level of autophagic vacuoles and lack the viral envelope protein-
mediated manipulation of the autophagy pathway [23]. Further mechanistic studies 
showed that despite the preservation of the initial stages of autophagy in HIV-infected 
macrophages, the autophagosome maturation process is inhibited by the HIV viral protein 
Nef [16]. This protein which assists in viral replication has been shown to interact with 
Beclin 1 which inhibits the maturation stages of autophagy and prevents lysosomal 
degradation of HIV while promoting biogenesis thereby enhancing viral yields. Conversely, 
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uninfected macrophages do not show envelope protein induction of autophagy but are 
instead affected by Tat to activate Src-AKT and STAT3 or suppress STAT1 (through IFNγ 
inhibition) pathways to culminate in autophagy repression [172, 173]. Since macrophages 
are generally not susceptible to HIV mediated cell death, autophagy can also play a role 
in the promotion of macrophage viral reservoirs [3]. 
 
CD4+ T cells can have slightly different responses to HIV infection and thus different 
effects on autophagy which makes many studies inconclusive. Many CD4+ T cells appear 
to remain uninfected yet still die through what is termed bystander T cell death which is 
thought to be mediated by the host’s responses to viral infection leading to chronic 
inflammation [6, 174]. When uninfected bystander T cells were co-cultured with cells stably 
expressing either R5- or X4-tropic envelope proteins, they tended to favor undergoing 
apoptosis and accumulation of autophagic vacuoles; however, when productively infected 
with R5- or X4-tropic HIV, these T cells had diminished accumulation of autophagic 
vacuoles [23, 175]. It is necessary to note that the study does not distinguish the cause of 
autophagic vacuole accumulation between autophagy induction or defects in autophagic 
maturation, so the precise cause of apoptosis is yet to be determined. Nevertheless, this 
supports the idea that the virus has evolved mechanisms to evade the antiviral functions 
of autophagy [176]. For example, in infected T-cells the viral protein Vif is able to block 
envelope protein induced autophagy typically seen in bystander T cells to prevent the 
autophagic degradation of Tat and allow productive infection [177, 178]. At the clinical 
level, in peripheral blood mononuclear cells (PBMCs) of HIV-infected persons termed HIV 
controllers i.e. those who remain asymptomatic for many years or have viremia below 
detection limits, have a significant increase in autophagic vacuoles with elevated mRNA 
levels of Beclin 1, as compared to normal progressors [179]. Though the interactions 
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between HIV pathogenesis and the autophagy pathway within the periphery may be 
complex, it provides a foundation for the study of the role of autophagy in HIV infection 
within the brain and the pathogenesis of HAND.   
 
1.8  Autophagy and Neurodegeneration  
Several neurodegenerative diseases have been shown to have dysregulations in the 
autophagy pathway [180]. Although autophagy is not induced in the central nervous 
system under starvation conditions, it plays a significant role in protein quality control 
maintenance and cellular homeostasis [181].  In general, autophagic activity within the 
brain is low but the conservation of basal autophagy is particularly essential to the CNS in 
the case of neurons owing to the fact that they are post-mitotic and rely heavily on 
clearance mechanisms such as autophagy for cell survival [182]. The ability of neurons to 
survey cellular contents for altered proteins or damaged organelles and process their 
degradation is essential to the prevention of intracellular buildup and eventual 
neurotoxicity [183]. Neural specific Atg5 and Atg7 knockout mice show accumulation of 
abnormal ubiquitinated proteins within neurons along with neurodegeneration and 
progressive motor deficits [158, 184]. Development of molecular probes such as LC3-
tandem sensors, and tracking methods such as lysotracker in combination with 
pharmacological inhibitors have allowed for the identification and better understanding of 
the individual stages being affected in diverse neurodegenerative disease. These include 
defects in autophagy induction, enhancement of autophagy repression, alterations in 
cargo recognition, inefficient autophagosome/lysosome fusion, or faulty degradation of the 
autophagic content within the lysosomes [180]. Comprehending when and where the 
autophagic halt is occurring in these neurodegenerative diseases is essential for the 
targeting of the autophagy pathway in potential therapeutics. Presently, the best studied 
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examples of proteopathies include two of the major neurodegenerative diseases: 
Alzheimer’s (AD) and Parkinson’s (PD) disease both of which have correlates to 
malfunctions in autophagy.   Genetic studies using mice with defective autophagy proteins 
have shown age-dependent neurodegeneration coinciding with the accumulation of 
protein aggregates [184]. In addition, the use of pharmacological agents which induce 
autophagy have been shown to inhibit symptoms associated with neurodegeneration in 
mouse models of AD and PD [155].Given that autophagy is found to be altered in a number 
of the ‘classical’ neurodegenerative diseases, it’s roles in other neurological disorders is 
of interest for study. 
 
1.9  Autophagy in HAND  
In terms of HAND, dysregulation of autophagy has been shown in the CNS in a number 
of studies. When the post-mortem brains of patients showing HIVE were analyzed for 
fluctuations in autophagy proteins, ATG5, ATG7, Beclin 1, and LC3-II were found to be 
increased as compared to non-HIVE tissue samples which showed no change in 
autophagy level. The same study also showed an increased number of autophagosomes 
and lysosomes indicative of autophagic blockade prior to degradation [185]. Later studies 
suggest that these characteristics are age dependent with aged HIVE patients showing 
more extensive neurodegeneration and reduced autophagy as compared to younger HIVE 
patients which showed increased autophagy markers [186]. Dever et al also demonstrated 
the changes to ATG gene expression in post-mortem brain tissues of HIV infected patients 
presenting with or without neurocognitive impairment (NCI) or encephalitis and suggested 
that these genes may be differentially regulated at the mRNA or protein level within the 
brain based on infection stage [187].  
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In neuronal cultures, exposure to HIV lead to increase of autophagosomes and 
suppression of autophagy [188]. Other studies also showed a decrease in neuronal 
autophagy when exposed to the supernatant of infected microglia indicating the indirect 
neurotoxicity neurons are subjected to [187, 189, 190]. When exposed to Tat, there was 
a dose dependent decrease in the autophagosome markers LC3-II and p62/SQSTM1 in 
neurons suggesting Tat increases autophagic degradation which when unchecked, can 
lead to autophagic cell death [191]. The same study saw in Tat transgenic mice, Tat 
expression caused an increase in autophagosome accumulation within neurons along 
with neurodegeneration which was largely associated with lysosomal-associated 
membrane protein 2A (LAMP2A).  
 
The autophagy pathway has been shown to be induced in microglia when infected by HIV 
with increased conversion of LC3-1 to LC3-II and increased expression of Beclin 1 and 
ATG5. This was also associated with accumulation of autophagosomes and increases in 
cytokines and chemokines [192]. Induction of autophagy has also been shown upon Tat 
treatment in glial cells by increasing the anti-apoptotic/pro-autophagic factor BCL2-
associated athanogene 3 (BAG3) levels [193]. While autophagy induction might seem 
beneficial, HIV has evolved ways to block the maturation of the pathway to prevent 
lysosomal degradation. For example, the viral protein Nef was shown to mimic the fusion 
inhibitor bafilomycin A1 and prevent autophagic degradation which can ultimately lead to 
increased viral presence [194]. This induction and later blockade has also been shown in 
astrocytes [188]. Given these results, it can be said that the role of autophagy in HAND is 
a complicated one with effects being cell type dependent and specific to particular stages 
of the autophagy pathway. 
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1.10  Interplay between HAND, opiates, and autophagy 
While the characteristics of HAND and the opiate induced exacerbation of its 
neuropathology have been widely studied and reviewed, the underlying mechanisms 
which lead to these effects are still unclear. Based on the interactions between HIV and 
autophagy previously discussed, it is possible that the degradative pathway converges on 
the HIV and opiate interaction. Despite limited literature on the interactions of autophagy 
and morphine, studies have seen that chronic morphine or morphine addiction activates 
the autophagy pathway in rodent hippocampus [195, 196]. In these studies, chronic 
morphine treatment was associated with cell death and decreased mitochondrial DNA 
copy number which were mediated by autophagy. A separate study showed that morphine 
was able to magnify LPS-induced initiation of autophagy; however, similarly to what is 
seen in HIV, the later stages of autophagosomal maturation are halted thus inhibiting 
pathogen clearance [197]. This was also shown in neurons which were exposed to the 
supernatant of HIV infected microglia treated with morphine resulting in a significant 
elevation of p62/SQSTM1 expression suggesting the inhibition of autophagic clearance 
[187].  Taken together, if the morphine inducing effects on autophagy parallel the induction 
of autophagy though HIV infection, this may explain the phenomenon of opiate and HIV 
interaction while providing the autophagy pathway as an underlying mechanism and 
potential target for intervention.  
 
1.11  Modeling HAND in mice 
In the efforts to further study the mechanisms and pathology of HAND, one of the most 
useful tools has been the use of animal models. Non-human primate models of HAND 
have been utilized to understand the neuropathogenesis of HAND; however, there are 
limits to gaining mechanistic insight into HAND as well as high cost for maintaining these 
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animals. Alternatively, rodent models have been shown to be highly useful in the study of 
HAND for their low cost, ease of use, and capability for genetic manipulation in the 
understanding pathological mechanisms at work.  
 
1.11.1 Transgenic mouse models 
The generation of transgenic mouse models have provided a wealth of information on the 
roles of HIV genes and their corresponding gene product functions in mediating HAND 
pathogenesis. Often these mice possess either constitutive or inducible expression of HIV 
proteins allowing researchers to study the effects of continuous exposure to viral proteins. 
This can be seen as representative of patients under cART regimen which have systemic 
viral replication under control but still have the production of viral proteins from viral DNA 
integrated cells or viral reservoir locations such as the brain [198]. Most cART drugs target 
the protease or reverse transcriptase actions of HIV and do not prevent the early 
production of viral proteins such as Tat, Rev, and Nef [7]. 
 
(a) Tat transgenic mouse model 
Tat transgenic mouse models were established by Jones et al shortly after the effects of 
intraventricular injection of human HIV Tat into mice brains led to inflammation, gliosis and 
apoptosis [199]. In human infection, Tat is the first viral protein to be secreted and is largely 
able to cross cell membranes with studies of its effects being tissue specific. In the early 
studies, transgenic mice with constitutive expression of Tat in most peripheral tissues 
showed elevated levels of Tat in serum; however, these studies were unable to detect Tat 
in the brain and lacked neurological impairment [200-203].  Subsequently, two brain-
specific Tat transgenic mouse models were generated from independent labs which 
placed Tat expression under the control of a glial fibrillary acidic protein (GFAP) promoter 
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which could be induced in astrocytes by doxycycline administration and showed 
neurological abnormalities [204, 205]. The GFAP-Tat transgenic mouse generated by Kim 
et al showed damage induced by Tat expression to be largely localized to the cerebellum 
and cortex [205]. The damage induced by Tat expression in the Fitting et al. study was 
more understated with observations of reduced neuronal spine density and dendritic 
pruning [204]. Later studies also showed deficits in learning and memory accompanied 
with synaptic dysfunction and suppression of long-term potentiation [206, 207]. In addition, 
Tat transgenic mice have been used to study blood brain barrier integrity and show barrier 
destabilization along with immune cell recruitment [208].  In the context of opioids, HIV Tat 
transgenic mice administered morphine showed not only an alteration in analgesic 
efficacy, but also increases in microglial and astroglial activation [100, 102, 209]. In 
addition, Tat transgenic mice treated with morphine revealed significant decreases in the 
density of dendritic spines within the striatum [204]. 
 
(b) Gp120 transgenic mouse model 
The envelope protein gp120 is shed as a soluble protein in the brain by macrophages and 
astrocytes which can also interact with and cause damage to neurons. The desire to 
understand its role in mediating neurotoxicity led to the generation of two distinct 
transgenic mouse models which expressed the gp120 encoded section of the env gene 
under control of a promoter [210, 211]. The Berrada strain expressed viral gp160 under 
the promoter control of human neurofilament light chain (NfL) in neurons within the brain 
stem and anterior horns of the spinal cords in addition to exhibiting dendritic swellings on 
motor neurons. However, this strain showed no expression to be detected within the 
cerebral cortex [211]. The Toggas strain has been well studied and expresses soluble 
gp120 in the brain under control of the astrocyte specific GFAP promoter. Gp120-
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transgenic mice illustrated the protein’s neurotoxic effects with pathological damage to the 
neocortex and hippocampus which was strikingly similar to that seen in human AIDS 
brains [210]. These mice displayed decreased synaptic and dendritic density, neuronal 
loss, as well as microglial activation. Additional studies have shown that these mice have 
dysfunctional differentiation and proliferation of neural progenitor cells, abnormal short- 
and long-term potentiation, and deficits in spatial retention and swimming velocity [212-
215]. Neuronal injury in these models have been suggested to be mediated by the 
enhancement of glutamate signaling through NMDARs and excessive activation of Ca2+ 
signaling pathways [216, 217].  
 
(c) Transgenic rat model 
As an alternative and more comprehensive means of studying the effects of viral proteins 
on the brain, the HIV transgenic model was generated which incorporates the HIV genome 
directly into the rodent model. These rodents express all but 2 of the 9 HIV viral genes 
(gag and pol) which in turn render them non-infectious and useful for mechanistic studies 
of viral protein effects [218]. The non-infectious pro-virus pEVd1443 was first used to 
generate an HIV transgenic mouse; however, these mice had inconsistent distribution of 
the transgene, inefficient tat transactivation, and limited clinical manifestation typical of 
HIV exposure [35, 219, 220]. Later, the pro-virus was introduced into the fertilized egg of 
F344 and Sprague Dawley bred rats with the transgene being incorporated hemizygously 
[35, 220]. Despite no viral replication within these rats, the HIV viral proteins are 
continuously expressed throughout the life of the animals within a number of tissues 
including the lymph nodes, spleen, and brain [221]. Studies utilizing this model have 
reported alterations in sensorimotor gating, cognition, dopamine function, and 
neuroinflammation with marked decrease in specific brain areas such as the subcortex 
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[221-223]. In terms of substance abuse, studies with morphine have suggested that HIV 
transgenic rats exhibit higher anti-nociceptive effects than normal controls in conjunction 
with elevated expression of mu-opioid and chemokine receptors which can in turn be 
modulated by cytokines [224, 225]. Later studies also showed an elevation of MOR 
expression in HIV transgenic mice which was further elevated under LPS-induced immune 
challenge [226].  
 
1.11.2 Humanized mouse models  
Humanized mouse models for the study of HIV have been generated using 
immunodeficient mouse strains such as severe combined immunodeficiency (SCID) mice. 
These mice lack T and B lymphocytes and are incapable of mounting regular adaptive 
immune responses. As such, it is possible to directly inject HIV-infected human monocytes 
into the CNS of these immunocompromised mice [227]. Following stereotaxic injection 
into the basal ganglia [228], putamen or cortex [229], infected macrophages are able to 
express HIV p24 antigen as well as present the histopathological features of HIVE [229]. 
This includes infection of perivascular macrophages, astrocytosis, microglial activation, 
neuronal apoptosis, and dendritic damage [230]. These mice have also been used to study 
potential therapeutics for treating HIV-associated neuroinflammation. Additional 
humanized mouse models have also been proposed for further study of the physiological 
effects of HIV. The humanized immune system or HIS model uses immunodeficient mouse 
strains such as the NOD/Shi-scid IL2rγ-/- (NOG), NOD/LtSz-scid IL2rγ-/- (NSG), or 
BALB/cRag2-/-γc-/- (BRG), all of which show defects in innate and adaptive immunity, and 
intravenously injecting CD34+ hematopoietic stem cells [231-233]. These cells mature into 
human immune cells which can later be infected with HIV and sustain infection; however, 
these models do not contain HIV-infected microglia or astrocytes. Jaeger and Nath 
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proposed a HIS-CNS model which suggests transplantation of both the human immune 
system and HIV-permissive cells of the human brain [227]. This would allow for the study 
of concurrent peripheral and CNS HIV-1 infection as well as the neuropathological 
characteristics of HAND. Studies which injected CD34+ hematopoietic stem cells into the 
brain were able to observe marked neuroinflammation, HIV replication in human 
mononuclear phagocytes, as well as encephalitis. Separately, NSG mouse transplantation 
with fetal brain cell cultures showed inclusion of human microglia in NSG mice [234]. 
 
1.11.3 Direct viral-injection models 
(a) EcoHIV 
An alternative approach to studying the effects of HIV was to modify the virus rather than 
the murine hosts. Previous studies which used human HIV co-receptors in mice failed to 
have efficient viral binding to either CCR5 or CXCR4 receptors and were poorly 
susceptible to HIV infection[235]. In the EcoHIV chimera virus, the gp120 coding region of 
HIV virus is replaced with the gp80 coding region of the murine leukemia virus [236]. This 
modified virus was selective to rodents and found to productively infect peripheral murine 
lymphocytes. These studies; however, showed limited detection in the brain following 
intraperitoneal injection of virus. Separately, Jones et al showed that as early as two-
weeks post infection, EcoHIV was able to alter BBB permeability [237]. Despite this 
apparent discrepancy, direct administration of virus into the brain by intracranial injection 
is a viable means of using EcoHIV to study the neurological effects of HIV and show robust 
HIV expression [238]. 
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(b) Viral protein injection 
In favor of determining the roles of individual viral proteins, direct injections of viral proteins 
into mice have been widely utilized [199, 239-241]. Direct injection of viral proteins into the 
CNS allows for uniform exposure without potential confounders such as the degree of 
doxycycline induction and effects associated with individual viral proteins. Neurotoxic 
responses following injection is rapid while also available to test targets which may 
ameliorate or exacerbate effects. For example, numerous studies have used direct 
injection of HIV Tat in conjunction with drugs of abuse to survey concurrent effects [241-
244]. Alternatively, parallel or subsequent exposure to potential therapeutic agents and 
whether they can ameliorate neurodegenerative effects are an additional benefit of the 
direct injection models.  
 
1.12  Potential applications and conclusions 
As investigation occurs into the mechanisms of HIV and opioid-induced 
neurodegeneration, the models for study have also expanded. In terms of studying the 
autophagy pathway, there are numerous means of examining its role in mediating HAND 
using the plentiful rodent models available. For example, to study how the autophagy 
pathway functions to mediate the direct effects of HIV/viral proteins, there are a number 
of autophagy-deficient mouse models available which can be combined with the direct 
injection method of HAND induction (Figure 1.8a) [136, 158, 184, 245]. This method of 
study allows for acute study of effects in the context of an autophagy deficient 
environment. The various existing autophagy models have mutations in varying stages of 
the pathway and can thus be used to determine the relative temporal importance in the 
autophagy/HIV interaction. A potential alternative approach would be to utilize both an 
autophagy-deficient mouse model and a viral protein/HIV transgenic mouse to create a 
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chimera which could have viral protein expression induced in an autophagy-deficient 
background (Figure 1.8b). Both models are capable of being used in conjunction with 
exposure to opioids by either subcutaneous morphine pellet or intraperitoneal injection for 
the study of HAND in the context of opioid abuse. The autophagy pathway poses an 
appealing target for ameliorating the effects of HAND in the opioid-abusing HIV-infected 
population. In addition, the humanized mouse models allow for the examination of 
potential therapeutics targeting the autophagy pathway with pharmacological inducers 
and inhibitors and the evaluation translational relevance which are the ultimate goal of 
these studies. The next steps in the field to determine how autophagy can be modulated 
to ameliorate the symptoms characteristic of HAND may lie in the pharmacological 
inhibition of specific stages in the pathway. For example, treatment of Tat-transgenic mice 
with the autophagy inducer rapamycin was able to reverse autophagosome accumulation 
and neurodegeneration [191]. Other avenues of treatment could include the use of siRNA 
Figure 1.8 Various mouse models which can be used to study autophagy in HAND 
pathogenesis 
(A.) Direct injection of neurotoxic viral proteins such as Tat or gp120 or the mouse-permissive 
chimera virus EcoHIV can be utilized to assess autophagy proteins which may contribute to 
neuropathogenesis. The stars (*) indicate the models used here with the viral protein Tat and the 
Beclin 1+/- mouse model. (B.) An alternate method to study autophagy protein contributions to HIV 
pathogenesis may generated by crossing inducible HIV-1 protein transgenic mice with autophagy-
protein-deficient mice creating a chimera. Both models can be used in combination with morphine 
co-exposure.  
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targeted towards autophagy proteins. Silencing of Beclin 1 in microglia and astrocytes was 
able to reduce inflammation as well as viral replication, making an attractive target for 
therapy [192, 246]. Based on this, the use of siRNA targeting Beclin 1 has been coupled 
to 1.) the guided drug delivery system of magneto-electric nanoparticles (MENPs), where 
is was able to cross the blood brain barrier without toxic effects [247] and 2.) a 
biodegradable linear polymer cationic polyethylenimine (PEI) complex for intranasal 
delivery to the brain. The realm of HAND and the mechanisms determining its 
pathogenesis are still not clear; however, the autophagy pathway is an up and coming 
facet showing great promise for future innovation. Furthermore, the established 
background provides the groundwork for the aims of this dissertation and advancing the 
understanding of HIV and opiate-induced neuropathogenesis.  
 
1.13 Dissertation hypothesis and specific aims 
Based on the existing literature presented in the previous chapter, HIV and opiate-induced 
neuropathogenesis is a relevant and significant burden. Our lab and others have shown 
the interactive effects of the HIV protein Tat and morphine in brain cells such as microglia 
and astrocytes to facilitate neuroinflammation and oxidative stress [79, 106]; however, the 
mechanisms at play are still widely unknown. Here we propose that the autophagy 
pathway, which is associated with HIV replication and persistence, may be a significant 
contributor to the virally-induced neuroinflammation and neuronal damage observed with 
HIV Tat and morphine co-exposure. In addition, previous in vitro data from our lab using 
human microglia treated with HIV-1 and morphine has shown induction of the autophagic 
pathway as well as accumulation of autophagosomes indicative of a halt in autophagic 
clearance [192]. When a key initiator of autophagy Beclin-1 was silenced using siRNA, 
there was a reduction of both HIV-1 replication in human microglia and astrocytes as well 
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as in the HIV-1 induced inflammatory response. These data suggest that induction of the 
autophagy pathway may serve as a mechanism mediating the damaging interactive 
effects of HIV Tat and morphine within the brain and that targeting of this pathway can be 
utilized to attenuate these effects. Given these findings, we hypothesize that by reducing 
the expression of the autophagy protein Beclin 1, the neurodegenerative effects of Tat 
and morphine exposure can be ameliorated at both the cellular and animal level. 
 
These hypotheses will be addressed in the experiments of the following Specific Aims: 
Specific Aim 1: To confirm if Tat and opiate-induced inflammation in astrocytes and 
microglia (glia) are mediated by the autophagy pathway 
These experiments assessed various aspects of glial dysfunction including 
neuroinflammation, oxidative stress, and calcium accumulation as a function of Tat and 
morphine treatment to mixed glial cell cultures (microglia and astrocytes) obtained from 
the striatum of wild type C57BL/6J and Beclin 1+/- (Becn1+/-) deficient mice. These mutant 
mice are heterozygous for the Becn1 allele and show expression compared to C57BL/6J 
littermates. 
 
Specific Aim 2: To examine the roles of autophagy in neuronal outcome upon Tat 
and opiate treatment 
Provided that neurons are the cell type ultimately affected by the disruption of homeostasis 
in the brain caused by HIV-1 infection, the cytoprotective or cytotoxic role of autophagy on 
neuronal damage, survival, and toxicity were gauged with respect to Tat and morphine 
exposure utilizing embryonically-derived neurons of C57BL/6J and Becn1+/- mice. 
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Specific Aim 3: To determine whether the in vitro observations seen in Specific 
Aims 1 and 2 translate to behavioral modifications and brain pathology in vivo seen 
in HIV-associated neurological impairment.  
C57BL/6J and Becn1+/- mice were exposed to intra-striatal Tat injections alone or in 
combination with subcutaneous morphine pellet implantation to evaluate effects on motor 
coordination and brain histology. 
 
We anticipate that this study will reveal what function, if any, the Beclin 1-dependent 
autophagy pathway plays in directly mediating the Tat and morphine neurodegenerative 
interactions within the murine brain which can then be modulated pharmacologically. 
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CHAPTER 2: CRITICAL ROLE OF BECLIN 1 IN HIV TAT AND MORPHINE-INDUCED 
GLIAL DYSFUNCTION 
Parts of this chapter appear in the Journal of Neuroimmune Pharmacology. 2018 May 11. 
doi: 10.1007/s11481-018-9788-3.  
 
2.1  Introduction 
HIV neuropathogenesis can be attributed to not only the propagation of infection in the 
brain, but also to viral proteins being secreted by infected cells that can also cause 
neurotoxicity. HIV Tat protein, responsible for regulating the initiation of HIV transcription 
and elongation, is released from HIV-infected cells and has been found to be neurotoxic 
independent of virus [57, 248]. The release of Tat contributes to the microglial-derived 
release of reactive oxygen species (ROS), nitric oxide (NO), calcium overload, and 
initiation inflammatory cascades, all of which impede neuronal survival [7, 249-252]. Other 
proteins within the HIV genome including Nef, gp120, Rev, Vpr and Vif also show varying 
effects on the brain and influence neurotoxicity through means of oxidative stress, 
secretion of pro-inflammatory molecules, and induction of apoptosis [7, 56]. Drugs of 
abuse such as opiates are known to increase risk of exposure to HIV infection and 
influence the progression to AIDS. IDU become highly susceptible to HIV not only because 
of shared contaminated needles but also due to opiate induced immune suppression 
[253]. Of HIV-infected patients that are IDU, a population show an accelerated progression 
of HIV-associated neural pathogenesis characterized by HIVE [86]. HIV viral proteins and 
drugs of abuse show similar mechanisms of injury such as proinflammatory response, 
oxidative stress, and induction of apoptosis [79]. As such, co-exposure to HIV and opiate 
metabolites such as morphine have been shown to enhance viral replication and 
exacerbate the detrimental effects of HIV/Tat in the infected brain and promote 
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progression to AIDS dementia [102, 103]. Despite studies to understand how the 
progression of HIV-associated neuronal pathogenesis is exacerbated by opiates, the 
mechanism is still not fully understood. 
 
Autophagy is a cellular process in which cytoplasmic contents such as organelles and 
proteins are encapsulated in the  double-layered membrane called an autophagosome 
and delivered to the lysosome for degradation and macromolecule recycling [254]. 
Autophagy can be initiated as a pro-survival response by a variety of stimuli such as 
environmental and cellular stress such as nutrient starvation, accumulation of aggregated 
proteins, or for pathogen internalization and degradation in innate immune cells [108]. This 
is particularly key in the brain cells since many are post-mitotic and require autophagy for 
maintaining homeostasis. Moreover, dysregulation in the autophagy pathway contributes 
to the development of a number of neurodegenerative diseases such as AD and PD [255]. 
Patterns of neurodegeneration similar to these diseases during HIV infection have been 
observed and linked to defects in the autophagy pathway. Though generally 
cytoprotective, autophagy plays an intricate role in viral replication with respect to infected 
cell type and can be induced or inhibited in order to bolster virus production at certain 
stages of the viral life cycle [23, 256].  
 
We have previously shown that siRNA mediated silencing of the BECN1 gene can 
significantly reduce HIV p24 levels and HIV and morphine-induced inflammatory cytokine 
and chemokine secretion from infected primary human microglia and astrocytes [192, 246, 
257, 258]. Beclin 1, a component of the phosphatidylinositol 3-kinase nucleation complex, 
regulates the initiation stages of autophagy preceding the formation of the isolation 
membrane of the autophagosome. As such, Beclin 1 poses an attractive target for future 
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therapeutic intervention and for gaining a better understanding of the interplay between 
HIV, autophagy, and drugs of abuse. In the present study, we use a mouse model 
possessing a monoallelic deletion of the mouse Becn1 gene as a potential therapeutic 
model to provide a direct link between the autophagy protein Beclin 1 and HIV Tat and 
their effects on glial dysfunction. The data also support the role of autophagy in mediating 
Tat and morphine-induced neuropathology.  
 
2.2  Materials and Methods 
2.2.1 Animals 
C57BL/6J mice (stock # 000664) and the Becn1 deficient mouse model (B6.129X1-
Becn1tm1Blev/J; stock #018429) were procured from The Jackson Laboratory (Bar Harbor, 
ME, USA) and bred in the animal facility at Florida International University. The 
Becn1tm1Blev mouse is heterozygous for the beclin1 allele and was originally generated by 
Qu et al. [136]. Briefly, a targeting vector was designed to replace exons 1 and 2 with a 
neomycin resistance cassette. The construct was electroporated into 129X1/SvJ-derived 
embryonic stem cells with correctly targeted cells injected into blastocysts and the 
resulting chimeric mice were bred to C57BL/6J. Offspring were backcrossed to C57BL/6J 
for 50 generations. Homozygous deletion of the targeted allele results in embryonic 
lethality. C57BL/6J and Becn1 mutant mice were bred as necessary for experiments to 
minimize colony population with cross-bred mice exhibiting Mendelian inheritance 
genetics. Of note, mice on a C57BL/6J background have a brownish (agouti) coat color 
which is believed to be a result of the effect of the Becn1 mutation on melanogenesis 
(Figure 2.1a). The guidelines of the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals were followed, and the Florida International University 
Institutional Animal Care and Use Committee approved all animal experimental protocols.  
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2.2.2 Mouse genotyping  
Genotyping of tail genomic DNA was performed to detect wild type and Becn1 knockout 
alleles by PCR amplification. The sense primer 5’-AGCCTCTGAAACTGGACACG-3’and 
the antisense primer 5’-TGGAAACAGGGTCTCATTCA-3’ were used to detect the wild 
type beclin1 allele (yielding a PCR product of 380 bp), and the sense primer 5’-
CTCCAGACTGCCTTGGGAAAA-3’ and the identical antisense primer were used to 
detect the knockout beclin1 allele (yielding a PCR product of approximately 400 bp). PCR 
was performed using AmpliTaq Gold® DNA Polymerase kit (Life Technologies) as per 
manufacturer’s instructions and the PCR product identified by agarose gel 
electrophoresis. 
 
2.2.3 Mixed glial murine cell cultures 
For primary murine glial culture, post-natal day 4-6 Becn1+/- mutant mice and C57BL/6J 
littermates were separated according to phenotypic coat color and sacrificed according to 
IACUC guidelines. Growth medium contained Dulbecco’s Modified Eagle’s Medium 
(DMEM; Invitrogen, Carlsbad, CA, USA)   supplemented with glucose (2 mg/mL; Sigma-
Aldrich), Na2HCO3 (6 mM; Invitrogen), 10% v/v heat inactivated fetal bovine serum (FBS; 
Hyclone, Logan, UT, USA), and 1% penicillin/streptomycin (100 U/mL / 100 µg/mL; 
Invitrogen) [101]. Striata were isolated and dissociated mechanically and enzymatically 
with 0.25% trypsin containing DNase (2.5 mg/ml) centrifuged, triturated, and twice filtered 
through 40 μM nylon mesh cell strainer. Cells were then plated and maintained in plates 
coated with poly-L-lysine (0.1mg/ml). Cultures were maintained for 5-10 days at 37˚C and 
5% CO2. 
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2.2.4 Immunocytochemistry 
4-well chambers containing adherent cells were washed with PBS, fixed in 4% 
paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked in 0.1% Triton X-100 
with 1% milk/1% goat serum and immunolabeled. Primary antibodies anti-GFAP (catalog 
# MAB360, Millipore) and anti-Iba1 (catalog # 019-19741, Wako Chemicals) were each 
used at 1:400 and 1:50 dilutions for astrocyte and microglia visualization respectively. 
Immunoreactivity was visualized with secondary antibodies from Molecular Probes 
(Carlsbad, CA, USA). Cells were mounted with ProLong® Gold antifade reagent with DAPI 
(Thermo Fisher Scientific). Images were analyzed using a Zeiss (Germany) inverted 
fluorescence microscope with a 560 Axiovision camera. 
 
2.2.5 Western blotting  
Whole cell lysates were prepared in RIPA buffer supplemented with a mixture of protease 
and phosphatase inhibitors and separated by SDS-PAGE for western blotting. Primary 
antibodies: Beclin 1 – 1:500 (Novus Biologicals, NB500-249), LC3A/B – 1:1000 (Cell 
Signaling, 12741S), P62/SQSTM1 – 1:500 (Novus Biologicals, NBP1-48320), LAMP1 – 
1:500 (Novus Biologicals, NB120-19294), β-actin – 1:200 (Santa Cruz, sc-47778). 
Following primary antibodies, blots were incubated with horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technology, 7076S; Sigma-Aldrich, 
A0545) used at a 1:1000 dilution. Immunoblots were exposed to SuperSignal West Femto 
Substrate (Thermo Fisher Scientific) and visualized using a ChemiDoc imaging system 
(Bio-Rad, Hercules, California). Protein expression was calculated using Image Lab 
software (Bio-Rad). 
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2.2.6 LC3 Autophagy Sensor 
Levels of autophagy in primary glia derived from C57BL/6J and Becn1+/- mice were 
assessed using the Premo™ Autophagy Sensor LC3B-GFP kit (Thermo Fisher Scientific, 
Grant Island, NY, USA) following manufacturer’s instructions. Cells were treated with 10 
µL of BacMam reagent containing the LC3B-GFP construct for 16 hours. Rapamycin 
(Sigma-Aldrich, St. Louis, MO, USA) was used at 2.5 µM as an autophagy inducer of 
autophagy. After incubation, cells were washed with PBS and mounted with ProLong® 
Gold anti-fade reagent with DAPI (Thermo Fisher Scientific). Images were analyzed for 
green fluorescence (LC3B positive autophagosomes) using a Zeiss (Germany) inverted 
fluorescence microscope with a 560 Axiovision camera 
 
2.2.7 Reagents and treatments 
Morphine sulfate (Sigma-Aldrich, St. Louis, MO) and HIV Tat1-86 IIIB (ImmunoDiagnostics, 
Woburn, MA) were used at concentrations ranging from 100 nM - 1 μM and 10 nM - 100 
nM respectively. The HIV Tat1-86 protein is derived from the CXCR4 tropic HIV-1 IIIB strain 
which was expressed in the E.coli expression system as a recombinant protein. 
Furthermore, it has been previously shown that the neurotoxic domain of Tat is well 
conserved across various strains of HIV [259]. This concentration of Tat has been shown 
to not only induce inflammatory cytokine production and other homeostatic dysregulations 
in glial cells in vitro, but also causes toxicity to neurons. Given that treatments of 100 
ng/mL and 1000 ng/mL correspond to approximately 8.3 nM and 83.3 nM concentrations 
respectively, we deemed the concentration range of 10 nM to 100 nM acceptable. It may 
also worth noting that both the Kruman and Nath studies utilize the HIV BRU Tat1-72 which 
may account for differences in extent of effects. In addition, this lab has used these 
concentrations in previous studies of Tat induced neuroinflammation [66, 102, 260, 261]. 
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Morphine at a concentration of 500 nM has been previously shown to fully activate MOR 
as well as enhance HIV Tat mediated neurotoxicity [101, 261]. µ-opioid receptor 
antagonist naltrexone (Sigma-Aldrich, St. Louis, MO) was used at a concentration of 500 
nM and was added 30 minutes prior to morphine exposure. Viral proteins Nef, Rev, and 
Gag were used at 1 and 5 nM envelope protein gp120 was used at 200 and 500 pM (NIH 
AIDS reagent program). 
 
2.2.8 ELISA 
Mouse glial cell culture supernatants were used to measure the levels of cytokines and 
chemokines, which have been shown to be released upon HIV Tat treatment [261]. These 
included interleukin (IL) -6, monocyte chemotactic protein-1 (MCP-1), regulated upon 
activation normal T-cell expressed and secreted (RANTES), and tumor necrosis factor 
alpha (TNF-α) which were assayed by ELISA (R&D Systems, Minneapolis, MN) according 
to the manufacturer’s instructions. The optical density was read at A450 with wavelength 
correction at A570 on a Synergy HTX plate reader (Biotek, Winooski, VT) 
 
2.2.9 Quantitative Reverse Transcription-Polymerase Chain Reaction 
Total RNA was isolated from glia following 24-hour treatments using the miRNeasy Mini 
Kit (Qiagen, Valencia, CA). Purity was assessed by microspot RNA reader (Synergy HT 
Multi-Mode Microplate Reader from BioTek) and RNA preparations with an OD260 
nm/OD280 nm absorbance ratio of at least 2.0 were used for cDNA synthesis. 1 µg of 
RNA was used for cDNA synthesis using High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems; Cat #: 4368814) as per the manufacturer’s protocol. Relative 
abundance of mRNA was assessed by SsoAdvanced Universal SYBR Green Supermix 
(BioRad, Cat #: 172-5271) in 20 µL real-time PCR reactions with gene specific primers 
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using a BioRad CFX96 real time system. All data were normalized to β-actin mRNA and 
presented as 2^-ΔΔCt for fold-change values. Primers used for amplification were as follows: 
mouse MOR, 5’-TGGAAACTTCCTGGTCATGT-3’ and 5’- 
AGATCACGATCTTGCAGAGG-3’ (182bp); mouse DOR, 5’-
GAGGATAAGTGGGGGATGGT-3’ and 5’-AGCCTCAGCCTCCACTATGA-3’ (175bp); 
mouse KOR, 5’-CCAGCATATTCACCTTGACC-3’ and 5’-
GAAGAGATCCCACCAGGAAT-3’ and mouse β-actin, 5’-
AAGAGCTATGAGCTGCCTGA-3’ and 5’-TACGGATGTCAACGTCACAC-3’ (160bp).  
 
2.2.10 Cell viability  
Toxicity of HIV Tat and morphine in mixed glial cultures was assessed using 12 mM MTT 
(3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) for cell survival and 
proliferation (Millipore, Temecula, CA). Cells were plated in poly-L-lysine coated 96 well 
plates at a density of 3 x 104 cells/well from T75 flasks and cultured overnight followed by 
treatment with 100 nM HIV Tat and increasing concentrations of morphine ranging from 
100 nM to 1 μM. After 24 hours, cells were refed with 100 μL fresh media and 10 μL of 12 
mM MTT was added to each well except for control and incubated for 2 hours to allow the 
formation of formazan crystals. Media was removed from wells and formazan crystals 
dissolved using DMSO. Absorbance was read at 570 nm with reference at 630 nm on a 
Synergy HTX plate reader (Biotek, Winooski, VT).  
 
2.2.11  Reactive oxygen species (ROS) 
Levels of intracellular ROS production were measured using dichlorodihydrofluorescein 
diacetate (CM-H2 DCFDA, Invitrogen, Carlsbad, CA), which is de-acetylated to 
dichlorofluorescein (DCF). Mixed glial cells were incubated with 10 μM CM-H2 DCFDA in 
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warm PBS for 1 hour according to the manufacturer’s protocol, washed then treated. N-
acetylcysteine, a precursor to the antioxidant glutathione, was used as a control at 10μM 
and pre-treated for 1 hour. H2O2 (0.001% v/v) was added at time of treatment as a positive 
indicator of oxyradical species. Dichlorofluorescein (DCF) fluorescence was measured at 
an excitation wavelength (λex) of 485 nm and an emission wavelength (λem) of 520 nm over 
24 hours using a Synergy HTX plate reader (Biotek, Winooski, VT). Relative DCF 
fluorescence estimated the levels of ROS present and were reported as DCF mean 
fluorescence intensity (MFI).  
 
2.2.12 Nitric oxide (NO) production   
Measurement of NO was assessed from the supernatant of control and HIV Tat ± 
morphine treated cells after 0, 1, 6, and 24 hours. Collected supernatant was measured 
for the concentration of nitrite (the oxidized metabolite of NO) and evaluated using a nitric 
oxide assay kit (BioVision, Milpitas, CA) according to manufacturer’s instructions. 
Absorbance was measured at 540 nm using a Synergy HTX plate reader (Biotek, 
Winooski, VT). The concentration of NO in samples was calculated based on the standard 
curve using known concentrations of nitrite.  
 
2.2.13 Intracellular calcium [Ca2+]i measurements 
Levels of [Ca2+]i in glial cultures were measured using the fluorescent marker Fura-2-AM 
(Invitrogen, Carlsbad, CA). Cells were loaded with 5 μM Fura-2-AM for 30 minutes at 37°C, 
5% CO2. After three washes, the cells were incubated in growth medium for an additional 
30 minutes to complete de-esterification of the AM group of the fluorophores. Cells were 
pre-treated with 10μM of the cell permeant calcium chelator BAPTA-AM (Tocris 
Bioscience) as a negative control prior to addition of Fura-2-AM. Baseline measurements 
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were recorded, followed by exposure to Tat and/or morphine. Fura-2 ratio at 340/380 nm 
excitation measurements were taken every 10 seconds for 30 minutes. Data is presented 
as percent of control values ± SEM from a 3 separate experiments (15-25 cells). 
 
2.2.14 Statistical analysis 
Results are reported as mean ± SEM of 3-6 independent experiments. Data were 
analyzed using analysis of variance (ANOVA) techniques, followed by Tukey’s post hoc 
test for multiple comparisons (GraphPad Prism 7 software, La Jolla, CA). A value of p < 
0.05 was considered significant. 
 
2.3 Results 
2.3.1 Molecular characterization of Beclin 1 using primary glial cell cultures derived 
from C57BL/6J and autophagy deficient mouse   
Beclin 1-mediated autophagy is of key importance in maintaining brain homeostasis, with 
dual deletion of the Becn1 allele (Becn1-/-) being embryonically lethal and conditional 
knockout causing neurodegeneration in mice [137, 262]. In order to study the role of host 
autophagy in the context of HIV viral protein effects, we instead make use of a monoallelic 
deletion mutant of Beclin 1 (Becn1+/-). B6.129X1-Becn1tm1Blev/J mice are heterozygous 
for the Becn1 allele (Becn1+/-) and have a brown (agouti) coat color which is believed to 
be a result of the effect of the Becn1 mutation on melanogenesis and can thus be 
distinguished from wild type littermates phenotypically. This study makes use of primary 
glia derived from C57BL/6J and Becn1+/- pups according to defined breeding scheme 
(Figure 2.1a). We first characterized Beclin 1 expression within the primary mixed glia 
derived from the mutant Becn1+/- mice. Mice initially separated by coat color 4-6 days after 
birth were genotyped to confirm the BECN1 single allele mutation using DNA isolated from 
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mouse tails and amplified by PCR. Amplification of the wild type sequence (14946) yielded 
a PCR product of 380bp in both black and agouti pups as expected, whereas the mutant 
primer (oIMR8619) yields a product of 400bp only in agouti pups, confirming the mutation 
(Figure 2.1b,c). Knockdown of Beclin 1 protein in murine mixed glia was confirmed by 
western blot analysis and indicated a 60% reduction in expression levels (Figure 2.1d).  
 
Before continuing with the study, it was important to ascertain whether the Beclin 1 
deficient glial cells could induce autophagy and to what extent the mutation reduced this 
Figure 2.1 Characterization of Beclin 1-deficient mixed glia 
C57BL/6J (Beclin 1+/+) and Becn1+/- mutant breeding scheme (a). Primers corresponding to the wild 
type and mutant beclin1 DNA sequence used for genotyping (b). Pups at P4-P6 were distinguished 
by coat color and mutation of the beclin1 gene was confirmed at the DNA and protein levels by 
PCR genotyping (c) and western blot (d). Lanes are grouped according to sample number (pup #1 
vs pup #2) and labeled according to the primer sequence used for amplification. Wild type 
sequence generates a PCR product of 380 bp and mutant sequence generates a PCR product of 
400bp (indicated by black arrows). Beclin 1 protein expression from isolated primary glia was 
normalized to β-actin. Data is presented as the mean ± SEM of 4 mouse pups per strain. P < 0.05 
# vs. C57BL/6J 
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capability. To determine whether a single allele mutation in the BECN1 gene is sufficient 
to considerably impair the autophagy pathway, we compared induction of autophagy in 
C57BL/6J and Becn1+/- derived glia using a fluorescent autophagy marker LC3-GFP 
assay. Upon induction of autophagy, LC3 localizes to pre-autophagosomal and 
Figure 2.2 Autophagy induction in C57BL/6J and Becn1+/- glia 
Representative images assessing basal autophagy induction by LC3-GFP puncta quantification 
upon treatment with the autophagy inducer rapamycin. Data was quantified from 2 independent 
experiments, averaging puncta per cell for 5 fields of view presented as mean ± SEM. P < 0.05 * 
vs. Control; # vs. C57BL/6J. Two-way ANOVA followed by Tukey’s test.   
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autophagosomal membranes which can be indicated by the punctate appearance of GFP 
staining [263]. We observed that untreated Becn1+/- glia show a slight but insignificant 
decrease in LC3-GFP puncta as compared to untreated C57BL/6J glia (Figure 2.2); 
however, when treated with the mTOR inhibitor and autophagy inducer rapamycin, 
C57BL/6J glia showed a 64% increase in LC3-GFP puncta whereas there was no 
corresponding increase in Becn1+/- glia. These findings further demonstrate that a 60% 
reduction in protein levels due to the heterozygous deletion of the Becn1 allele correlates 
to a reduction of autophagic induction in glial cells upon autophagy induction. Morphology 
and glial cell components were also assessed by immunofluorescent labeling with the 
astrocyte marker, GFAP, and the microglia marker, Iba1 (Figure 2.3).  
 
Figure 2.3 Immunocytochemistry for glial cell presence identifying GFAP+ astrocytes in red 
and Iba1+ microglia in green 
Primary glial cultures were immunolabeled to assess cell population and morphology. Red: GFAP+ 
astrocytes, Green: Iba1+ microglia, Blue: DAPI stained nuclei.  
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2.3.2 Beclin 1+/- glia show reduced inflammatory molecule induction upon exposure 
to the viral protein Tat  
We have recently shown that HIV replication and viral-induced neuroinflammation are 
regulated via a Beclin 1-dependent pathway [192, 257, 258]. Given the established role of 
Tat as a mediator of neuroinflammation, we sought to determine whether the underlying 
mechanism is through Beclin 1. Mouse models, including the use of glial cells, have been 
widely used in the studies of HIV-induced neurotoxicity. While true that murine cells are 
restricted for HIV infection, exposure to viral proteins such as Tat, Nef, and gp120 elicit 
glial cell activation, inflammatory molecule secretion, macrophage infiltration into the brain, 
metabolic dysfunction, and signaling pathway alterations which are also seen in primary 
human glia, despite lacking infectious capability, and reflect levels seen 
pathophysiologically [65, 199, 240, 261, 264]. Glial cells derived from C57BL/6J and Beclin 
1 (Becn1+/-) deficient mice were treated with increasing concentrations of the viral protein 
Tat for 8 and 24 hours for assessment of cytokine and chemokine secretion by ELISA 
(Figure 2.4). After 8 hours post-treatment, Tat caused a significant concentration-
dependent increase in the release of RANTES, MCP-1, and IL-6 in C57BL/6J glia where 
Becn1+/- glia showed significantly less secretion by comparison (Figure 2.4; red, blue, and 
green arrows). These decreases were maintained at 24 hours for RANTES and IL-6 
secretion. At 100 nM Tat treatment, RANTES, MCP-1, and IL-6 secretion in Becn1+/- glia 
were reduced by 1.6, 2.7, and 1.3-fold at 8 hours, respectively; and 2.2, 1.3, and 1.2-fold 
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at 24 hours respectively. Secretion of the pro-inflammatory cytokine TNF-α was also 
assessed; however, no differences were seen between Tat treatments or glial strains (data 
not shown). From this data, it can be inferred that Tat utilizes Beclin 1 to induce 
inflammatory molecule secretion and that 60% reduction in Beclin 1 expression level, can 
decrease this cytokine and chemokine release. To confirm the effects of Tat on 
cytokine/chemokine secretion were dependent on active protein, Tat was heat inactivated 
for 30 minutes at 95°C before being treatment to C57BL/6J and Becn1+/- glia and 
incubated for 24 hours (Figure 2.5). Secretion of RANTES was reduced by 7-fold (Figure 
2.5a), and 3-fold in MCP-1 and IL-6 (Figure 2.5b,c) from glia treated with heat inactivated 
Tat illustrating the specific effects of active Tat on wild type and Beclin 1 mutant murine 
glia. Inflammatory effects of additional viral proteins were also surveyed though secretion 
was either less than that of Tat or showed no significant difference between the strains 
(Figure 2.6). Interestingly, the viral protein Nef also showed a significant degree of 
Figure 2.4 Beclin 1 facilitates Tat-induced inflammatory molecule secretion 
Indicated cytokines and chemokines secreted from C57BL/6J and Becn1+/- mixed glia supernatants 
were measured by ELISA at 8 (a) and 24 hours (b) following increasing concentrations of HIV Tat 
(10 nM, 50 nM, 100 nM). Arrows indicate decreased Tat-induced secretion of RANTES (red), MCP-
1 (blue), and IL-6 (green) from Becn1+/- derived glia. Values were determined from standard curves 
and are presented as the mean ± SEM of 5 independent experiments. P < 0.05 * vs. Control; # vs. 
C57BL/6. Two-way ANOVA followed by Tukey’s test.   
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cytokine and chemokine induction from glia at low concentrations (1 nM) and were nearly 
on par with that of Tat at a higher concentration (5 nM) after 24 hours of treatment. In 
addition, whereas lack of Beclin 1 mediated autophagy was able to stem Tat-induced 
cytokine/chemokine secretion, treatment with Nef at high concentrations was able to 
override any ameliorating effects of the Becn1+/- glia with the exception of MCP-1. This 
was further highlighted with the enhanced secretion of TNF-α at a high concentration of 
Nef treatment (Figure 2.6c,d; grey arrows). Overall, this supports the role of HIV Tat 
protein as a major facilitator of neuroinflammation in glia which can be regulated by the 
Figure 2.5 Inactive Tat is unable to interact with Beclin1 to induce cytokine secretion 
C57BL/6J and Becn1+/- derived glia were treated with heat inactivated Tat (50 nM or 100 nM) for 
24 hours and showed limited secretion of RANTES (a), MCP-1 (b), and IL-6 (c). Heat inactivated 
treatments are indicated in colored boxes. Values were determined from standard curves and are 
presented as the mean ± SEM of 3 independent experiments. P < 0.05 * vs. Control; # vs. 
C57BL/6J; $ vs. Tat (50 nM). Two-way ANOVA followed by Tukey’s test.   
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presence or absence of Beclin 1 while other viral proteins such as Nef play lesser but still 
significant factors potentially independent of Beclin 1.  
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Figure 2.6 Effects of viral proteins on inflammatory molecule secretion through Beclin 1 
Indicated cytokines and chemokines secreted from C57BL/6J and Becn1+/- mixed glia supernatants 
were measured by ELISA at 8 (a & c) and 24 hours (b & d) following treatments of recombinant 
viral proteins. Nef (1 Nm/5 nM), Rev (1 nM/5 nM), Gag (1 nM/5 nM), gp120 (200 pM/500 pM). a: 8 
hours, Nef (1 nM), Rev (1 nM), Gag (1 nM), gp120 (200 pM); b: 24 hours, Nef (1 nM), Rev (1 nM), 
Gag (1 nM), gp120 (200 pM); c: 8 hours, Nef (5 nM), Rev (5 nM), Gag (5 nM), gp120 (500 pM); d: 
24 hours, Nef (5 nM), Rev (5 nM), Gag (5 nM), gp120 (500 pM). Values were determined from 
standard curves and are presented as the mean ± SEM of 3 independent experiments. P < 0.05 * 
vs. Control; # vs. C57BL/6J. Two-way ANOVA followed by Tukey’s test.   
59 
Numerous studies have reported on the interplay between inflammation and autophagy, 
with induction of autophagy able to regulate inflammatory molecule secretion while 
conversely, cytokine secretion also being able to induce autophagy [265-267]. As such, 
we were interested in the effects of Tat on the expression of key autophagy proteins Beclin 
1, LC3, and the ubiquitin-binding protein, p62/SQSTM1 since these proteins represent the 
initiation, autophagosome formation, and maturation stages of the autophagy pathway 
[79]. Correlating to the effects of Tat on cytokine secretion, there were concentration 
dependent changes in expression of autophagy related proteins Beclin 1 and 
p62/SQSTM1 in C57BL/6J-derived glia (Figure 2.7) suggesting induction of the autophagy 
pathway as well as accumulation of p62/SQSTM1 upon Tat treatment. Becn1+/- glia show 
reduced expression of Beclin 1 as expected; however, these levels were elevated with 
increasing Tat concentration. Interestingly, p62/SQSTM1 expression was unchanged with 
increasing concentration of Tat, though significantly less than C57BL/6J, which may 
suggest autophagic degradation is still ongoing, perhaps through Beclin 1-independent 
mechanisms. Taken together, this data indicates that the inflammatory molecule secretion 
induced by Tat is somewhat facilitated through an association with Beclin 1 and possibly 
the activation of the autophagy pathway.  
Figure 2.7 Tat induction of autophagy dysregulation 
Whole cell lysates from C57BL/6J and Becn1+/- glia after 24-hours of treatment were subjected to 
immunoblotting with antibodies to Beclin 1 (a), LC3 (b), and p62/SQSTM1 (c). Densitometry was 
performed for quantification, and the ratios of each protein to β-actin are presented graphically. 
Error bars show the SEM of 3 independent experiments. P < 0.05 * vs. Control; # vs. C57BL/6J. 
Two-way ANOVA followed by Tukey’s test.   
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2.3.3 Beclin 1 mediates glial inflammation induced by Tat alone and in combination 
with morphine  
 Given the co-morbidity of opiate abuse and HIV infection, we were next interested in the 
role of Beclin 1 on the effects of co-exposure to Tat and morphine on cytokine and 
chemokine secretion. First, we sought to determine the effect of morphine on C57BL/6J 
and Becn1+/- glial cytokine secretion over a range of morphine concentrations (100 nM, 
250 nM, 500 nM, and 1000 nM) for 24 hours of exposure (Figure 2.8). While no significant 
difference to MCP-1 (Figure 2.8b) secretion was observed across the various 
concentrations of morphine, there were concentration dependent fluctuations in RANTES 
secretion from C57BL/6J glia and IL-6 secretion from both C57BL/6J and Becn1+/- glia 
(Figure 2.8a & 2.8c). In addition, Becn1+/- glia showed reduced levels of chemokine 
secretion as compared to C57BL/6J glia, while strain differences in IL-6 secretion were 
not significant. Despite these changes, overall, morphine-induced cytokine secretion is 
quite minimal and not comparable to that of Tat induced secretion making morphine 
treatment alone experimentally irrelevant (Figure 2.8).   
 
It has been shown that glial co-exposure to Tat and morphine provokes the enhanced 
secretion of cytokines and chemokines which contribute to the neuroinflammation 
characteristics of neuroAIDS [242, 261]. Moving forward with 500 nM morphine which has 
been previously shown to saturate MORs [261], we exposed C57BL/6J and Becn1+/- glia 
to Tat alone and in combination with morphine to confirm whether Beclin 1 is involved in 
the interactive effects of Tat and morphine-induced cytokine/chemokine secretion. MCP-
1, RANTES, and IL-6 secretion were induced by Tat treatment to C57BL/6J and 
significantly less in Becn1+/- glia (Figure 2.8). Co-exposure with morphine significantly 
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enhanced Tat-induced cytokine secretion from both strains of glia. Interestingly, co-
exposure with Tat and morphine in Becn1+/- glia showed a significant reduction of about 
1.8-fold in RANTES and a significant reduction of about 1.5 fold in MCP-1 secretion when 
compared to similarly treated C57BL/6J glia (Figure 2.8a & 2.8b; red and blue arrows) 
suggesting that 60% reduction in Beclin 1 protein expression is sufficient to significantly 
reduce Tat and morphine-induced RANTES and MCP-1 secretion. Despite this reduction 
in cytokine secretion from Becn1+/- glia, these cells are still expressing approximately 
40% of the Beclin 1 protein which may explain the enhancement in inflammatory 
molecules detected with combination Tat and morphine treatment.  Co-treating the murine 
glia with heat inactivated Tat and morphine showed significant reduction of RANTES and 
MCP-1 secretion and minimal induction of IL-6 secretion, further supporting the interactive 
Figure 2.8 Tat and morphine induced inflammatory effects show contribution of Beclin 1 
Cell culture supernatants from C57BL/6J and Becn1+/- derived glia after indicated treatment for 24-
hours were assessed for cytokine and chemokine secretion by ELISA (a-f). Cytokine secretion was 
assessed following 24-hour treatment with increasing concentrations of morphine: 100 nM, 250 nM, 
500 nM, and 1000 nM (a-c). Tat and morphine co-exposure were assessed after 24-hours (d-f). 
Arrows indicate reduction in RANTES (d, red), MCP-1 (e, blue), and IL-6 (f, green) secretion from 
Becn1+/- derived glia relative to C57BL/6J derived glia for given treatment. Values were determined 
from standard curves and are presented as the mean ± SEM of 4 independent experiments. P < 
0.05 * vs. Control; # vs. C57BL/6; $ vs. Tat. Two-way ANOVA followed by Tukey’s test.     
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effects of morphine and active Tat. Using the MOR antagonist naltrexone prior to morphine 
administration was able to significantly decrease RANTES, MCP-1 and IL-6 secretion to 
the levels of Tat alone indicating the interaction is acting through MOR. Of note, Tat and 
morphine enhanced MCP-1 release in Becn1+/- glia was significantly reduced to the level 
of Tat alone with pre-treatment of naltrexone, implying Beclin 1 and MOR dependent 
mechanisms (Figure 2.8e).  
 
Looking further at the actions of Tat and morphine occurring at the MOR which is widely 
present throughout the brain, particularly the striatum, mRNA levels were measured by 
qRT-PCR (Figure 2.9a). Analysis showed that with Tat treatment, mRNA levels of MOR 
were increased by 3.5-fold in C57BL/6J glia whereas in Becn1+/- glia, there was only a 
slight decrease in MOR as compared to the untreated control. The co-exposure of Tat and 
morphine to C57BL/6J glia also caused an increase in MOR mRNA, albeit, not as robust 
as Tat alone treatment. Addition of naltrexone to Tat and morphine treatment resulted in 
mRNA levels like that of combined Tat and morphine. Interestingly in Becn1+/- glia, Tat 
and morphine treatment led to higher MOR mRNA levels than that of Tat alone which was 
reduced to the level of Tat by naltrexone; however, this was not significantly different from 
untreated control. In addition, we also looked at how other opioid receptors might be 
contributing to these effects given that there is often co-stimulation of the different opioid 
receptors through off-target effects [96]. C57BL/6J glia treatment with Tat had significant 
effects on the mRNA levels of both the DOR (Figure 2.9b) and KOR (Figure 2.9c). When 
combined with morphine treatment, the trend observed was similar that that of the MOR 
with decreased levels compared to that of Tat alone though not significant. Intriguingly, 
these effects on DOR and KOR were less pronounced in the Becn1+/- treated glia with Tat 
treatment causing mild upregulation of DOR and showing no effects on KOR. 
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To ensure the combined treatment was not drastically or differentially reducing the viability 
of the glia and therefore reducing cytokine/chemokine production or mRNA, an MTT assay 
was performed to determine cell viability across a range of morphine concentrations 
(Figure 2.10). Approximately 20% cell death was observed with each of the treatments, 
with no significant difference between concentrations of morphine. This reinforces the idea 
that the effects of Tat and morphine on microglia and astrocytes are on cellular function 
rather than inducing toxicity in regard to both the wild type and mutant cells. Overall, from 
the data it can be taken that the autophagy pathway intercedes in Tat and morphine-
induced cytokine production. It is important to note that the observed 60% reduction of 
Beclin 1 protein expression (Figure 2.1) is sufficient to reduce Tat-induced inflammation 
but not sufficient to completely prevent the enhanced inflammation detected in Becn1+/- 
Figure 2.9 Differential effects on opioid receptor mRNA upon Tat and morphine exposure 
mRNA levels of murine μ-opioid (MOR), δ-opioid (DOR), and κ-opioid (KOR) were assessed by 
qRT-PCR following treatment with Tat and/or morphine in the presence and absence of naltrexone. 
Values were determined by 2^-ΔΔCT method and normalized to β-actin. Error bars show SEM for 
3 independent experiments. P < 0.05 * vs. Control; # vs. C57BL/6; $ vs. Tat. One-way ANOVA 
followed by Tukey’s test.     
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glia when co-exposed to morphine and Tat as compared to Tat-treated glia,  suggesting 
that additional mechanism(s) may be at work in regulating the release of inflammatory 
molecules in conjunction with Beclin 1 and the autophagy pathway, or that complete or 
>60% protein reduction is required for better inhibition of neuroinflammation. 
 
2.3.4 Tat and morphine use Beclin 1 to alter the autophagy pathway  
After determining the effects of Tat and morphine on cytokine release (Figure 2.8) and the 
concentration dependent effects of Tat on autophagy protein expression (Figure 2.9), we 
were interested to see how the autophagy pathway might be altered upon co-exposure 
with morphine. Beclin 1 expression was elevated with Tat treatment in both strains, 2-fold 
in C56BL/6J and 1.4-fold in Becn1+/- (Figure 2.11a,b). Co-exposure to morphine increased 
C57BL/6J Beclin 1 expression as compared to control; however, there was no enhancing 
interactive effect as compared to Tat. Morphine was seen to cause a slight elevation in 
Beclin 1 expression in both C57BL/6J and Becn1+/- derived glia. Interestingly, Tat and 
morphine co-exposure to Becn1+/- glia caused no change in Beclin 1 expression compared 
Figure 2.10 Glial toxicity of Tat and morphine 
Toxicity of combined Tat and increasing morphine dose in C57BL/6J and Becn1+/- derived glia was 
assessed by MTT assay. Data are presented as percent viability compared to Tat treated cells (a). 
Error bars show SEM for 3 independent experiments. P < 0.05 * vs. Control; # vs. C57BL/6; $ vs. 
Tat. Two-way ANOVA followed by Tukey’s test.     
65 
to control. The expression ratio of LC3 II/LC3 I showed small fluctuations following Tat 
and morphine treatments alone or in combination from which conclusions on 
autophagosome formation may not be drawn (Figure 2.11c,d). Surprisingly, morphine 
treatment to Becn1+/- glia reduced the LC3 II/ LC3 I ratio which may be suggestive of either 
reduced lipidation and reduced autophagosome formation or enhanced autophagic flux. 
Upon analysis of p62/SQSTM1, we observed Tat caused increases in expression within 
C57BL/6J glia that were not seen in Becn1+/- glia (Figure 2.11e,f) taken as accumulation 
of p62/SQSTM1 and halt of autophagic degradation. Similar to what was seen with Beclin 
1 expression, no additive effects on p62/SQSTM1 expression were seen with Tat and 
morphine co-exposure for either C57BL/6J or Becn1+/- glia; however, where C57BL/6J 
was slightly elevated with co-exposure, the Becn1+/- was on level with control. Although 
not considered an autophagy protein, we also looked at expression of lysosomal-
associated membrane protein1 or LAMP1, a transmembrane protein predominantly 
located across lysosomal membranes which acts as a glycoprotein carbohydrate ligand 
[268]. We found that C57BL/6J treatment with Tat alone or in combination with morphine 
increased the expression of LAMP1 which correlated with the observed changes in 
p62/SQSTM1 expression (Figure 2.12g,h). Coupling C57BL/6J LC3 and p62/SQSTM1 
expression, the data suggests that where Tat alone can prevent p62/SQSTM1 and thus 
autophagosome degradation, when in combination with morphine, the increase in LC3 II/I 
and p62/SQSTM1 may indicate increased number of autophagosomes which are also not 
being degraded. This is also supported by the increased expression of LAMP1 with Tat 
and morphine treatment which may imply an increased number of lysosomes or 
autolysosomes. By comparison, the reduced LC3 II/I and unchanged p62/SQSTM1 
expression in Becn1+/- glia treated with Tat alone or in combination with morphine, imply 
a degree of ongoing autophagic flux despite the reduction of Beclin 1. Analysis of 
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autophagy-related gene expression at the RNA level by qRT-PCR yielded no significant 
differences from Tat and/or morphine exposure within each strain (data not shown). The 
data provide evidence that Tat alone or in combination with morphine can initiate the 
autophagy pathway but prevent autophagosome degradation by the lysosome, which in 
the context of HIV, would allow for enhanced viral replication. However, by reducing the 
levels of Beclin 1, autophagosome degradation may persist, albeit at lowered levels. 
 
2.3.5 Tat and morphine induced effects on intracellular calcium are mediated by 
Beclin 1 
Although astrocytes are non-excitable compared to neurons, activation by ligands such as 
glutamate can trigger Ca2+ oscillations in glial cells leading to Ca2+ waves. These waves 
can be used as a means of communication amongst astrocytes and with surrounding 
neurons [269]. Astrocytic waves can not only modulate neuronal cytosolic Ca2+ but may 
also trigger the release of gliotransmitters like glutamate, ATP, D-serine, TNF-alpha, and 
Figure 2.11 Beclin 1-mediated autophagy dysregulation by Tat and morphine 
Whole cell lysates from C57BL/6J and Becn1+/- derived glia following 24 hours of the indicated 
treatments were subjected to immunoblotting with antibodies to Beclin 1 (a-b), LC3 (c-d), 
p62/SQSTM1 (e-f), and LAMP1 (g-h). Densitometry was performed for quantification on separate 
blots, and the ratios of each protein to β-actin are presented graphically. Error bars show the SEM 
of 3 independent experiments. P < 0.05 * vs. Control; # vs. C57BL/6J; $ vs. Tat. One-way ANOVA 
followed by Tukey’s test.   
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arachidonic acid metabolites [270]. Calcium excitotoxicity is a feature of HIV-induced 
neuronal death pathology which can be stimulated by inflammatory and oxyradical 
stressors potentially causing altered glutamate and NMDAR signaling and excessive 
release of calcium stores from the endoplasmic reticulum [271-274]. Previous studies, as 
well as our own recently published data, have shown that increases in intracellular calcium 
caused by HIV in human astrocytes can lead to neuronal injury [246, 251]. In these studies, 
we use Tat, which we have previously shown to induce calcium release in brain cells [261, 
264]. To assess the role of autophagy in glial calcium homeostasis we use the fluorescent 
indicator Fura-2. As expected, we observed a significant increase in [Ca2+]i in C57BL/6J 
glia treated with Tat, which was significantly increased in the presence of morphine (Figure 
2.12a). In contrast, Tat-induced [Ca2+]i was significantly reduced in Becn1+/- glia and 
further exacerbation with morphine was abrogated when compared to similarly treated 
C57BL/6J glia (Figure 2.12b). To ensure that the increased Fura-2 ratios corresponded to 
intracellular calcium release, we pre-treated murine glia with the intracellular calcium 
chelator, BAPTA/AM. Pre-treatment with BAPTA abrogated calcium levels in C57BL/6J 
and Becn1+/- derived glia confirming that the increased levels in Fura-2 ratios were due to 
the release of intracellular calcium. This data suggests that the reduction of Beclin 1 
expression allows primary murine glia to prevent Tat and morphine-induced excessive 
[Ca2+]i release.  
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2.3.6 Limited Tat and morphine-interactive effects on oxidative stress are not 
mediated by Beclin 1 
In conjunction with neuroinflammation, glial oxidative stress is an additional pathological 
effect common to HAND and is often characteristic of Tat-induced glial dysfunction [275, 
276]. The production of ROS and RNS, has not only been associated with the activation 
of intracellular inflammatory signaling, but also has been shown to cause lipid 
peroxidation, DNA damage, and facilitate excitotoxicity through the release of glutamate, 
ultimately leading to neuronal damage or death [250, 271, 277-280]. To evaluate the role 
of autophagy in mediating the effects of Tat and morphine on oxidative stress in mixed 
glia, intracellular ROS formation was assessed by DCF reactivity and reactive nitrogen 
species (RNS) determined nitrite accumulation. Peak levels of DCF fluorescence were 
recorded after 16 hours of treatment for both C57BL/6J and Becn1+/- glia (Figure 2.13). At 
16 hours, Tat treatment was seen to illicit the highest level DCF fluorescence for both 
C57BL/6J and Becn1+/- glia with no apparent additive effect with morphine. Notably, 
though the increases in ROS caused by Tat were not substantial, within the strains, Tat 
evoked a 35% increase in ROS in C57BL/6J glia compared to untreated control (Figure 
2.13a) whereas there was only a 20% increase in Becn1+/- glia (Figure 2.13b). In addition, 
although no enhancing effect with Tat and morphine was observed in either strain, when 
compared to untreated control, Tat and morphine raised ROS by 20% in C57BL/6J derived 
glia compared to a 13% increase in Becn1+/- derived glia. RNS assessed by NO production 
Figure 2.12 Tat and morphine enhanced intracellular calcium release is prevented by 
reduction of Beclin 1 expression 
Intracellular calcium release from C57BL/6J (a) and Becn1+/- (b) glia was assessed by Fura-2 over 
800 seconds following treatment with Tat ± morphine. The calcium channel blocker BAPTA was 
used as a control. Arrows indicate time of treatment. Results represent the percentage of control 
values and are the mean ± SEM from 3 independent experiments. P < 0.05 * vs. Control; # vs. 
C57BL/6J; $ vs. Tat . One-way ANOVA followed by Tukey’s test  
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was measured by Griess assay, which is based upon the accumulation of nitrite as the 
product of NO metabolism. C57BL/6J glia showed no significant differences in NO 
accumulation upon treatment with Tat alone or in combination with morphine (Figure 
2.13c) compared to untreated control. In Becn1+/- glia, we observed a temporary spike in 
NO accumulation early after Tat treatment which stabilizes at later time points (Figure 
2.13d). In addition, Tat and morphine causes a gradual accumulation of NO in Becn1+/- 
glia, which is only significantly different after 24 hours of treatment. These studies suggest 
an effect on ROS and NO production upon exposure to Tat but detect no interactive effect 
when combined with morphine with minimal intervention by Beclin 1.  
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2.4 Discussion 
In this chapter, we use glial cells from mouse possessing a monoallelic deletion of the 
Becn1 gene to examine to consequences of autophagy deficiency in regulating HIV and 
morphine-induced inflammation, specifically through Tat. Given that homozygous deletion 
of the Becn1 allele results in embryonic lethality, using a murine model with heterozygous 
deletion of the Becn1 allele provides a reduced autophagic environment while maintaining 
sufficient expression for growth and development. This model not only showed reduced 
expression of the autophagy protein Beclin 1 (Figure 2.1), but also showed less LC3 upon 
induction of autophagy by the mTOR inhibitor rapamycin (Figure 2.3). Studies in neuronal 
cells also indicated the necessity of initial stages of autophagosome formation for Tat-
induced GFP-LC3 puncta accumulation demonstrated by Beclin 1 knockdown [191]. The 
Premo™ LC3B-GFP Autophagy Sensor has been utilized in literature for the assessment 
of autophagosome formation in the presence and absence of autophagy inducers [281-
283]. Importantly, this assay only provides a static snapshot of LC3, specifically 
autophagosome formation, since GFP fluorescence is quenched within the lysosome. 
Given that LC3B-GFP puncta can result from both activation of the autophagy process or 
a defect in autophagosome maturation, further studies are necessary to distinguish the 
two events. Neuroinflammation is a well-documented characteristic of HIV associated 
dementia-like symptoms and plays a key role in HIV-induced neuropathogenesis [54].   In 
Figure 2.13 Beclin 1 is independent of oxidative stress induced by Tat with limited 
contribution of morphine 
ROS production was assessed by dichlorofluorescein diacetate fluorescence (DCF) over a period 
of 24 hours following the indicated treatments to C57BL/6J (a) and Becn1+/- (b) glia. Mean DCF 
relative fluorescence was used as an estimate of ROS and was compared for each treatment. 
Results are the mean ± SEM from 6 independent experiments. NO production by C57BL/6J (c) and 
Becn1+/- (d) glia were examined at 0, 1, 6 and 24 hours following the indicated treatments. Nitrite 
levels were assessed using the Griess reaction with conversion of known concentrations of nitrate 
to nitrite as standards. Results represent the mean ± SEM of 3 independent experiments. P < 0.05 
* vs. Control; # vs. C57BL/6J; $ vs. Tat. Two-way ANOVA followed by Tukey’s test   
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addition, studies have shown in vitro exacerbation of cytokine and chemokine secretion 
from astrocytes and microglia treated with HIV or Tat with co-exposure of morphine [242, 
261, 264, 284]. Kyei et al has previously shown that autophagy is used to augment viral 
biogenesis in macrophages by HIV [16] which provides a basis for studying the role of 
autophagy in mediating neurodegeneration both by HIV and in the context of drugs of 
abuse. Further, studies on viral proteins have illustrated not only their role in inducing 
neuroinflammation through the secretion of inflammatory cytokines, but also intervening 
in various stages of the autophagy pathway [16, 194, 285-290]. The viral protein Tat has 
long been demonstrated to induce damage to the brain in murine studies through cytokine 
driven inflammation and gliosis [199]. The penetrative capabilities of the recombinant 
protein across cell membranes is well documented. Extracellular Tat is able to be 
internalized through its basic domain within exon 1 and its RGD domain which is able to 
bind integrin receptors [37].  Given that Tat can enter the cell and possesses a nuclear 
localization signal allowing it to localize in the nucleus, there are a number of pathways 
such as NFκB which may be activated to induce these inflammatory effects [31, 291].  
 
From the viral proteins we assessed, Tat was found to have the most robust inflammatory 
response from the C57BL/6J and Becn1+/- glia; however, other proteins did show effects 
(Figure 2.6). This study used the viral proteins Rev, Gag, gp120, and Nef, many of which 
possess neurotoxic capacity, to examine interactions with Beclin1 and whether they 
mediate neurotoxic effects [7]. The protein Rev is responsible for post-transcriptional gene 
expression within the HIV genome and has been shown to possess neurotoxic properties 
by disrupting membrane phospholipids [287]. The viral protein Gag, which is present in 
the HIV nucleocapsid, interacts with LC3, localizing virus to the autophagosome and 
facilitating viral proliferation within. However, the nonstructural protein Nef, a facilitator of 
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viral replication, directly interacts with Beclin1, allowing the virus to escape the 
degradation phase of autophagy [16]. Nef causes toxicity to neurons and glial cells, in 
addition to inhibiting autophagy [194, 285, 290]. The envelope protein gp120 is 
responsible for viral entry into cells and is considered to determine viral tropism [289]. 
Neurotoxic in and of itself, gp120 has been shown to induce secretion of cytokines and 
chemokines such as IL-6, TNF-α, RANTES, and IL-1β [288]. In addition, studies in 
neuroblastoma cells have reported gp120 to induce autophagy with increases in Beclin1 
expression and LC3-GFP positive puncta [286]. While we saw no significant up regulation 
of the pro-inflammatory cytokine TNF- with Tat, there was a marked increase when 
treated with the viral protein Nef which was heightened by reduction of Beclin 1. Reports 
have shown that Nef is able to induce cytokine and chemokine secretion in astrocytes and 
microglia through the mitogen pathway (p38 MAPK) and the transcription factor, NF-κB 
[292, 293]. TNF-α, in particular, has been associated with elevated levels of Nef and 
increased infectivity in astrocytes [294, 295]. We also observed that the differences 
between strains which were seen with Tat treatment were absent with Nef treatment, apart 
from TNF-α. This may be explained by Nef’s ability to alter early endosomal compartments 
and vesicles, similar to that of the autophagosome in autophagy, in astrocytes [296, 297]. 
Comparing the effects of the individual viral proteins shown here to our laboratory’s 
previous data demonstrating the effects silencing Beclin 1 in HIV-infected microglia and 
astrocytes on inflammatory molecule secretion, it is clear that the viral proteins weigh 
different contributions to HIV-induced neuroinflammation [192, 246]. 
 
In our present study, Tat was shown to have a concentration dependent effect on 
neuroinflammation through the secretion of cytokines and chemokines, with lack of Beclin 
1 able to significantly attenuate these effects (Figure 2.4). This is consistent with previous 
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studies by our lab showing that silencing of Beclin 1 in microglia and astrocytes reduces 
HIV replication as well as HIV and morphine-induced inflammation [192, 246, 257]. In 
addition, here we provide evidence that Tat, an established promoter of 
neuroinflammation, can also be modulated by autophagy within brain glia using Beclin 1. 
We observe Tat concentration dependent changes to autophagy-associated proteins 
Beclin 1 and p62/SQSTM1 in C57BL/6J glia which are limited in the Becn1+/- glia (Figure 
2.7). Studies have shown that the effects of Tat on autophagy are largely dependent on 
conditions, concentration, and cell type, either activating or suppressing autophagy 
function in glial cells or neurons [191, 193, 298]. While activation of autophagy by Tat 
should direct the viral protein for degradation as shown in CD4+ T lymphocytes [178], 
dysregulation in the degradation of the autophagolysosome may allow for persistence of 
Tat and autophagosome accumulation [248]. The study by Sagnier et al also found that it 
is possible for Tat to exhibit ubiquitin-independent, direct interaction with p62/SQSTM1. 
Though there is a possibility the changes to p62/SQSTM1 within our studies may be 
independent of ubiquitination and LC3, this would require further study. Notably, the 
Sagnier study was performed in CD4+ T cells and it is likely that these interactions of Tat 
may be cell-type specific.   
 
The interactive effects of Tat and opiates on glial function have been previously reported 
by our lab and others [106, 264], yet the mechanistic role of Beclin 1-mediated autophagy 
has not been fully confirmed. Examining the interactive effects of Tat and morphine on 
cytokine and chemokine production, we observed that morphine was able to exacerbate 
the levels of RANTES, MCP-1, and IL-6 secretion induced by Tat, which were mediated 
by MOR (Figure 2.8). Although diminished Beclin 1 expression was able to significantly 
reduce Tat and morphine-induced cytokine secretion as compared to C57BL/6J derived 
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glia, this reduction alone was not sufficient to abrogate RANTES and MCP-1 release. This 
agrees with our previous studies which showed significant but not complete abrogation of 
cytokine and chemokine release in HIV and morphine-exposed microglia and astrocytes 
transfected with siRNA against Beclin 1 [192, 246]. Of note, previous studies by Turchan-
Cholewo et al on the effects of Tat and morphine on opioid receptor surface expression 
and mRNA levels imply cell-specificity with differing effects between primary murine 
astrocytes and microglia and cell lines [299]. That group suggested the cell type specificity 
of Tat and morphine action at the MOR may determine the role of opioid receptors in brain 
inflammatory signaling responses, which is supported by our qRT-PCR results (Figure 
2.9). Although morphine is a classical MOR ligand, we did detect alterations to DOR and 
KOR mRNA levels with both Tat and morphine treatments respectively. The same group 
found a similar trend in primary microglia with Tat-induced up regulation of DOR which 
was slightly decreased when combined with morphine, and little to no effect on KOR. 
Interestingly, in primary astrocytes Tat showed insignificant effects to DOR or KOR. Given 
that our system uses a mixed glial culture (astrocytes + microglia), our results may be an 
intermediate of those findings. Our studies also show increased opioid receptor mRNA 
with pre-treatment of naltrexone. This antagonist can reversibly bind MOR, and to a lesser 
extent DOR and KOR and has been reported to increase the density of opioid receptors, 
despite, by definition, being neutral or negative in efficacy [300]. It is important to note that 
the Turchan-Cholewo study used primary astrocytes and microglia from the forebrain 
unlike the striatum used in these studies. In addition, differential induction of chemokines 
and their receptors by Tat and morphine has been suggested to have cell type-specific 
bidirectional, cross-sensitization with opioid receptors which may also modulate their 
expression [301]. Therefore, it is possible that the Beclin 1-dependent responses to Tat 
and morphine are cell-type specific with the relative presence of microglia and astrocytes 
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potentially masking the ameliorating effects of autophagy reduction in our mixed-glial 
model. Another factor to examine is cell surface receptor dynamics. In general, morphine 
is considered a lower efficacy agonist and may only induce receptor internalization under 
certain conditions in certain cell types [302]. Given that Beclin 1 has functions outside of 
autophagy such as endocytosis (through its interaction with UVRAG and Vsp34), it is also 
possible alterations in trafficking machinery causing impaired internalization of the opioid 
receptors may explain the Tat and morphine-induced differences in mRNA between the 
strains [262, 303, 304].  
 
The autophagy pathway can be modulated by HIV or Tat exposure, with other HIV-
proteins also able to modulate autophagy. Other studies have reported that upon HIV 
treatment, human astrocytes show increased protein expression of Beclin 1 indicative of 
autophagy initiation in conjunction with elevated LC3 [188]. In addition, it has been 
reported that Tat is able to stimulate autophagy by increasing the levels of BAG3 in human 
glial cells shown by increased LC3 II protein via western blot and immunofluorescence 
[193]. Our studies agree as we detected elevated expression of Beclin 1 in C57BL/6J 
derived glia treated with Tat; however, though also increased relative to untreated control, 
no interactive effect was detected when co-administered with morphine (Figure 2.11a). 
This is consistent with our previous studies in HIV-infected human astrocytes and 
microglia co-exposed to morphine [192, 246]. It is of note that Tat exposure to Becn1+/- 
derived glia moderately increased Beclin 1 protein expression, albeit not as significantly, 
when compared with C57BL/6J derived glia and even less so with Tat and morphine 
treated Becn1+/- derived glia (Figure 2.11b). This seems to contradict the LC3-GFP studies 
in mutant glia which suggested that these cells inefficiently induce autophagy activation. 
A study in rat hepatocytes demonstrated that early inhibition of autophagy by the PI3K 
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inhibitor 3-methyladenine prevented LC3 lipidation while maintaining bulk cargo 
autophagic flux [305]. It is therefore a possibility that with the 60% reduction in Beclin 1 
protein expression in the mutant glial cells, may be able to carry out autophagy, if only to 
a lesser extent. In our studies here, we did not detect significant changes in LC3 II/I ratio 
with Tat treatment alone or in combination with morphine (Figure 2.7b, 2.11c,d). Tat 
treatment has shown to increase LC3 II expression in both astrocytes and neurons [191, 
193]. It is possible that these differences may be due to lack of antibody sensitivity for LC3 
II which may cause the signal ratio of LC3 I and LC3 II to be skewed and improperly reflect 
the ratio of cytosolic and membrane-bound LC3 [306, 307]. In addition, inhibitors of 
autophagic degradation such as bafilomycin A1 or chloroquine should also be utilized to 
establish LC3 II increase and thus confirm autophagosome accumulation. Despite being 
the most commonly utilized tool for assessing autophagy, it is important to note that LC3 
expression levels alone are not sufficient to determine autophagic flux due to the fact that 
LC3 II is in equilibrium in terms of its formation and degradation [308]. As such, data must 
be analyzed in conjunction with other markers such as the adaptor protein p62/SQSTM1 
or in the presence of autophagosomes [307]. Expression of LC3 and p62/SQSTM1 in Tat 
treated C57BL/6J derived glia was suggestive of reduced LC3 leading to the accumulation 
of p62/SQSTM1. When combined with morphine, p62/SQSTM1 protein levels were 
elevated compared to untreated control, which may indicate accumulation of 
autophagosomes due to impaired clearance (Figure 2.11c & 2.11e). Notably, these effects 
were significantly minimized in glia derived from the Becn1+/- mouse (Figure 2.11d & 
2.11f). If autophagic activation is associated with increased numbers of autophagosomes, 
we would expect a corresponding increase in the number of lysosomes [268]. Here we 
see increased expression of the lysosome protein LAMP1 when C57BL/6J but not Becn1+/- 
glia are treated with Tat alone or combined with morphine (Figure 2.11g,h). Studies in 
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human astrocytes demonstrated that late stage autophagy could be interrupted by the HIV 
protein Nef as characterized by LC3 and p62/SQSTM1 accumulation [194]. Similarly, 
although in neurons, Hui et al has reported that Tat can also disrupt endolysosome 
degradation [248]. Also, in HIVE patient post-mortem tissues, Zhou et al described 
increased expression autophagy proteins as well as the lysosomal marker LAMP1 [185]. 
As such, it is possible that Tat induces Beclin 1 expression to initiate autophagy in glia 
while concurrently preventing its own degradation through targeting of late stage 
autophagy (Figure 2.14). This type of hijacking of the autophagy pathway allows for the 
protection of viruses within the autophagosome and allows for the enhanced viral 
replication observed in HIV infected brain cells [309].  Our findings show that by reduction 
of Beclin 1-mediated autophagy, Tat and Tat and morphine-induced alterations to 
autophagy protein expression can be prevented and ultimately limit their effects; however, 
additional studies on autophagic flux are still needed to confirm impaired maturation. 
Subsequently, we can then determine whether autophagosome to lysosome fusion is 
occurring, and second determine any effects on autophagolysosome acidification. 
Moreover, the presence and accumulation of autophagosomes and lysosomes should be 
confirmed by electron microscopy.  
81 
 
Tat-induced neurotoxicity is largely facilitated through the activation of the brain glia which 
leads to oxidative stress through excitotoxic mechanisms often involving calcium [250]. 
Becn1+/- glia provided further evidence supporting the role of Beclin 1 in mediating calcium 
release in astrocytes. Similar to what was shown in HIV-infected human astrocytes, Tat 
was able to induce calcium release from C57BL/6J derived glia, which was significantly 
enhanced by co-exposure to morphine (Figure 2.12). Moreover, Tat or Tat and morphine-
induced calcium release was significantly decreased in Becn1+/- derived glia which 
paralleled the siBeclin 1 treatment decreases shown in HIV-infected human astrocytes. 
Provided that intracellular Ca2+ is a key second messenger to numerous signaling 
pathways and is essential to the maintenance of glial homeostasis, it was of key 
importance to this study to validate the role of Beclin 1 as a potential alleviating factor for 
Tat and morphine-induced calcium accumulation. It should be noted that intracellular 
Figure 2.14 Schematic diagram summarizing the differential effects of Tat and morphine on 
the autophagy pathway in C57BL/6J and Beclin 1-deficient mouse glia 
Green arrows indicate an induction/accumulation. Reducing the expression of Beclin 1 in mouse 
glia prevented excessive Tat and morphine associated induction of the autophagy pathway while 
also limiting the accumulation of the adaptor protein p62/SQSTM1 and the lysosomal protein 
LAMP1. Future studies on the fate of the autophagosome are currently pending to determine the 
mechanism by which the autophagy pathway is initiated by Tat and morphine, but the process 
halted before degradation may occur.      
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calcium assessments generally appear as oscillations over time with varying intensity 
which we did not observe in these studies. This may be due to over-loading of the Fura-
2-AM dye or over-exposure of the fluorescent readings, thus minimizing the oscillations 
for each reading point. Future studies will reduce the amount of Fura-2-AM from 5 μM to 
1 μM. We also recently showed using gene silencing against Beclin 1 and the autophagy 
inducer, rapamycin, a role of autophagy in buffering the release of calcium, ROS, and NO 
in HIV-infected human astrocytes exposed to morphine [246]. Analysis of ROS production 
in the present study did not detect an enhancing effect upon Tat and morphine treatment 
of either C57BL/6J or Becn1+/- derived glia (Figure 2.13a,b) contradictory to our previous 
study with HIV-infected astrocytes or studies in microglia [107]. This may be due to 
saturation of the fluorescent reading which may explain the H2O2 kinetics. Future studies 
will require further optimization of the DCF dye to identify a suitable range for 
measurement as well as microscopy to confirm loading. Interestingly, we were able detect 
a slight, albeit significant, interactive effect of Tat and morphine on RNS production in 
Becn1+/- derived glia (Figure 2.13c-d) similarly to what was seen previously seen in HIV-
infected human astrocytes [246]. It has been previously shown that interruption of the 
autophagy pathway may also aggravate toxicities due to the virus [310]. Using glia derived 
from a Beclin 1-deficient mouse we further confirmed that Tat and morphine-induced 
calcium, but not ROS and NO release, are mediated via a Beclin 1-mediated pathway. In 
conclusion, using glial cells derived from Beclin 1-deficient animal, we observe an 
association between the autophagy protein Beclin 1 and the HIV protein Tat, which may 
underlie a mechanism for glial neuropathology in the context of opiate abuse and provide 
insight into targeting of future therapeutics.  
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CHAPTER 3: BECLIN 1 IS A REGULATOR OF NEURONAL OUTCOME AND KEY 
COMPONENT IN MEDIATING NEURO-GLIAL INTERACTIONS UPON TAT AND 
MORPHINE EXPOSURE 
 
3.1 Introduction 
HIV exposure in the brain is associated with a host of neurological complications, despite 
advancements in cART. As research into the etiology of these deficits has expanded, the 
cause has been attributed to neuronal damage, dysfunction, and loss. Despite these 
findings, there is no evidence that supports HIV infection of neurons [311, 312]. Rather, 
numerous studies find that HIV exerts its harmful effects to neurons through either 1.) 
direct effects of viral protein products such as Tat or 2.) indirect effects mediated by the 
changes to the cellular environment regulated by local glial cells [66, 202, 240, 241, 290, 
296, 313, 314]. In particular, the viral protein Tat is considered one of the most important 
arbitrators of HIV-induced neurotoxicity with studies showing that Tat exposure into the 
mouse striatum leads to neuronal apoptosis, synaptic destruction, dendritic pruning and 
gliosis [239]. Secreted into the extracellular space by infected cells and unaffected by 
cART, Tat is able to bind extracellular receptors or cross membranes to enter neuronal 
cells, ultimately wreaking havoc on neuronal signaling, membrane permeability, and 
initiating apoptotic cascades [30, 260]. In addition, as discussed in the previous chapter, 
Tat exposure to glial populations results in glial activation, stimulation of 
neuroinflammation, oxidative stress, and homeostatic disruption, all of which culminate in 
severe stress for the neuronal bystander [60, 66, 67, 100, 202, 208, 275]. Tat triggers toxic 
glutamate release from glial cells which in turn activates AMPA receptors (AMPARs) and 
NMDARs which can trigger excitotoxicity through the opening of calcium channels and 
depletion of intracellular stores [315]. Moreover, in vitro studies have demonstrated that 
84 
Tat is able to increase neuronal Ca2+ flux through interaction with NMDARs which can 
cause excessive neuronal signaling and damage to synapses [251, 260, 273].  Synergistic 
effects of Tat and morphine in neurons have also been reported to enhance neuronal 
death and intracellular calcium accumulation illustrating their neurodegenerative effects 
[101, 204, 316, 317]. Furthermore, studies using inducible Tat transgenic mice have 
shown a variety of pathologies depending on brain location such as astrocytosis, neuronal 
collapse, degeneration of dendrites, and progressive loss of the cortex [205, 207]. 
Considering that both the direct and indirect attacks of HIV on neurons are bolstered by 
opiate co-exposure, the HIV-infected/drug abusing population is at considerable risk for 
neuronal damage and the clinical manifestations of HAND [86, 100].  
 
Currently, there is still much to be understood regarding the precise mechanisms of 
neuronal injury and death following Tat and opiate co-exposure. While effects such as 
excitotoxicity, mitochondrial dysfunction, dendritic damage, and neuronal apoptosis have 
been identified as being triggered by Tat and morphine, questions surrounding how these 
phenomena are being regulated remain unclear. Consequently, one such pathway which 
may be considered is the autophagy pathway. Studies have shown that it is possible for 
HIV or its proteins to induce neurodegeneration through the clearance pathway [185, 186, 
189-191]. In post-mortem brain tissues of HIV-infected persons with encephalitis, there 
was a marked increase in expression of autophagic proteins and autophagosome number 
as compared to uninfected brains or HIV brains without encephalitis [185]. Similar results 
were also reported when examining autophagy in the post-mortem brain tissues of HIV-
infected persons with varying degrees of NCI prior to death as well as history of drug 
abuse [187]. As reviewed earlier, autophagy has associations to both HIV pathogenesis 
and numerous neurodegenerative diseases, with dysregulation of the pathway frequently 
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leading to significant pathology. This is particularly important for post-mitotic cells such as 
neurons which rely on the pathway for excessive/damaged protein and organelle removal 
[183]. In addition, the balance of autophagy lies deeply intertwined with initiation of 
apoptosis and may provide the driving force in determining neuronal outcome.  It is on this 
basis that we sought to determine how the autophagy protein Beclin 1 mediates the 
neuronal responses triggered by Tat and morphine co-exposure.  
 
3.2 Materials and Methods 
3.2.1 Timed-pregnancy and primary murine neuron cell cultures 
Approximate timed pregnancies were utilized to retrieve embryonic neurons at stages of 
high neurogenesis. Briefly, male and female mice aged 8 to 15 weeks were kept isolated 
for at least 24 hours prior to mating. After 24 hours, females were introduced into the 
breeding cage with the males in the early evening. Female mice were monitored 
periodically for 48 hours after initial introduction to detect for the presence of a vaginal 
plug indicating intercourse. The day on which the plug is observed is considered day zero 
and mouse weight is recorded every 3 days to ensure pregnancy.  
 
Primary murine striatal neurons were obtained from the embryos of anaesthetized 
pregnant dams at a gestational age of approximately E15-E17. Tail clips of individual 
murine embryos were taken for genotyping confirmation of strain as described in chapter 
2.2.2. Brains from each embryo was considered as an independent sample (n=1).  Growth 
medium contained Neurobasal medium™ (Gibco/Life Technologies, Grand Island, NY) 
supplemented with B-27 (2% v/v; Gibco/Life Technologies), L-glutamine (0.5 mM), and 
1% penicillin/streptomycin.  The striatal area, which contains mostly medium spiny 
neurons, was dissected from whole brain and cell isolation performed similarly to as 
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described in chapter 2.2.3 for primary murine glia. Cells were plated and maintained in 24-
well plates or 4-well chambers coated with poly-L-Lysine for 5 to 7 days. 
 
3.2.2 Reagents and treatments 
Morphine sulfate (Sigma-Aldrich, St. Louis, MO) and Tat1-86 IIIB (ImmunoDiagnostics, 
Woburn, MA) were used to treat C57BL/6J and Becn1+/- neurons at the concentrations 
described in chapter 2.2.7. Supernatant from C57BL/6J and Becn1+/- primary glia treated 
with Tat and morphine alone or in combination for 24 hours as described in chapter 2.2.7 
was collected and added to neuronal cultures to assess neuronal survival. Conditioned 
media (CM) from treated primary glia was centrifuged and filtered through a 0.22 m filter 
to remove cellular debris leaving only soluble secretions and diluted 4-fold in neuronal 
growth media. Conditioned media (CM) was used to treat cultured C57BL/6J-derived 
neurons and untreated C57BL/6J neurons served as controls.  
 
3.2.3 Time-lapse assessment of neuronal survival  
Time-lapse digital images were assessed as described previously [257]. Briefly, images 
of neurons were recorded using an inverted microscope with an automated computer-
controlled stage and environmental chamber (37˚C, 5% CO2) (Zeiss). For each well, 6-10 
non-overlapping fields were selected. A total of 15-30 individual medium spiny striatal 
neurons were identified in each field by their distinctive morphology in digital images. 
Time-lapse images of the same series of fields were recorded at 30-minute intervals for 
36 hours after concurrent Tat and/or opiate treatment. At the end of each experiment, all 
preselected neurons were assessed for viability in digital images taken at each time point 
during the entire treatment period. Neuronal death was identified visually by the collapse 
and fragmentation of the cell body. Neuronal survival is reported as the percentage of 
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viable cells at a given time point compared to the initial time point 0.  Phase contrast 
images were taken at 20x magnification. 
 
3.2.4 Cell viability 
Viability of neurons was confirmed using a live/dead cell fluorescence assay, which 
combines fluorescent reagents to yield two-color discrimination of the population of live 
cells indicated by green fluorescence, from the dead-cell population indicated by red 
fluorescence (ScienCell Research Laboratories). Cells were imaged using an inverted 
fluorescence microscope.  Neuronal viability was also assessed by trypan blue exclusion 
assay and measured using an automated cell counter (Bio-Rad).   
 
3.2.5 Growth factor array 
Glial growth factor secretion was measured using the RayBio® C-Series Mouse Growth 
Factor Array 3 (catalog #: AAM-GF-3-8; RayBiotech). C57BL/6J and Becn1+/- glial cells 
were treated with Tat and morphine alone and in combination under reduced serum 
conditions (1% FBS) for 24 hours. Collected supernatant was used to semi-quantitatively 
detect the levels of 30 mouse proteins present in the cell culture media according to 
manufacturer’s instructions. Signal levels were detected by chemiluminescence and 
intensities normalized to positive control on each membrane and membranes normalized 
to the untreated media reference array. Results are presented as fold change relative to 
untreated media.  
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3.2.6 Intracellular calcium [Ca2+]i measurements 
Levels of [Ca2+]i release in neuronal cultures were measured as described in chapter 
2.2.13. Data is presented as percent of control values ± SEM from 4 separate experiments 
(15-25 cells). 
 
3.2.7 Immunohistochemistry 
Chambers containing treated neurons were immunolabeled as described in chapter 2.2.4. 
The primary antibody used was anti-MAP2 (Millipore, MAB378) at a 1:100 dilution for 
neuron visualization. Immunoreactivity was visualized with secondary antibodies from 
Molecular Probes (Carlsbad, CA, USA). Cells were mounted with ProLong® Gold antifade 
reagent with DAPI to label cell nuclei (Thermo Fisher Scientific). Images were analyzed 
using a Zeiss (Germany) inverted fluorescence microscope with a 560 Axiovision camera 
at 40x. Microtubule-associated protein 2 (MAP-2) fluorescently labeled neurons were used 
to assess dendritic beading following 24 hours of Tat ± morphine treatment. Neurons were 
assessed blindly from three independent experiments. The total number of beads were 
counted and divided by the total number of neurons assessed per treatment for each 
experiment.  
 
3.2.8 Statistical analysis 
Results are reported as mean ± SEM of 3-6 independent experiments. Data were 
analyzed using analysis of variance (ANOVA) techniques, followed by post hoc testing for 
multiple comparisons and/or repeated measures (GraphPad Prism 7 software, La Jolla, 
CA). A value of p < 0.05 was considered significant. 
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3.3 Results 
3.3.1 Neuronal Beclin 1 deficiency contributes to aberrant Tat-induced intracellular 
calcium accumulation and dendritic injury 
Neuronal signaling is heavily reliant on ion flux which regulates much of its functionality 
such as action potential firing and neurotransmitter release [318]. One of the most 
essential and highly regulated of these ions is intracellular calcium. The capability of Tat 
to have excitatory Ca2+ mobilization effects on neurons through interactions with both 
plasma membrane receptors and intracellular stores is well documented, along with 
highlighting the exacerbating effects of co-exposure with opiates ultimately leading to 
excitotoxicity [75, 316, 319]. Given the results on Ca2+ flux we observed in the mixed glial 
cultures (Figure 2.12), here we sought to determine what role, if any, Beclin 1-mediated 
autophagy plays in neuronal Tat and morphine-induced Ca2+ dysregulation. For these and 
future purposes, we isolated primary striatal neurons from the embryonic pups of 
C57BL/6J and Becn1+/- bred mice (Figure 3.1). Tail clips were taken from the E15-E17 
pups for genotyping as described in Chapter 2.2.2. As expected, Tat treatment to 
C57BL/6J neurons caused a significant increase in [Ca2+]i (1.63x increase) which was 
elevated when co-exposed with morphine (2.05x increase) when compared to the 
Figure 3.1 Primary culture and imaging of C57BL/6J and Becn1+/- neurons 
Primary neurons were isolated from the striatum of pups of cross-bred pregnant dams (C57BL/6J 
x Becn1+/-) at approximately E16. Genotyping on embryonic tails was performed to confirm strain. 
Morphology differences between strains were assessed by immunostaining with the neuronal 
marker MAP-2 (green). Nuclei are stained with DAPI (blue). 
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untreated C57BL/6J control (Figure 3.2a). To our surprise, Tat treatment to Becn1+/- 
neurons also caused a significant increase in [Ca2+]i (2.72x increase) compared to 
untreated Becn1+/- neurons (Figure 3.2b). This was significantly higher than the Tat-
induced increase seen in C57BL/6J neurons. Interestingly, while the combined addition of 
Tat and morphine to Becn1+/- neurons also caused an increase in [Ca2+]i compared to the 
untreated control (2.44x increase), the effect was less than that of Tat treatment alone. 
Morphine alone showed no significant effects to either C57BL/6J or Becn1+/- neurons. The 
calcium chelator BAPTA served as a negative control. This data suggests that reduced 
autophagy by proxy of Beclin 1 deficiency may intercede in Ca2+ signaling leading to 
intracellular accumulation which may be a hindrance to neuronal survival through 
excitotoxicity.  
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As neurons are subjected to stress within the environment, intracellular signaling 
cascades and responses are triggered which often manifest as structural changes.  An 
early morphological hallmark for neurotoxicity is the presence of beading or varicosities 
along neurites. A response to axonal and/or dendritic injury, its presence tends to parallel 
neuronal death and is observed in many neurological diseases [318, 320] and has also 
been reported as a result of HIV injury [321]. As such, we continued to examine the effects 
of neuronal Beclin 1 deficiency upon Tat and morphine neurotoxic challenge using 
immunocytochemistry. MAP-2 fluorescently immunolabeled neurons were observed 
qualitatively for neurite beading after 24 hours of Tat and/or morphine treatment (Figure 
3.3a; white arrows). Comparing the untreated C57BL/6J and Becn1+/- groups, the mutant 
neurons had a significant degree of beading without any neurotoxic exposure (2.36-fold 
higher). Tat treatment significantly increased neurite beading in both C57BL/6J and 
Becn1+/- neurons (2.82 and 2.29-fold increase compared to respective strain controls). 
Combined Tat and morphine treatment to C57BL/6J neurons caused a similar degree of 
neurite beading as observed in Tat treated neurons (2.64-fold increase compared to 
untreated control). Tat and morphine co-exposure to Becn1+/- neurons also caused neurite 
beading; however, to a lesser degree than Tat treatment alone (1.32-fold increase 
compared to control) (Figure 3.3b). Beading caused by morphine treatment alone was 
slight and considered a negligible increase. Taken together, it appears as though lack of 
Beclin 1 drives neurons to an excitotoxic/stressed state with a heightened sensitivity to 
neurotoxins such as Tat.     
Figure 3.2 Becn1+/- neurons exhibit increased intracellular calcium accumulation upon Tat 
exposure 
Intracellular calcium release from C57BL/6J (a) and Becn1+/- (b) neurons was assessed by Fura-2 
over 980 seconds following treatment with Tat ± morphine. The calcium chelator BAPTA-AM was 
used as a control. Arrows indicate time of treatment. Results represent the percentage of control 
values and are the mean ± SEM from 4 independent experiments. P < 0.05 * vs. Control; # vs. 
C57BL/6J; $ vs. Tat. One-way ANOVA followed by Tukey’s test.   
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3.3.2 Becn1+/- derived neurons show reduced viability with Tat and morphine 
exposure 
Neuronal autophagy is a key process in the maintenance of neurological health with 
aberrant or dysregulated activity being associated with the development of CNS disorders 
such as Alzheimer’s, Parkinson’s, and Huntington’s diseases [322, 323]. While glial 
contributions to neuroinflammation have been documented to have adverse effects on 
neuronal health and outcome, studies have shown that Tat can also directly induce toxicity 
and neuronal cell death which is enhanced by morphine co-exposure [87, 100, 102, 104, 
204, 241, 324, 325]. In addition, previous studies on the effects of Tat and morphine on 
primary human neurons indicated inhibition of autophagy, reduced endolysosome pH, 
accumulation of autophagosomes, and an observed obstruction of autophagosome to 
lysosome fusion [187, 248]. Given what we have observed in regard to the effects of 
reduced Beclin 1 on neuronal Ca2+ and dendritic injury, we sought to examine the role of 
Figure 3.3 Tat exposure to Becn1+/- neurons induces elevated dendritic beading 
C57BL/6J and Becn1+/- neurons treated with Tat  morphine for 24 h were immunolabeled with 
neuronal marker MAP-2 to identify morphological changes and dendritic beading indicative of injury 
(a). Total number of beads per treatment was quantified and averaged over total number of neurons 
assessed per treatment per experiment. Error bars show mean  SEM for 3 independent 
experiments. P < 0.05 * vs. Control; # vs. C57BL/6J; $ vs. Tat. Two-way ANOVA followed by 
Tukey’s test.          
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Beclin 1-mediated autophagy in Tat and morphine-induced neuronal outcome. Individual 
neurons were tracked over 36 hours using environmentally controlled time-lapse imaging 
to monitor morphological changes and cell death over time (Figure 3.4a) [86, 102, 326]. 
Tat treatment to C57BL/6J derived neurons showed only a slight, but statistically 
significant, decrease in viability (5%) that was further decreased when combined with 
morphine (11%) after 36 hours of exposure as determined by repeated measures two-way 
ANOVA (Figure 3.4b). No significant changes were seen with morphine treatment alone. 
Although mild toxic effects were induced in the C57BL/6J neurons by Tat and morphine, 
we observed marked increases in neuronal losses from Becn1+/- neurons from an early 
time point regardless of treatment when compared to C57BL/6J neurons (Figure 3.4c). 
Tat exposure caused a decrease in neuronal viability (10%); however, when combined 
with morphine, there was no significant enhancement of neuronal death (12%) 
comparable to that which was seen in C57BL/6J neurons. Neuronal viability was 
confirmed by fluorescent live/dead staining (Figure 3.4d) and trypan blue exclusion. 
Although the effects to C57BL/6J neuronal viability were not as drastic as have been 
reported in other studies, these results agree with existing literature in regard to the toxicity 
of Tat and morphine on neurons. In addition, these time-lapse results are analogous to 
what was observed in the neuronal calcium and dendritic beading studies with Tat and 
morphine co-treated Becn1+/- neurons. This supports the concept that a 60% reduction in 
Beclin 1-mediated autophagy has detrimental effects to neuronal health and enhances 
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injury when faced with stress, thus further confirming the essential role of Beclin 1 and 
autophagy in neuronal protection, which can significantly be hindered by Tat exposure.  
97 
  
98 
3.3.3 Reduction of Beclin 1 expression in glia treated with Tat and morphine lessens 
indirect toxicity to neurons  
Having surveyed the direct effects of Tat and morphine on neuronal survival, we next 
questioned how these effects might be modulated in a more complex experimental system 
which incorporated glial contributions as a closer representation of the brain environment. 
As previously prefaced, excessive glial activation and dysfunction play a significant role in 
establishing HIV and Tat-induced neurotoxicity through the production of reactive species, 
glutamate release, and cytokine/chemokine secretion culminating in neuroinflammation 
and subsequent neuronal death [54, 86, 327, 328]. Using supernatant/conditioned media 
(CM) from C57BL/6J and Becn1+/- glia treated with Tat and/or morphine, we assessed 
whether the reduced expression of Beclin 1 in activated glia could ameliorate the 
neuroinflammation and subsequent indirect toxicity experienced by neurons in the CNS. 
Based on the poor survival outcomes of Becn1+/- neurons, these experiments proceeded 
with C57BL/6J neurons only. Time-lapse monitoring revealed a statistically significant 
Figure 3.4 Neurotoxic effects of Tat and morphine are more severe in Becn1+/- neurons 
Individual C57BL/6J (b) and Becn1+/- (c) neurons were assessed for survival following Tat and 
morphine treatment using time-lapse imaging over 36 h. Representative phase contrast images of 
individual neurons are shown at 20x magnification (a). Red circles depict dead neurons. Becn1+/- 
neurons were found to be highly susceptible to death independent of treatment. Error bars show 
the SEM for 3 independent experiments with at least 40 cells per experiment. P < 0.05 * vs. Control; 
$ vs. Tat. RM Two-way ANOVA followed by Tukey’s test (treatment effects). Neuronal viability was 
confirmed using a live/dead fluorescence assay (d). A representative image of dead (red) and live 
(green) cells acquired at 20x magnification is shown. Viability was manually quantified following 
the indicated treatments at 36 h. Error bars show SEM for replicates of a representative experiment. 
P < 0.05 * vs. Control; # vs. C57BL/6J; $ vs. Tat. Two-way ANOVA followed by Tukey’s test.             
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decrease in neuronal survival when given Tat-treated C57BL/6J CM (13% decrease) and 
was prominently enhanced when Tat was combined with morphine (30% decrease) 
(Figure 3.5b). Morphine-treated C57BL/6J CM did slightly decrease neuronal survival but 
was not significantly different from what was seen in the untreated CM (7% decrease). 
These studies yielded vastly different results when neurons were exposed to CM from 
Becn1+/- glia (Figure 3.5c). While the survival of neurons given untreated Becn1+/- CM was 
comparable to that of untreated C57BL/6J CM at 36 hours (C57BL/6J - 69%; Becn1+/- - 
74%), all other treatments were starkly different than the similarly treated wild type. Tat, 
morphine, and Tat + morphine treated Becn1+/- CM all reduced neuronal survival 
compared to untreated Becn1+/- CM, but there were no detectable differences between 
those 3 treatments (65%, 67%, and 65% respectively). Viability was confirmed by 
live/dead assay and trypan blue exclusion which showed similar results (Figure 3.5d). This 
data supports our hypothesis that targeting the autophagy pathway, specifically Beclin 1, 
in glial cells can diminish the indirect toxicity and neurodegeneration instigated by Tat and 
morphine co-exposure in the neuronal microenvironment. 
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3.3.4 Beclin 1 associated alterations in growth factor secretion upon Tat and 
morphine exposure  
Based on existing literature and the findings here, glial dysfunction is a clear arbitrator of 
neurotoxicity and neurodegeneration. As reviewed in Chapter 1, microglia and astrocytes 
have distinct and crucial functions in moderating the neuronal environment and neuronal 
homeostasis which are disrupted by HIV and its viral proteins. By that token however, 
when investigating the effects of HIV on glial function, it is essential to consider the effects 
duly in terms of gain of function (glial over-activation/production) and loss of function (glial 
shutdown/under-production). One key task of glial function in support of neuronal 
homeostasis is the production/secretion of growth/neurotrophic factors. Neurotrophic 
growth factors are endogenous soluble proteins which regulate a plethora of neuronal 
actions and functions. These include regulating neuronal survival, growth, morphological 
plasticity/synthesis, and protein synthesis for differentiated neurons [329, 330]. To 
evaluate the changes to soluble factor support potentially experienced by neurons due 
Figure 3.5 Decreased toxicity of neurons exposed to supernatant from Becn1+/- glia treated 
with Tat and morphine 
Individual C57BL/6J neurons were assessed for survival following exposure to supernatant from 
Tat and morphine treated C57BL/6J (b) and Becn1+/- (c) glia using time-lapse imaging over 36 h. 
Representative phase contrast images of individual neurons are shown at 20x magnification (a). 
Red circles depict dead neurons. Error bars show the SEM for 3 independent experiments with at 
least 30 cells per experiment. P < 0.05 * vs. Control; $ vs. Tat. RM Two-way ANOVA followed by 
Tukey’s test (treatment effects). Neuronal viability was confirmed using a live/dead fluorescence 
assay (d). A representative image of dead (red) and live (green) cells acquired at 20x magnification 
is shown. Viability was manually quantified following the indicated treatments at 36 h. Error bars 
show SEM for replicates of a representative experiment. P < 0.05 * vs. Control; # vs. C57BL/6J; $ 
vs. Tat. Two-way ANOVA followed by Tukey’s test.             
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glial Tat and morphine exposure, we measured growth factor secretion from C57BL/6J 
and Becn1+/- supernatant using the RayBio® C-Series Mouse Growth Factor Array. This 
array probed for the secretion of 30 growth factors, where from that 30, those with 
significant fold changes are included in Table 3.1. From that list, several growth factors 
have known associations to HIV-induced dysfunction and/or regulating neuronal health 
(Figure 3.6).   Basic fibroblast growth factor (bFGF), insulin-like growth factor 1 (IGF-1), 
macrophage colony-stimulating factor (M-CSF), and platelet-derived growth factor 
(PDGF) are all mitogenic growth factors which are secreted by cells to stimulate growth 
and differentiation, maintain cell survival, recruit circulating cells, and regulate the cellular 
microenvironment. Just as in the periphery, these functions are executed within the brain 
by the resident microglia, astrocyte, and neuronal cells in response to an initial stimulus. 
bFGF, for example, is secreted by astrocytes where, in addition to its promotion of cell 
survival and proliferation, it has been reported to stimulate the neurite expansion and 
branching of neurons [331, 332]. IGF-1 is primarily associated with astrocytes and neuron; 
when bound to its receptor IGF1R, triggers pro-survival signaling cascades, enhances 
nerve growth, and promotes synaptic plasticity (the process by which changes in synaptic 
activity strengthen or weaken synapse strength) [333-335]. M-CSF regulates myeloid cell 
activation and growth in the periphery but in the CNS, where it is produced by glial cells, 
promotes the survival and proliferation of microglia as well as regulates their activity [336, 
337]. In addition, some studies report neuroprotective actions of M-CSF in 
neurodegenerative disease models such as the AD mouse model [338].  PDGF is made 
by platelets and regulates cell growth and division but can also be made by astrocytes 
and is required for normal early development. Here we were able to detect significant 
differences in bFGF, IGF-1, and M-CSF between the wild type and mutant strains when 
exposed to Tat and morphine alone or in combination (Figure 3.6). Becn1+/- glia treated 
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with Tat and morphine both showed the highest levels of these neurotrophic growth factors 
with the difference between it and similarly treated C57BL/6J glia being quite substantial. 
This may represent Becn1+/- glia more efficiently responding to Tat and morphine 
exposure and subsequent neuronal damage through the secretion of mitogenic pro-
survival neurotrophic growth factors. As such, targeting Beclin 1 expression in glia may be 
considered beneficial to neuronal survival. Separately, the differences in PDGF-AA were 
more subtle and not statistically significant (Figure 3.6d). Others have described the 
neuroprotective potential of a PDGF isoform, PDGF-BB, which was shown to attenuate 
Tat and morphine-induced damage to human neurons; however, in our studies we found 
no detectable levels of PDGF-BB in either C57BL/6J or Becn1+/- supernatant [339]. In 
summary, this data establishes a role of Beclin 1 in regulating glial growth factor production 
and highlights a different, potentially overlooked, aspect of glial function and response 
which may contribute to enhancement of neuronal survival.  
Table 3.1 Soluble growth factor release in C57BL/6J and Becn1+/- glia treated with Tat and 
morphine 
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3.4 Discussion 
In this chapter, we examined the role of the autophagy protein Beclin 1 in mediating direct 
and indirect neuronal toxicity upon Tat and morphine co-exposure. As in the previous 
chapter, to do this we make use of mice possessing a monoallelic deletion of the Becn1 
gene and embryonically-derived primary neurons isolated from them. Neuronal autophagy 
is a highly sensitive process of which aberrant activation or inhibition frequently cause 
dysfunction leading to disease. These long-lived cells are post-mitotic and do not have the 
luxury of cell division to serve as a contingency under pathological conditions where 
damaged and dysfunctional organelles often accumulate. As such, neurons are heavily 
reliant on the proteasome and lysosome systems for the maintenance of neuronal function 
[158, 322, 340]. Tat exposure in neurons has been shown to greatly affect cellular 
Figure 3.6 Tat and morphine treatment in Becn1+/- glia increases secretion of neurotrophic 
growth factors 
Selected growth factors showed significant modulations in secretion from Tat  morphine exposure. 
P < 0.05 * vs. Control; # vs. C57BL/6J; $ vs. Tat. Two-way ANOVA followed by Tukey’s test.              
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autophagy, although to different extents. Hui et al found Tat1-72 to cause the accumulation 
of abnormally large endolysosomes with elevated pH paired with decreased expression 
of autophagy proteins LC3, ATG5, and increased p62/SQSTM1, implying an inhibition of 
autophagy in hippocampal neurons [248]. Another study by Fields et al reported that Tat1-
86 also caused a reduction of autophagy in cortical neuronal neurons also with abnormal 
accumulation of autophagosomes; however, though somewhat contradicting, found that 
Tat could reduce the autophagic blockade effects of the V-ATPase inhibitor bafilomycin 
A1 which suggests that Tat promotes autophagosome and lysosome fusion in neurons 
[191]. In studies of HIV exposure, one study reported inhibition of autophagy in cortical 
neurons exposed to supernatant from SIV infected microglia with decreased LC3 and 
increased p62/SQSTM1 which could be rescued by autophagy induction using rapamycin 
[189], whereas two separate studies found increased expression of autophagy proteins 
Beclin 1, ATG5, ATG7, and LC3 in the post-mortem tissues of HIVE patients [185, 187]. 
Taken together, it is apparent that the effects of HIV and the viral protein Tat on neuronal 
autophagy are complex.  
 
In these studies, we first investigated the direct effects of Tat and morphine co-exposure 
on neuronal function, structure, and survival to ascertain the part played by Beclin 1 in 
mediating these effects. Neuronal function is largely dependent on the various signaling 
pathways regulated by the levels of intracellular ions such as calcium. Excessive 
increases in intracellular calcium have been documented to be triggered by Tat interacting 
with/entering cells through receptors and surface proteins such as CXCR4, NMDAR, 
heparan sulfate proteoglycans, and low-density lipoprotein (LDL) receptor-related 
proteins, and often lead to neuronal cell death [319, 341-344]. The 
glutaminergic/ionotropic NMDARs may be activated by Tat leading to ionic imbalances 
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and excitotoxicity [273, 345]. Here we were able to detect Tat induced increases in 
intracellular calcium in C57BL/6J neurons as has been previously reported [251, 260]. 
This was further increased by the addition of morphine which was previously 
demonstrated by Fitting et al to converge on MORs and exacerbate calcium accumulation 
by mobilizing intracellular stores [316]. While these effects on C57BL/6J neurons were to 
be expected, we had not expected the heightened effects of Tat and morphine on Becn1+/- 
neurons compared to the wild type counterparts. Although we did not observe any additive 
or synergistic effects with Tat and morphine co-exposure in the Becn1+/- neurons, both 
treatments of Tat alone and in combination with morphine surpassed that which was seen 
in the C57BL/6J (Figure 3.2). From this it can be suggested that Beclin 1 and the 
autophagy pathway may have direct ties to mediating neuronal excitotoxicity. One study 
on traumatic brain injury found that glutamate could induce excitotoxity in cortical neurons 
through N-methyl D-aspartate receptor subtype 2B (NR2B) while in parallel activating the 
autophagy pathway and increasing expression autophagy proteins like Beclin 1 and LC3. 
When NRB2 was pharmacologically antagonized, this prevented both glutamate toxicity 
and autophagy induction [346]. A separate study found that NMDA-induced autophagy in 
cortical neurons as well as dendrimer-mediated siRNA delivery against Beclin1 was able 
to potentiate NMDA toxicity [347]. This may be correlated with studies of Tat which also 
showed that exposure can cause activation of neuronal autophagy [191]. These studies 
and the calcium data presented in this chapter suggest that Beclin 1 may be part of a 
defense mechanism against excitotoxicity and further establishes the neuroprotective role 
of autophagy in neurons within the context of Tat and morphine induced excitotoxity. 
Despite this, the question of how exactly autophagy proteins and structures interact with 
NMDARs to prevent calcium overload still stands. This may be through the triggering of 
pro-survival proteins such as BCL-2 or p53, mitochondrial membrane destabilization and 
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outer membrane puncture, targeting of Ca2+ or V-ATPases, or through phosphorylation 
signaling cascades involving development/cell division proteins such as CDK5 and Wnt/β-
Catenin all of which have been associated with induction of neuronal autophagy and 
glutamate excitotoxicity in models of ischemia or HAND [348-353]. Ultimately, more 
research into the exact mechanisms are still required. 
  
The neuroprotective functions of Beclin1 and autophagy was also illustrated by our 
findings in neurite beading (Figure 3.3). Here we saw that while Tat, alone and in 
combination with morphine, did increase neuronal beading as has been shown in previous 
studies [187, 316], this was significantly heightened in Becn1+/- neurons. Synaptodendritic 
injury is comprised of structural changes such as dendritic pruning and focal swelling 
displayed as varicosities or beads which disrupt communication at the synapse and axonal 
transport [321]. The development of these beads along the dendrites is considered a 
marker for neuronal injury and excitotoxic stress which links beading with intracellular ion 
flux. Functionally, when NMDARs are activated, the channel opens and allows for the 
influx of not only Ca2+ ions but also Na+ at a higher rate [354]. Elevated intracellular Na+ 
not only accompanies Ca2+ but is also able to modulate NMDAR gating and expression 
which exacerbates ionic imbalances [355-357]. It has been suggested this excess of [Na+]i 
and dysregulated [Ca2+]i causes the structural manifestation of neurite beading through 
not only excitotoxic influx on ions, but also the accompanied alterations in cellular 
energetics and ATP generation which are dependent on Na+/K+ ATPase activity and is 
also associated with autophagic cell death or autosis [356, 358, 359]. Further, a recent 
study in HIV-infected macrophages found that a Tat-Beclin 1 peptide was able to induce 
this form of autophagic cell death mediated by Na+/K+ ATPase activation [360]. Taken 
together, this may explain our beading results shown in Figure 3.3 from treated Becn1+/- 
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neurons and correlates it with our findings from Tat and morphine induced Ca2+ 
accumulation in Becn1+/- neurons shown in Figure 3.2. It should be noted that dendritic 
beading is a reversible occurrence so other assessments of neuron morphological 
damage can also be utilized in future experiments such as evaluating spine density, 
dendritic length and branching which may correlate to synaptic damage [361]. 
 
The importance of Beclin 1 and autophagy in regulating neuronal health was further 
confirmed when C57BL/6J and Becn1+/- neuronal survival was monitored over 36-hours 
by time-lapse imaging following Tat and/or morphine treatment. Previous studies have 
examined the effects of Tat and morphine alone and in combination on neuronal viability 
and have found the exacerbating effects to striatal neurons through apoptotic pathways 
[101]. We similarly found that 100 nM Tat treatment caused mild neuronal toxicity in 
C57BL/6J neurons which was augmented by morphine co-exposure (Figure 3.4b); 
however, this toxicity was magnified in similarly treated Becn1+/- neurons (Figure 3.4c). 
This reiterates the importance of Beclin 1 in neurons and corroborates the neurotoxicity 
suggested by the [Ca2+]i and neurite beading assessments (Figure 3.2 and 3.3). It should 
be noted that time-lapse assessment of viability monitors death over a duration of time but 
does not incorporate assessment of apoptosis. As discussed in chapter 1.7.2, Beclin 1 
and the autophagy process is tightly coordinated with apoptosis. Based on this, in future 
studies it is essential to distinguish the mechanisms of neuronal death, whether through 
apoptosis, autophagic cell death, or other contributing mechanisms which can be done 
using methods such as TUNEL and annexin V staining in combination with inducers and 
inhibitors of autophagy and apoptosis [362, 363]. Studies have demonstrated the 
neuroprotective functions of Beclin 1 in neurodegenerative diseases such as AD and PD 
[364, 365]. One study by McKnight et al highlighted the importance of Beclin 1 when they 
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showed how in cerebellar Purkinje , cortical, and hippocampal neurons where the protein 
is conditionally deleted, neurons experience rapid degeneration and increased mouse 
mortality as early 6 weeks with all mice dying by the age of 4 months [262]. This is 
understandable since complete Beclin 1 deletion (Becn1-/-) is shown to be embryonically 
lethal whereas the Becn1+/- mice used here have been shown to live up to 18 months, 
although they do exhibit late onset lung carcinomas, hepatocellular carcinomas and 
lymphomas [136, 137]. However, in the study by Pickford et al which uses the same 
heterozygous Becn1+/-mutant mice used in our study, neuronal Beclin 1 deficiency also 
resulted in synaptodendritic degeneration, abnormal lysosomes with electron dense 
granules, and reduced MAP-2 and synaptophysin (neuronal/synaptic markers) 
immunoreactivity in vivo, all of which were enhanced when Becn1+/- mice were crossed 
with the APP+ transgenic mouse, an AD mouse model [364]. Taken together, this 
establishes the compromised state of Becn1+/- striatal neurons as determined by [Ca2+]i 
accumulation and increased dendritic damage which is further exacerbated by Tat and 
morphine exposure, ultimately leading to rapid neuronal loss. 
 
As referenced earlier, the neuronal damage mediated by HIV and its viral proteins does 
occur independently without the contributions of the glial cells in the CNS environment, 
especially in the context of drug abuse. Glia-mediated neuroinflammation through the 
secretion of cytokines and chemokines is noted as a key facet of HAND, in addition to 
metabolic dysfunction, impaired neurotrophic activity, reactive gliosis, and oxidative stress 
all of which inevitably prompt neuronal injury and loss [60, 106, 312, 366]. In this study we 
examined the effects of glial conditioned media on neuronal survival as assessed by time-
lapse monitoring. The differences in C57BL/6J neuronal survival between the experiments 
of direct exposure to Tat and morphine and exposure to the glial secretions as a result of 
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Tat and morphine exposure were stark (Figures 3.4b and 3.5b). Neuronal viability was 
dramatically impaired when exposed to the CM from Tat or Tat + morphine treated 
C57BL/6J glia compared to the when the neurons were exposed directly. This coincides 
with existing literature which underscore the importance of glia in eliciting neuronal death 
upon Tat exposure [54, 56, 66, 87, 240]. This is particularly important in the context of Tat 
and morphine co-exposure [86, 87, 100, 106, 243, 261, 264, 284]. Zou et al for example 
demonstrated the importance of not only glia in mediating the neurodegenerative effects 
of Tat and morphine combined exposure, but also the necessity of glial MOR expression 
to potentiate these effects [102]. The study found that glial conditioned media enhanced 
the synergistic toxicity to neurons upon Tat and morphine exposure of which synergy was 
dependent on the presence of glial, but not neuronal, MOR expression as determined by 
using MOR1-/- knockout mice. These potentiating effects were even greater when neurons 
were placed into direct contact with glia, emphasizing the importance of soluble factor 
secretion in augmenting toxicity. Other studies which exposed neurons to the conditioned 
media of either SIV/HIV-infected microglia or Tat-treated glia also showed 
neurodegeneration in the forms of dendritic pruning and cell death which may be attributed 
to dysfunctional neuronal autophagy [187, 189]. When we examined the effects of Becn1+/- 
CM on neuronal survival, we observed an attenuation of Tat and morphine-induced toxicity 
compared to that of C57BL/6J CM. Based on the data presented in the previous chapter 
on inflammatory molecule secretion, reduction of Beclin 1 expression in glia is able to 
partially abrogate inflammation induced by Tat alone or in combination with morphine 
(Figure 2.8) which we have also seen with HIV-infected microglia and astrocytes [192, 
246]. In addition, although glutamate buffering was not shown here, our previous studies 
in human astrocytes demonstrated that silencing Beclin 1 by siRNA can also rescue 
impaired glutamate uptake caused by HIV infection which contributes to excitotoxicity in 
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neurons [246].   This supports the notion that targeting glial, but not neuronal, autophagy 
through Beclin 1 can help to attenuate Tat and morphine induced neurotoxicity. Our 
analysis of glial growth factor secretion following Tat and/or morphine exposure may 
further substantiate this concept. Tat and morphine were found to cause significant 
elevation of growth factors such as bFGF, IGF1, and M-CSF in Becn1+/- glia (Figure 3.6). 
While this may seem counterintuitive, studies have shown the upregulation of growth 
factors in neurodegenerative diseases such as AD, PD, and HAND [367, 368]. This may 
possibly be explained by glial efforts to counteract the neuronal damage such as dendritic 
beading being caused by toxic exposure in the brain [366]. bFGF for example has been 
documented to be significantly raised in reactive astrocyte dense areas of the brains of 
patients with AIDS dementia complex [367]. It was hypothesized that glia secrete 
neurotrophic factors to stimulate pro-survival cues in the ailing neurons but ultimately lose 
that battle. By that note, it is possible, through some yet to be determined mechanism, for 
Tat and morphine exposure within a Beclin 1-deficient host cell to trigger sufficient 
production of neurotrophic factors (while also limiting inflammatory molecule secretion) 
and activate neuroprotective mechanisms to prevent further, and possibly reverse, 
neuronal damage. The neuroprotective qualities of neurotrophic growth factors in 
response to oxidants or excitotoxicity have been documented and are considered in 
potential treatments for neurodegenerative disease [330, 339, 369-371]. As such, the 
capability of Beclin 1 to modulate not only Tat and morphine induced inflammation, but 
also neuroprotective growth factor secretion poses an attractive target in the design of 
future therapeutic interventions for HAND in the context of drug abuse and prevent further 
neuronal damage. Currently, further studies are ongoing to delve further into the 
mechanisms of autophagic cell death which are mediated by Tat and morphine exposure. 
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CHAPTER 4: CONTRIBUTIONS OF BECLIN 1 TO TAT AND OPIOID 
NEUROPATHOLOGY AND MOTOR IMPAIRMENT WITHIN THE MOUSE STRIATUM   
 
4.1 Introduction 
The umbrella term HAND encompasses a wide breadth of cognitive, motor, and behavioral 
abnormalities associated with CNS presence of HIV [52]. Currently, diagnosis of HAND is 
somewhat challenging since clinical features are no longer as pronounced as in the pre-
cART era. Initially, the AIDS Task Force of the American Academy of Neurology (AAN) 
founded the criteria by which the neurological stages of HIV are defined; however, these 
were revised to account to the lesser pronounced and more mild forms of neurological 
impairment [372]. The updated criteria of HAND assess neuropsychometric performance 
(NP) which includes attention information processing, language, memory (learning and 
recall), sensory perceptual skills, simple motor skills, and complex perceptual motor skills 
where deficits may appear in ANI or later progress from it.  However, initial early 
identification is reliant on self-reporting which may incorporate bias [373].  Neuroimaging 
is also increasingly being utilized to monitor metabolic, structural, and functional changes 
within HAND patients [374].     
 
Advancements in antiretroviral treatments have greatly changed the landscape of HIV and 
neurological decline. Adherence to cART significantly reduced both the incidence and rate 
of mortality due to HAD, the most severe manifestation of HAND. In spite of these 
therapeutic successes, the rates of the lesser forms of HAND, MND and ANI, have 
gradually been on the rise [375]. These two classifications also bring their own, more 
subtle, clinical manifestations which are still prevalent in the post-cART era and hinder the 
day to day quality of life in HIV infected persons.  There are a number of contributing 
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factors which may explain the continued prevalence of HAND clinical characteristics 
including variable antiretroviral penetrance to the brain, antiretroviral toxicity, and 
continuous exposure to secreted viral proteins, all of which are compounded by the 
increased life span of HIV infected individuals [376, 377].  
 
Although HIV has the capability of affecting multiple brain regions, pathology associated 
with infection has been most prominent in the basal ganglia, with the frontal cortex and 
hippocampus also displaying significant levels of viral burden [378-380]. Coinciding with 
these locations of high viral load, patients with HIV often presented with the inability to 
complete tasks, delayed speech output, impaired fine motor skills, and unsteady gait [13]. 
In addition, patient brain histopathology indicated cortical atrophy, formation of 
multinucleated giant cells, and immune cell infiltration leading to encephalitis [381, 382]. 
This was also found to be more rapid and severe in patients who were IDU, likely because 
virus laden areas like the basal ganglia are also highly rich in opioid receptor expression 
[380, 383]. Focusing on the basal ganglia, the motor disorders associated with HIV include 
Parkinsonism in more severe occurrences. In more mild cases of impairment, reports 
include isolated eye movement impairment, bradykinesia, impaired facial expression, and 
tremors [384-390]. In general, these clinical demonstrations in HAND are attributed to 
abnormalities within the basal ganglia, particularly the striatum upon virus or viral protein 
exposure. In vitro/vivo studies have reported neuronal loss, metabolic dysfunction 
(dopaminergic pathways), astrogliosis, and inflammation; however, there is still much to 
be understood in the regulation and eventual prospective treatments for this pathology. In 
this chapter, we first sought to recapitulate the motor deficits seen in HAND patients using 
an animal model treated with the viral protein Tat, which has been shown to induce brain 
pathology, and examine any potential additional dysfunction with morphine co-exposure. 
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In parallel, we also used the Becn1+/- mouse as a potential “therapeutic” model to 
determine whether any observable behavioral deficits and accompanying pathology of Tat 
and morphine co-exposure were modulated by the autophagy pathway, and if Beclin 1 
intervention can rescue this phenomenon.   
 
4.2 Materials and Methods 
The guidelines of the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals were followed, and the Florida International University Institutional 
Animal Care and Use Committee approved all animal experimental protocols for these 
studies.  
 
4.2.1 Animals 
C57BL/6J and Becn1+/- mice were obtained as described in Chapter 2.2.1 and bred. Mixed 
litters were separated after weaning for later age-matched experiments. Only adult male 
C57BL/6J and Becn1+/- mice age 3-5 months and weighing approximately 25-30g were 
used for these experiments. All mice were housed 3–5 per cage and were maintained in 
a temperature- and humidity-controlled room on a 12:12 h light/dark cycle with lights off at 
6:00 pm with ad libitum access to food and water. Mice from each strain were randomly 
divided into 4 treatment groups: (a) intrastriatal vehicle + placebo implant, (b) intrastriatal 
vehicle + morphine implant, (c) intrastriatal Tat + placebo implant, (d) intrastriatal Tat + 
morphine implant (Figure 4.1).    
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4.2.2 Chemicals 
Morphine sulfate (25 mg) and placebo pelleted implants were obtained from the National 
Institute on Drug Abuse (NIDA, Drug Supply System). Morphine pellets were continuous 
time-release pellets and were used to continuously deliver drugs for 5 days (approximately 
5 mg/day). Recombinant HIV Tat1-86 IIIB was purchased from ImmunoDiagnostics. 
 
4.2.3 Surgical Manipulation  
Mouse surgery was performed as using previously established protocols [244]. Mice were 
anesthetized by 2.5% isoflurane and subsequently placed in a mouse stereotaxic 
apparatus (Stoelting Co.) Under aseptic conditions, mice were administered sterile saline 
(vehicle control) or 10 g of Tat in a volume of 10 L that was injected over 5 minutes at 
a rate of 2 L/min into the striatum using a 33-gauge syringe (Hamilton Co.) attached to 
an automated infusion pump (Hamilton Co). Striatal injections were made at the 
coordinates AP = +0.7 mm, ML = 2.0 mm, and DV = -4.0 mm from the bregma (Figure 
Figure 4.1 Experimental design and surgical plan of Tat and morphine exposure 
Under anesthesia, 10ug (in 10 μl) of recombinant HIV Tat1-86 protein was injected into the striatum of C57BL/6J 
and Becn1+/- mice. Subsequently, a 25 mg morphine pellet was implanted subcutaneously beneath the 
scapula. Saline was used as a control for Tat. A placebo pellet was used as a control for morphine. 
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4.2) [242]. After 1 minute of incubation to allow tissue to return to original conformation 
and prevent backflow, the needle was slowly withdrawn. While still under anesthesia and 
maintaining aseptic conditions, subscapular skin was lifted, and a 3 mm incision made 
creating a subcutaneous pocket and the placebo or morphine pellet was inserted. Mice 
not given morphine were administered 0.25% bupivacaine (6 mg/kg) as local anesthesia 
before final skin closure using Vetbond surgical glue. Mice recovered on a heating pad 
(28C) until consciousness was regained and normal activity continued before being 
returned to cages. All animals were carefully monitored daily for signs of distress, weight 
loss, or changes in behavior.  
 
Figure 4.2 Stereotaxic coordinates and surgical example 
Striatum was located by stereotaxic reference (AP = +0.7 mm, ML = 2.0 mm, and DV = -4.0 mm) 
relative to the bregma. Injections were done in the caudate/putamen area. 
118 
4.2.4 Behavioral Assays 
After 2- and 5-days post-surgery, behavioral tests assessing motor skill were performed 
(Figure 4.3). On the day of behavior testing, mice were habituated in the testing room for 
one hour prior to assessment. Mice were allowed 3 attempts for each behavior test (unless 
otherwise stated) with a 5-minute time interval between trials and the best score recorded. 
Each animal was given a 10-minute rest period between behavior tests. Any mice 
perceived as being in distress or incapable of performing behavioral tasks were excluded 
from study results. All mice performed all of the behavior tests.  
 
Accelerating Rotarod 
The rotarod is an elevated rotating rod which exploits the natural fear of falling to evaluate 
balance, motor coordination and endurance. The Rotarod treadmill (San Diego 
Instruments) consists of a 1.25 in diameter cylindrical treadmill raised 18 in above the 
cushioned based connected to a computer-controlled motor driven drum which is 
programmed to operate in an accelerated mode. Each compartment possesses 7 
photobeams placed strategically below the running rod. When the animal falls off the 
rotating rod, the amount of time elapsed from starting until the photobeam was passed 
Figure 4.3 Representative images of motor skill behavioral assessments 
On days 2 and 5 post-surgery, mice were assessed in 3 tests to assess motor performance and 
skill. N= 4-8 mice per treatment. 
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was recorded by the computer automatically. All mice were naïve to the rotarod test until 
testing on day 2 post-surgery. Mice were placed on the elevated rod and the rod 
accelerated from 1 to 50 rpm in 5.0 rpm stages per 5 seconds with latency to fall recorded 
in seconds.  
 
Grip Strength 
The grip strength test (Chatillon force measurement; San Diego Instruments) assesses 
muscle weakness based on the instinctual tendency of mice to grasp objects with its 
forelimbs [391]. The apparatus is comprised of a push/pull digital force gauge meter 
connected to a computer for recording. Each mouse was weighed before forelimb grip 
strength test. The mice were held by the tail and lowered towards the computerized grid 
until it gripped the bar with both forepaws. The mouse was then gently and steadily pulled 
by the tail perpendicularly to the grid until the grid was released. Peak force was recorded 
in grams of force. Tests were repeated 5 times in 30 second intervals with the highest 
tension value being used as the animal’s measure of strength. Peak grip was normalized 
to mouse body weight for each animal. 
 
Horizontal Bar 
Horizontal bars are an additional measure of forelimb strength and coordination using 
elevated 2- and 4-mm diameter bars (44 cm length) suspended by metal poles (50 cm 
height). Holding the mouse by the tail, the mouse was placed on the benchtop and quickly 
slid backwards to align the mouse perpendicular to the bar and placed on the bar in the 
center of the two poles so that the mouse grasps the bar with its forelimbs only. Once 
grasping the bar, the mouse tail was released, and the timer started.  Mice were tested on 
ability to hold on to each bar and/or traverse the bar to the end poles (supporting the bar). 
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End point criterion was either falling from the bar, reaching the end pole, or reaching the 
maximum assessment time of 30 seconds. Duration of stay before falling or reaching the 
end pole was scored from 1-5, with 5 being the highest score. Scoring criterion are listed 
in Table 4.1. Mice were tested on the 2 mm bar followed by the 4 mm bar (to increase 
difficulty) for 3 trials on each bar. The best scores for each bar were then added.  
 
4.2.5 Tissue preparation and histology 
Following behavior experiments on day 5, mice were sacrificed, and brains collected 
intact. Brains were fixed for 24 hours in 4% paraformaldehyde, then serially submerged in 
15% and 30% sucrose for 24 hours, and finally embedded in in OCT compound and frozen 
for histology. Embedded frozen brain tissues were cut into coronal sections at 10 m 
thickness beginning at the forebrain and including the striatum (approximately ranging 
Section 18-25 in a mouse stereotaxic atlas [392]). Tissue sections were stained with cresyl 
violet acetate solution (Nissl) to stain the neuropil and identify the neuronal bodies within 
the brain as an indicator of decreased neuronal number. Briefly, sections were dehydrated 
in an ethanol series (70%, 95%, 100%), incubated in cresyl violet for 20 minutes, 
rehydrated, and cleared with xylene. Slides were then mounted with Permount and cover 
Table 4.1 Scoring used in horizontal bars assessment 
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slipped. Images of the striatum taken arbitrarily within a 600 m x/y distance from the 
injection epicenter were analyzed using a Zeiss (Germany) inverted fluorescence 
microscope with a 560 Axiovision camera in non-overlapping fields (Figure 4.4). In total, 
2 animals per group, 2 tissues per animal, and 4 images per tissue were used for 
histological assessment with representative images shown at 100x. Cells that contained 
Nissl substance in the cytoplasm, loose chromatin and prominent nucleoli were 
considered to be neurons and were manually counted semi-blind, whereas in contrast, 
glial cells lack a conspicuous nucleolus and contain less endoplasmic reticulum and were 
excluded [393-395]. Nissl+ glia identified by these morphological criteria were not 
considered in the estimation of total neuron numbers. Quantification was performed at 40x 
magnification. The data were represented as the number of cells per mm2.    
 
 
Figure 4.4 Post-fixed brain tissue and schematic representation of image sampling for 
histological assessment 
On day 5 post-surgery, mice were sacrificed, brain tissues collected, fixed, and frozen. Tissues 
were sectioned by cryostat in the coronal plane at 10 m and every 6th tissue used to Nissl staining. 
Images were taken approximately 600 m from the injection point. N=3 mice per treatment, per 
strain. 
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4.2.6 Statistical Analysis 
All data were analyzed with Prism7 software. Results are reported as the mean of each 
treatment group  SEM based upon total number of mice assessed. Data were analyzed 
by either one-way or two-way analysis of variance (ANOVA), followed by post hoc analysis 
using Tukey’s (treatment), Sidak’s (strain) tests for multiple comparisons. P values of 
<0.05 were considered statistically significant.  
 
4.3 Results 
With the introduction of cART, the manifestation of clinical symptoms in HIV patients has 
drastically decreased in severity with these deficiencies falling under the MND and ANI 
classifications of HAND [373]. In the study of the effects of Tat (and opiates) on brain 
function, many studies have focused on damage to the hippocampus and subsequent 
deterioration of cognitive function, memory, and behavior such as fear conditioning and 
anxiety [206, 207, 396]. Despite the occurrence of motor deficits being more prevalent in 
HAD within the pre-cART era, patients with HIV-associated neurological impairment may 
still show difficulties in motor coordination and fine motor skill, especially within the drug 
abusing population [397, 398]. Given the glial-induced inflammation and neuronal losses 
within striatal-derived cells observed in the previous chapters, we sought to determine if 
these effects could be recapitulated in vivo and translate to impaired motor skill, as well 
as determine what role Beclin 1 plays in regulating these behaviors.  Following intrastriatal 
injection (Saline vs Tat) and subcutaneous pellet implantation (Placebo vs Morphine), 
mice were assessed for motor impairment.  We first examined effects of Tat and morphine 
on mouse mortality (Figure 4.5). We found that while Tat/placebo treatment at 10 g to 
either C57BL/6J or Becn1+/- mice showed no significant effects on mortality (94%, 100% 
survival), Tat/morphine administration appeared to strongly affect survival with no 
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difference in mortality between the strains (50%, 50% survival). This may be a 
consequence of consistent morphine exposure since mice treated with saline/morphine 
also showed a decrease in survival and the C57BL/6J mice seemingly more affected by 
morphine than the Becn1+/- mice. This is particularly interesting since other studies have 
shown mice to tolerate 25 mg and 75 mg dosages of the extended release morphine 
pellets in studies [244, 399, 400]. Morphine is a well-studied analgesic with side effects 
that include constipation, respiratory depression, and hypothermia when entering the 
withdrawal state at approximately 24 hours after implantation which is when plasma drug 
concentrations are reported to peak [401-403]. As such, the study numbers shown 
represent the increased pool of test subjects to accommodate for these losses. 
 
Figure 4.5 Mortality of mice following intracranial injection and subcutaneous pellet 
implantation 
Morphine exposure led to significant mortality to both C57BL/6J and Becn1+/- mice over the 5-day 
experimental period with losses of up to 50% of mice.  
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4.3.1 Rotarod 
The accelerating rotarod test is a forced function test surveying utilizing fear of falling to 
assess motor activity as a function of gait, balance, coordination, and endurance [404, 
405].  To examine the effects of Tat and morphine co-administration on motor skill and 
whether Beclin 1 deficiency is a beneficial or detrimental factor in mediating these 
outcomes, the accelerating rotarod assay was performed. To our surprise, we detected 
no significant differences in latency to fall on day 2 between saline/placebo and 
Tat/placebo treated mice for either strain of mice (Figure 4.6a). Instead, we were able to 
observe a morphine effect in both strains of mice, with a significant decrease in latency 
for both saline/morphine and Tat/morphine treated mice. This further indicates the lack of 
a Tat effect given the absence of any additive or synergistic effects with Tat and morphine 
co-exposure. Similar results were also seen at day 5 post-surgery with no apparent Tat-
induced detriments in latency and a reduced morphine effect compared to day 2 (Figure 
Figure 4.6 Tat exposure causes no detectable impairment of rotarod performance in 
C57BL/6J or Becn1+/- mice  
Four different groups (Saline/Placebo, Tat/Placebo, Saline/Morphine, Tat/Morphine) per strain 
were injected with 10 μg of Tat protein into the striatum and implanted with a 25 mg extended 
release pellet subcutaneously on day 0. Motor activity was assessed on day 2 (a) and day 5 (b) 
post-surgery. There was no difference in Tat effect on day 2 or day 5. However, there was a 
morphine-induced decrease on both days. There was no difference between C57BL/6J or Becn1+/- 
mice on either day. P < 0.05 * vs. Control; # vs. C57BL/6J; $ vs. Tat. Two-way ANOVA followed by 
Tukey’s and Sidak’s test.           
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4.6b). Here we see no observable impairment of motor skills with Tat alone or in 
combination with morphine, rather, a morphine-induced diminishment which was 
indistinguishable between C57BL/6J and Becn1+/- strains. 
 
4.3.2 Forelimb Grip Strength 
The measurement of grip strength represents not only fine motor function but also 
neuromuscular capabilities which may be affected under experimental conditions [406]. 
As such, we sought to determine whether striatal-injected Tat, in the presence and 
absence of systemic morphine, would present as CNS motor deficits in C57BL/6J or 
Becn1+/- mice affecting the strength of the forelimbs.  Similar to what was seen in the 
rotarod experiments, we detected no significant differences in peak grip with Tat/placebo 
exposure on day 2 post-surgery within or between the strains (Figure 4.7a). Interestingly, 
at 5 days post-surgery, there was a slight decrease in C57BL/6J peak grip strength when 
treated with Tat/placebo; however, this difference was not statistically significant from 
saline/placebo treated C57BL/6J mice or from Tat/placebo treated Becn1+/- mice. In 
addition, there was a significant Tat/morphine combined effect at 5 days post-surgery for 
both C57BL/6J and Becn1+/- mice which was significant from saline/placebo treatments 
(Figure 4.7b). These data suggest that there might be a time-dependent effect of Tat on 
neuromuscular strength in C57BL/6J mice but not Becn1+/- but that the addition of 
morphine causes significant impairment regardless of strain.  
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4.3.3 Horizontal Bars 
We next examined how treated C57BL/6J and Becn1+/- mice would fare at horizontal bars, 
an additional test which also requires forelimb strength and coordination for sufficient 
performance. At 2 days post-surgery, we were able to detect a Tat effect for both 
C57BL/6J and Becn1+/- mice treated with Tat/placebo compared to the saline/placebo 
controls (Figure 4.8a). However, when examining the co-exposure effects with morphine, 
it appears as though the Tat effect is lost or potentially masked by the significant morphine 
effect. Comparing the saline/morphine and Tat/morphine treatments in C57BL/6J mice, 
there was a decrease, though statistically insignificant, in horizontal bar score and no 
difference with Becn1+/-. Only Tat/morphine treatment to Becn1+/- mice showed a 
statistically significant difference from Tat/placebo treatment. At day 5 post-surgery the 
effect of Tat on Becn1+/- mice seemed to be reverted with no significant difference from 
saline/placebo treated mice (Figure 4.8b). Whereas in C57BL/6J mice, similar to what was 
seen at 2 days-post surgery, there was a small decrease in horizontal bar score, though 
Figure 4.7 Tat and morphine exposure show delayed effects to grip strength 
To further compare the effects of Tat and morphine exposure in vivo forelimb grip strength was 
tested within the 4 treatment groups of the C57BL/6J and Becn1+/- strains on day 2 (a) and day 5 
(b). There was no detectable difference in grip strength with Tat exposure on day 2 and a moderate 
decrease on day 5 in C57BL/6J mice. Both C57BL/6J and Becn1+/- mice showed a significant 
difference in grip strength with co-administered Tat and morphine on day 5. P < 0.05 * vs. Control; 
# vs. C57BL/6J; $ vs. Tat. Two-way ANOVA followed by Tukey’s and Sidak’s test. 
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this difference also not statistically significant. Interestingly, Tat/placebo treated Becn1+/- 
mice did out-perform similarly treated C57BL/6J mice at both 2- and 5-days post-surgery 
which may suggest that lack of Beclin 1, at least in this particular motor assessment, 
reduces the effects of Tat on motor impairment. Once again, there was a significant 
morphine effect to both strains which may also have concealed the more understated Tat 
effects which were previously detected; however, this morphine effect was particularly 
apparent with the Becn1+/- mice, with Tat/morphine being significantly different from either 
the saline/placebo or the Tat/placebo. From this, we can infer that a test which assess 
coordinated motor skill and muscle strength like the horizontal bars test can be subtly 
affected by Tat intrastriatal exposure in a time-dependent fashion but is drowned out with 
morphine co-administration, particularly in Becn1+/- mice.  
 
Figure 4.8 Becn1+/- mice outperform C57BL/6J exposed to Tat but not co-treated with 
morphine in horizontal bars 
Horizontal bars assessment of motor coordination was done with the 4 treatment groups of the 
C57BL/6J and Becn1+/- strains on day 2 (a) and day 5 (b). There was a decrease in horizontal bars 
score with Tat treatment on day 2 in both strains though there was no significant difference between 
strains. Morphine also has a marked effect on day 2. Only C57BL/6J mice were still affected by Tat 
on day 5 and morphine effects were lessened but still present with Tat and morphine co-exposure 
causing minor decreases. P < 0.05 * vs. Control; # vs. C57BL/6J; $ vs. Tat. Two-way ANOVA 
followed by Tukey’s and Sidak’s test. 
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4.3.4 Striatal neuron losses caused by Tat and morphine co-exposure  
The detrimental effects of viral proteins on neuronal populations in vivo have been 
reported for brain areas including the striatum, hippocampus, and substantia nigra [241, 
407-409]. Following motor skill assessment, histological sections were stained by Nissl 
method to identify neuronal morphology and approximate any changes in neuronal 
number within the striatal area of interest (Figure 4.9a). Cells were identified as neurons 
based upon guidelines described by Garcia-Cabezas et al [393]. Nissl staining of the 
striatum revealed a significant reduction in the number of neurons of both C57BL/6J and 
Becn1+/- mice (1.4-fold, 1.5-fold respectively) which had been exposed to Tat (Figure 
4.9b,c). Additionally, we also observed an enhanced toxicity in C57BL/6J neurons within 
the Tat/morphine treatment group (1.8-fold decrease from control, 1.3-fold decrease from 
Tat/placebo) which was unseen in the similarly treated Becn1+/- group (1.1-fold decrease 
from control.) To our surprise, Tat/morphine treated mice displayed less neuronal death 
than the Tat/placebo treatment group (1.4 -fold increase from Tat/placebo). 
Saline/morphine treatment exhibited no neuronal losses to either C57BL/6J or Becn1+/- 
mice and may indicate mild neuroprotection [410, 411]. Our results show that Becn1+/- 
mice present less damage to neurons upon intrastriatal Tat and systemic morphine 
exposure compared to C57BL/6J mice which provides an additional glimpse into the role 
of Beclin 1 in mediating neuropathology.  
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4.4 Discussion 
In this chapter, we sought to examine the role of Beclin 1 in mediating Tat and morphine-
induced motor impairment in vivo. As in the previous chapters, to do this we make use 
mice possessing a monoallelic deletion of the Becn1 gene but here we use 3-5-month-old 
mice which underwent intra-striatal Tat exposure and subcutaneous morphine pellet 
implantation. In the previous chapter, we observed the death of striatal neurons in vitro 
following exposure to Tat and morphine. In addition, this death was significantly enhanced 
by the inclusion of conditioned media from C57BL/6J glia treated with Tat and morphine 
but less so when treated with conditioned media from Becn1+/- glia. From this, we 
questioned whether the observed striatal neuron death could be translated to in vivo motor 
impairment. The basal ganglia are a group of sub-cortical structures within the brain 
comprised of the dorsal striatum (caudate and putamen), ventral striatum (nucleus 
accumbens and olfactory tubercle), globus pallidus, substantia nigra, and subthalamic 
Figure 4.9 Tat and morphine co-exposure causes less neuronal loss in the Becn1+/- striatum 
Staining of striatal tissue for Nissl substance in saline/placebo, Tat/placebo, saline/morphine, 
Tat/morphine treated C57BL/6J and Becn1+/- mice (a). Panels show sections at 100x magnification 
of the striatum in coronal sections (a). Scale bars: 20 m. Black arrows indicate neurons. Neurons 
were quantified for each treatment and averaged based upon the striatal areas captured (~0.3 
mm2). Cell counting showed a reduced number of Nissl-stained striatal neurons when treated with 
Tat in both C57BL/6J and Becn1+/- mice. Morphine co-administration enhanced neuronal loss in 
C57BL/6J mice but not Becn1+/- mice. N=2 mice per group, 2 tissues per mouse, 4 images per 
tissue. P < 0.05 * vs. Control; $ vs. Tat. One-way ANOVA followed by Tukey’s test.       
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nucleus. These areas are primarily responsible for motor control in addition to motor 
learning, executive functions, and behavior [412]. Early studies of AIDS dementia reported 
clinical features similar to those seen in PD, a neurodegenerative disease of attributed to 
dopaminergic neuron death in the substantia nigra. These included bradykinesia, impaired 
manual dexterity, postural instability, rigidity, and gait abnormality [41, 42]. 
Neuropathological studies both in humans and animals have shown that the striatum is an 
area with heavy HIV burden and so the presentation of numerous motor deficits in early 
patients was quite prevalent, even without accompanying cognitive dysfunction [378, 385]. 
Fast forward several decades, and cART has radically changed the landscape of living 
with HIV with a severely decreased incidence of HAD; however, neurocognitive 
impairments still remained high [373, 413]. Whether due to lack of cART penetrance, 
inherent cART toxicity, or continued presence of HIV proteins in the CNS, there is still 
significant need to understand the driving forces leading to HAND and potential therapies 
to negate them, especially in the drug abusing population where neurodegeneration is not 
only enhanced but occurs at a faster rate.  
 
In these studies, we injected C57BL/6J and Becn1+/- mice with either saline or 10 g of 
Tat and subcutaneously implanted either a placebo pellet or 25 mg extended-release 
morphine pellet (Figure 4.1) and assessed for deficits in motor skill 2 and 5 days after 
surgery. We saw no observable effect of Tat on rotarod performance for either strain of 
mice, but a significant effect of morphine (Figure 4.6). Studies which have looked at the 
effect of HIV or its viral proteins on rotarod performance have been quite varied in their 
results with some studies finding significant impairment in accelerated rotarod 
performance [409, 414-417], and some studies finding no differences [214, 396, 399, 418-
420], as we have here. There were, however, two significant differences between those 
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studies and the ones performed here. The first difference lies is in how the mice were 
exposed to Tat. Many of the studies found in the literature make use of transgenic mouse 
models such as the doxycycline-inducible Tat transgenic mouse or the HIV transgenic rat 
models in their rotarod assessments of motor impairment as briefly summarized in 
Chapter 1.11.1. Those established transgenic mouse models used to study HIV 
neuropathogenesis are designed to produce virus/viral proteins under the control of a 
GFAP promoter so that the protein(s) of interest are produced within the brain upon the 
introduction of doxycycline into the diet [227]. As such, it is difficult to know exactly how 
much of a protein such as Tat is being produced in a specific area such as the striatum. 
Conversely, our study injects a pre-determined concentration of Tat directly into the 
striatum. Furthermore, our study presents a one-time exposure to Tat whereas the Tat 
transgenic models display a continuous production of the protein. Given that Tat is readily 
oxidized or taken up in to cells and has a short half-life [7, 421], injection of Tat may provide 
only brief snapshot of direct effects whereas the Tat transgenic mice are exposed to Tat 
more chronically which may explain why we did not see the pronounced difference in 
rotarod performance. In addition, other studies have used up to 25 g of the viral protein 
Tat when investigating its effects on neurodegeneration so it is possible that a higher 
concentration may be necessary to portray in vivo behavior impairments. While Tat 
concentrations in the serum of HIV patients have been reported to be between 2 and 40 
ng/mL, it is often through that concentrations in the brain are higher, and as such, future 
experiments at a higher concentration would still be clinically relevant [342, 422, 423]. The 
second difference lies in the assessment of rotarod performance in that the present study 
did not train the mice prior to surgery for assessment. It was also curious to see the distinct 
effect on rotarod performance caused by morphine in both strains. Similar to the literature 
on rotarod performance in HIV models, results on mouse/rat motor coordination following 
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morphine treatment are also divided with some reporting no differences with morphine 
exposure [424, 425], and others stating that morphine can compromise motor function at 
antinociceptive doses [426-429]. One study by Fitting et al which used the inducible Tat 
transgenic mouse model reported that poor rotarod performance was tied to rapid 
increases in Tat within the striatum and that acute morphine administration could increase 
the latencies of mice on the rotarod [209]. Taken together, more studies at higher 
concentrations of Tat may be needed to gain a better understanding of whether Beclin 1 
plays a translational role in motor coordination.   
 
When we surveyed the effects of Tat and morphine on forelimb grip strength, we also saw 
mild effects, many of which were not statistically significant and were apparent only on 
day 5 after surgery (Figure 4.7b).  Neurodegenerative diseases where the basal ganglia 
is affected will often show reduced strength of forelimbs, although we did not detect any 
in these studies [430]. It should be noted that although we normalize for body weight, other 
factors such as motivation to continue gripping the bar have been shown to affect the 
assessment of rodent grip strength [431]. One study examining the gender influences on 
Tat-induced neurological impairment using the inducible Tat transgenic mice however 
reported that forelimb strength was significantly reduced in male Tat+ mice compared to 
female Tat+ or Tat- mice of either gender [417]. Similar to what was seen in the rotarod, it 
is possible that at a higher exposure of Tat, deficits may become more apparent. 
Interestingly, there seemed to be an interactive effect, though independent of strain, in Tat 
and morphine treated mice on day 5. This has also been shown in studies on the effects 
of morphine on behavioral task performance in SIV-infected rhesus macaques [432]. 
Animals showed reduced performance in the behavioral tasks assessed like forelimb 
force, which was significantly further reduced after infection. Although this study uses large 
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animals in a chronic morphine paradigm, it demonstrated an effect of morphine to produce 
behavioral deficits and act synergistically with SIV to exacerbate motor deficits.   
 
Once termed the “string test” or “”coat hanger test”, the horizontal bars assessment 
measures both forelimb strength and coordination [433].  A combination of both the motor 
programming of the basal ganglia and the posture programming of the cerebellum, the 
horizontal bars test has been used to study motor defects caused by targeted null 
mutations and surgical/neurochemical lesions within those areas of motor ability [434]. 
Given that the mouse’s ability to grip the bar is inversely proportional the diameter of the 
bar, studies use increasing sizes (2 mm, 4mm, 6 mm) to increase difficulty and better 
differentiate mouse ability [433]. In these studies, we observed a Tat effect in both 
C57BL/6J and Becn1+/- mice on day 2, but only the C57BL/6J mice retained the deficits 
on day 5. Here we also detected a significant morphine effect to both strains of mice on 
both days of testing which was particularly prominent in Becn1+/- mice (Figure 4.8). From 
these results we may speculate that the lack of Beclin 1 might trigger a delayed 
compensatory or recovery mechanism which rescues the Tat effects on behavior by day 
5; however, in terms of Tat and morphine co-exposure, the addition of morphine may mask 
any benefits of Beclin 1 deficiency or simply does not have synergistic effects with Tat.   
While the manifestations of motor impairment in Tat and morphine co-exposed C57BL/6J 
and Becn1+/- mice might have been mild at the given concentrations of viral protein, deficits 
appear to be time dependent.  
 
Many of the deficits in neurodegenerative diseases stem from neuronal losses within the 
brain locations responsible for their function. The neuropathology and clinical presentation 
including anxiety, memory, learning, and motor deficits correlated with HAND are 
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associated with degeneration of sub-cortical structures such as the amygdala, 
hippocampus, and basal ganglia [13, 435]. Despite observing only modest impairment of 
motor function in certain assessments with Tat exposure alone or in combination with 
morphine within the strains, we were able to find significant differences in estimated 
neuronal number both with respect to treatment and strain (Figure 4.9). It is necessary to 
note this crude quantification did not span the entire length of the striatum and it is possible 
the areas assessed were not areas of significant impairment. These neuropathological 
analyses are consistent with our studies here and others presented elsewhere of neuronal 
Tat toxicity [199, 241, 408, 409]. Similar to the existing literature on Tat effects in locomotor 
skill, studies on the histological effects of Tat exposure are at odds with some reports 
finding no significant effect on the number of striatal neurons [436], and others finding 
great neuronal tissue losses [241, 408]. Opposite with our findings here, one such study 
stated that Tat production in the rat striatum caused impairment of behavioral 
performance, but found no extensive neuronal loss, attributing deficits to neuronal and 
synaptic dysfunction [409]. Likely, it is a combination of both striatal neuron death and 
dopaminergic malfunction leading poor motor performance. For example, Tat has been 
demonstrated to diminish expression of tyrosine hydroxylase (TH), the rate determinant 
of dopamine synthesis, in the substantia nigra following striatal injection, in addition to the 
loss of TH+ neurons, and development of subclinical PD-like disease when treated with 
the stimulant amphetamine [437]. Although the studies here lack the quantitative backing 
of stereology, it is an initial step into understanding how targeting of Beclin 1 in the context 
of Tat and opiate toxicity may be neuroprotective. As the study of Beclin 1 and autophagy 
in the context of Tat and opiate co-exposure is expanded, future studies will also look at 
other afflictions and diseases caused by HIV exposure.  
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In conclusion, the aforementioned data provide further evidence that exposure to Tat plays 
a meaningful role in the deterioration of motor function experienced by HAND patients and 
worsened in the drug abusing population. The autophagy protein Beclin 1 may yet still 
play a role in the manifestation of Tat and morphine-induced deficits. The absence of 
discernable motor impairments between either strains or with Tat administration in certain 
assessments, coupled with the presentation of neuronal loss within the striatum make for 
a complicated landscape requiring additional study. One possibility could be that the 
induced damage might not yet be sufficient to destabilize the functionality of striatal motor 
circuits.  In addition, motor function is a coordinated effort with other brain areas such as 
the cerebellum which will also play a role in motor performance. Given the data presented 
in previous chapters, future studies can advance the work further by incorporating more 
advanced models of HIV CNS infection to establish Beclin 1 as a glial target for reducing 
HIV and opiate induced neurodegeneration capable of rescuing motor and potentially 
cognitive deficits.  
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CHAPTER 5: FINAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
The goal of this dissertation was to investigate the mechanisms underlying HIV and opiate-
induced exacerbation of neurodegeneration. Here we provide literature and experimental 
rationale supporting the role of the autophagy pathway, specifically the initiation protein 
Beclin 1, in mediating viral inflammation, neurotoxicity, and motor impairment. To do this, 
we utilize a heterozygous Beclin 1 deletion mutant, Becn1+/-, which displays an 
approximate 60% reduction in Beclin 1 expression. Given that mice are not permissive to 
HIV infection without genetic modification, we instead use the viral protein Tat which is 
secreted by HIV infected cells and demonstrates significant neurotoxicity [241, 438]. This 
is also currently relevant in terms of cART adherent patients which may exhibit reduced 
or undetectable levels of HIV in circulation but may still be producing Tat in locations of 
viral reservoirs such as the CNS. 
 
We first sought to characterize what effects a reduction in Beclin 1 expression would have 
on glial cell responses to Tat and opiate exposure. Tat is an established inducer of 
cytokine and chemokine secretion from microglia and astrocytes, inflicting widespread 
neuroinflammation as well as dysregulating typical functions performed by these cells 
within the microenvironment [66, 100, 106, 439]. Reduced expression of Beclin 1 in mixed 
glial cultures significantly reduced Tat and morphine-induced secretion of inflammatory 
molecules like RANTES, MCP-1, and to a smaller extent IL-6 as well as intracellular Ca2+. 
From this it can be taken that Beclin 1 can partake in the regulation of neuroinflammation.  
However, Becn1+/- glia did not appear to rescue oxidative stress in terms of ROS and NO 
production. This may be a pitfall of the study design and execution based upon the 
readings obtained for the positive control H2O2. In general, H2O2 release should increase 
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over time; however, here we observed an elevated but fairly steady state level of DCF 
fluorescence. From this it can be hypothesized that the signal reached maximally 
detectable levels and corresponding readings may be lacking the necessary sensitivity. 
Further optimization of the CM-H2 DCFDA dye concentrations are necessary in 
conjunction with validation by fluorescent microscopy. Additionally, we examined was the 
effects of Tat and morphine on the glial autophagy pathway which is a key pathway abused 
by HIV. We found that where Tat and morphine increased expression of autophagy 
proteins like Beclin 1, p62/SQSTM1 and LAMP1 in wild type C57BL/6J glia, this effect is 
negated in Becn1+/- without significant glial toxicity. These effects on the autophagy 
pathway suggest that Tat and morphine trigger the autophagy pathway (indicated by 
elevated Beclin 1 expression) but that maturation and degradation are inhibited (indicated 
by elevated p62/SQSTM1 and LAMP1), potentially causing autophagosome 
accumulation. By reducing Beclin 1 expression in Becn1+/-, it is possible to diminish, but 
not completely abrogate, autophagy activation caused by Tat and morphine exposure. 
Despite these findings, the prevention of autophagosome accumulation through reducing 
Beclin 1 can only be confirmed by electron microscopy. In addition, confirmation of 
impaired autophagic flux should be confirmed with the use of RFP-GFP-LC3B tandem 
sensors which use fluorescent tags to indicate autophagosome and lysosome co-
localization [308].  
 
From the basis of this chapter, future work can look at the exact mechanisms causing Tat 
and morphine to trigger autophagy. One can speculate it involves ion dysregulation and 
stress sensing mechanisms such as JNK or MAP kinase pathways. We and others have 
shown that Tat and morphine is able to increase intracellular calcium which is prevented 
in Becn1+/- glia; this ionic imbalance may subsequently lead to aberrant signaling and 
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activation of stress responses. MAPK signaling serves many roles in cell survival with JNK 
and p38 MAPK being shown to be activated by pro-inflammatory cytokines and 
environmental stress [440]. In addition, HIV or viral protein exposure can activate JNK 
and/or p38 MAPKs with inhibition of these pathways reducing toxic effects [60, 441]. 
Provided that JNK has the capability of phosphorylating BCL-2, separating it from Beclin1, 
it is possible that such pathways may explain the Tat-mediated activation of the autophagy 
pathway [442]. Currently, ongoing studies are interested in the protein-protein interactions 
going on within glial cells treated with Tat. Since Tat easily crosses cell membranes and 
its basic domain can interact with many structures, it is curious what, if any, interacting 
partners it has in the autophagy pathway. The viral protein Nef is known to interact with 
Beclin 1 [16], and we have also shown a significant Nef effect in respect to inflammatory 
molecule secretion (Figure 2.6). Since we have shown that reduction of Beclin 1 has 
inflammation and autophagic dysregulation alleviating capabilities within glia, determining 
direct interacting partners would further the understanding of these mechanisms. 
 
Next, given that the HIV and opiate effects on glia converge on neurons, we ventured to 
determine how Beclin 1 reduction would affect neuron response to these stressors. We 
found that Becn1+/- neurons are highly sensitive to injury and stressors such as Tat and 
morphine. While co-exposure to Tat and morphine caused elevations in intracellular 
calcium accumulation and dendritic beading in C57BL/6J neurons as has been previously 
published [204, 316], these were enhanced in Becn1+/- neurons, although Tat alone had 
a higher effect than Tat and morphine combined (Figures 3.2 and 3.3). This effect was 
further showcased upon assessment of neuronal viability by time-lapse recording showing 
significant neuronal death with or without treatment (Figure 3.4). Given that HIV 
neuropathogenesis is a glially-driven and with the promising reductions in inflammation 
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seen in Becn1+/- glia, we desired to see how neuronal outcome might vary with exposure 
to the indirect toxicity of supernatant from Tat and morphine treated C57BL/6J and Becn1/- 
glia. We found that C57BL/6J neurons treated with Becn1+/- supernatant had more 
favorable outcomes than those treated with C57BL/6J supernatant (Figure 3.5). When 
postulating what soluble components within the supernatant could be mediating these 
effects, we found that in addition to the stemming of inflammatory molecule secretion, this 
may also be due to increase secretion of neuroprotective growth factors (Figure 3.6). 
  
Our studies on the neuro-glial interactions are only in the preliminary stages. Now that we 
have found that reduced Beclin 1 in glia can reduce the Tat and morphine toxicity to 
neurons, future studies will examine neuronal functionality which can be just as important 
as neuronal viability. These would include studies on neurotransmitter release which is 
reported to be dysregulated with Tat exposure [416]. For example, the striatum is a 
location with predominantly GABAergic medium spiny neurons but receives both 
dopaminergic and glutamatergic inputs from various sources [412]. As such, glutamate 
uptake and dopamine release from these neurons are key aspects of function. One study 
on the effect of Tat and methamphetamine in rat striatal neurons showed that the 
treatment lead to striatal dopamine deficit which contributed to the manifestation of motor 
impairment [416]. The evaluation of neuronal viability performed here also requires further 
exploration into the mechanisms of neuronal death whether apoptosis dependent or 
independent pathways. Future studies can also take the co-culture paradigm further by 
direct contact of glia and neurons. Assessing how neuronal survival and responses 
(including neuronal autophagy) to Tat and morphine shift in the presence of Becn1+/- glia 
can provide confirmation that targeting of glial Beclin 1 is a viable therapeutic strategy for 
HIV and opiate neuropathogenesis.  
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Finally, we wanted to see if the beneficial results seen in Becn1+/- glia and with Becn1+/- 
supernatant on neurons could be translated into positive outcomes in motor impairment in 
vivo following Tat and morphine exposure. To do this we performed stereotaxic surgery 
on C57BL/6J and Becn1+/- mice and injected 10 g of Tat into the mouse striatum while 
also implanting a 25 mg extended-release morphine pellet (Figure 4.1). These surgical 
methods have been done before for analysis of glial dysfunction and tissue damage, but 
never in the context of autophagy [242, 244]. At 2- and 5-days post-surgery, motor activity 
was assessed by three motor coordination tests: rotarod, forelimb grip strength, and 
horizontal bars. To our surprise, we were unable to detect any Tat effects in rotarod on 
either day for either strain but noted a significant morphine effect to both strains on day 2 
(Figure 4.6). Forelimb grip strength performance showed a similar lack of effect on day 2; 
however, on day 5, we observed a Tat effect in C57BL/6J mice but not Becn1+/- mice, 
although not statistically significant (Figure 4.7). Both C57BL/6J and Becn1+/- mice showed 
an apparent Tat and morphine co-exposure effect. There were somewhat different results 
in the horizontal bars assessment of motor coordination (Figure 4.8). On day 2 we 
perceived a Tat effect in both C57BL/6J and Becn1+/- mice; however, the observed 
morphine effect was so robust, we theorize that it may be obscuring any potential 
synergistic effects of Tat and morphine. Interestingly, on day 5 C57BL/6J mice retained 
the observed Tat effect whereas Becn1+/- mice returned to control levels; the morphine 
effect however was still potent, though not to the extent of day 2 performance. Due to the 
varied results which can be quite common in animal studies, we found that the behavior 
data may not correlate with the in vitro results observed in Chapters 2 and 3. We also 
inspected histological changes within the striatum of treated mice by Nissl staining and 
found significantly reduced neuronal numbers in C57BL/6J mice treated with Tat that was 
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exacerbated by morphine co-exposure, whereas Becn1+/- mice showed losses only with 
Tat treatment. It is difficult to reconcile the seemingly contradicting results within the motor 
assessments and tissue evaluation. One can postulate that the neuronal losses seen 
within the tissue may not yet be extensive enough to translate into motor impairment. 
These studies were done for up to 5 days whereas in HIV patients, Tat exposure is more 
continuous allowing for more extended attack on the CNS.  Tat protein is also rapidly 
oxidized so it may be necessary to have more continuous exposure to the protein for 
detectable outcomes. However, it must be noted that assessment of Nissl staining was 
done manually instead of the more appropriate and accurate stereological quantification. 
This would also require screening of the entire striatum rather than the anterior most 
sections due to variable distribution and projections of neurons throughout the striatum. 
Another consideration would be the systems at play in motor coordination. Notably, each 
of the motor assessments yielded somewhat different results, likely because each test 
appraises slightly different aspects of motor coordination: rotarod measures motor 
coordination, grip strength measures muscular ability, and horizontal bars measure a mix 
of the previous two [434].  
 
There are many options for future studies to advance the work presented here. Continuing 
with this model, it might be necessary to increase the amount of Tat used for injections or 
to concentrate the protein to reduce the injection volume. While we detected no backflow 
of Tat from the injection site, such a volume (10 L) may leak into the ventricles or drain 
into the CSF or lymphatic system. One study performed 1 L canula injections of Tat at 
the same concentration used in our studies (10 g) in the rat striatum and saw significant 
motor impairment and neuronal death [416]. Separately, additional assessments and brain 
locations could be incorporated into the study design. For example, other brain locations 
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like the hippocampus are also affected by heavy HIV burden [207, 378, 379, 408]; it would 
be pertinent to see how other brain structures are affected by Tat and morphine co-
exposure within the Becn1+/- mice. Nociception is another clinically relevant avenue for 
study with these mice. Given that neuropathic pain is an issue afflicting HIV patients, how 
HIV and opioids interact to modulate pain perception is of particular importance, especially 
in the current opioid epidemic climate [209, 443]. Alternatively, the work could proceed 
with another, more advanced, injection model using the mouse permissive EcoHIV virus. 
As reviewed earlier (Chapter 1.11.3), this modified virus is infectious in mice and though 
it does not cross into the brain efficiently, can be directly injected into the brain and 
replicated vigorously [238]. Infecting Becn1+/- mice with this chimera virus (in combination 
with morphine pellet implantation) would provide a greater understanding and further proof 
of concept of the therapeutic potential of targeting Beclin 1 in HIV. As studies move more 
into treatment and translational paradigms to be used as adjuvants in conjunction with 
cART, humanized mouse models of HIV will be useful to see the therapeutic relevance of 
reducing Beclin 1 in the aim of ameliorating the neurodegenerative effects of HIV both in 
the aging AIDS population and the drug abusing population. Based on our results here, it 
would be essential to target glia specifically, as to not hinder neuronal survival by reducing 
autophagy in those cells as seen in Figure 3.4. Currently our lab has explored various 
drug delivery systems for delivering siRNA against Beclin 1 to the brain [257, 258], and 
with the studies shown here, we can continue to fine tune therapeutic strategies for what 
are hopefully widespread benefits to the HIV population and beyond. 
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